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Hepatic encephalopathy, or the syndrome of disturbed conscious-
ness often associated with advanced chronic or acute hepatic failure, 
is believed to be a biochemical disturbance of cerebral function . 
Since it has been shown that there is no shortage of energy inter-
mediates in the brain, and transmission failure rather than energy 
failure is thought to be the primary event, investigations into the 
aetiology of hepatic encephalopathy have recently focussed on factors 
involved in neurotransmission. 
X 
This thesis describes studies of changes in some substances in-
volved in neuroregulation in the brain, and their precursors, during 
chronic and acute hepatic failure in the rat . These substances can be 
divided into two groups: neuroregulators associated with ammonia 
metabolism (the amino acid neuroregulators, glutamate, glutamine, 
aspartate and GABA, derived from glucose), and those derived from the 
aromatic amino acids tryptophan, phenylalanine and tyrosine. 
Because of the importance of blood-brain barrier transport for the 
availability of the aromatic amino acids to the brain, plasma/brain 
amino acid relationships were also studied. The results suggested that 
the transport mechanism for these and the other neutral amino acids 
(leucine, isoleucine, valine, methionine and threonine), might be 
altered during hepatic failure; therefore this possibility was investi-
gated in a separate series of experiments. The effect of continuous 
intravenous infusion of solutions with and without amino acids, on 
plasma and brain metabolites, was studied in chronic hepatic failure. 
xi 
Chronic hepatic failure was studied in rats four weeks after per-
forming an end-to-side portacaval shunt operation. These rats were 
pair-fed with sham-operated controls, and at the time of sampling there 
was no difference in body weight between the two groups. The biochemical 
changes observed closely resembled those seen in human chronic hepatic 
encephalopathy. No abnormalities in behaviour were seen during the 
four-week period. 
Acute hepatic failure was produced in either of two ways: 
(a) two-stage hepatic devascularization (portacaval shunt fol-
lowed 65 hours later by hepatic artery ligation), or 
(b) intravenous injection of the specific hepatotoxin galactosamine-
HCl. 
The surgical method (a) leads to an inactive and unresponsive con-
dition about four hours after hepatic artery ligation and finally death 
after a further two to five hours. During the entire period, body 
temperature and blood glucose levels (which otherwise decrease markedly) 
were maintained within the normal ranges. The rats were sampled when 
unresponsive to all but severe stimuli four to seven hours after 
hepatic artery ligation. 
Galactosamine (b) was used as an alternative in order to compare 
the biochemical changes in acute hepatic failure produced by two 
entirely different methods. The dose of galactosamine used was 2 g/kg 
given in two doses three to six hours apart. Thirty to 60 hours after 
injection the rats lapsed into a clearly distinguishable coma. Two 
behavioural states were defined, precoma and coma, and rats sampled 
from each group. The use of galactosamine had the advantage of avoiding 
the surgical trauma of the devascularization method. In addition, a 
xii 
definite coma was produced by galactosamine-induced hepatic necrosis, 
which was not always evident after hepatic devascularization. 
The alterations in brain and plasma metabolites during acute 
hepatic encephalopathy produced by the two methods were strikingly 
similar, confirming the assumption that these were due to the failing 
liver. They also closely resembled those seen in acute hepatic failure 
patients, suggesting that these are suitable models for the study of 
this condition. The metabolite changes will now be described in more 
detail. 
Changes in brain ammonia and related metabolites were qualitatively 
similar during chronic and acute hepatic failure; however much larger 
alterations were found in the acute condition. The most marked changes 
were increases in brain ammonia and glutamine content. Changes in 
ammonia have long been implicated in the development of hepatic en-
cephalopathy but it is now clear that it is not the primary aetiologic 
agent. However, because of its association with the metabolism of 
several important neuroactive substances, it may affect the pools of 
these neuroregulators and thus influence brain activity. 
The increase in brain glutamine is of great interest since it may 
be related to various other changes which occur during hepatic failure. 
For example, a role for glutamine has been postulated in the mechanism 
of transport of the amino acids across the blood-brain barrier, which 
is altered during hepatic failure (see below). Glutamine is syn-
thesized exclusively in brain glial cells which are the only structures 
to show morphological alterations during hepatic failure, and which 
surround the brain capillaries where transport of substrates into the 
brain occurs. In addition, glutamine may affect levels of glutamate 
in the brain, as well as having some "false neurotransmitter," 
i.e. inhibitory action, itself. All these factors together 
suggest that glial metabolism may be of great importance in 
hepatic encephalopathy and should be further investigated, es-
pecially in view of the absence of any other information regard-
ing localization of the events leading to disturbed brain function 
in this condition. 
xiii 
Small but significant decreases in brain glutamate or aspartate 
were seen in both chronic and acute hepatic failure. There is now 
good evidence that these substances act either as excitatory neuro-
transmitters or as neuromodulators, i.e. substances which alter the 
effectiveness of the neurotransmitters (a convenient collective term 
for these two groups is neuroregulators). Such a role in addition to 
their involvement in intermediary metabolism is made possible by 
functional compartrnentation. There was also a possible increase in 
GABA during acute hepatic failure which has not been previously reported. 
Thus, in general, hepatic encephalopathy was associated with de- . 
creases in the excitatory- and increases in the inhibitory neuroregula-
tor amino acids. This imbalance between excitatory and inhibitory sub-
stances was also observed when considering the aromatic amine neuro-
regulators and their amino acid precursors. Other studies have shown 
that noradrenaline is decreased and serotonin is increased in the brain 
during hepatic failure. In this study large increases in the three 
aromatic amino acids tryptophan, tyrosine and phenylalanine, which in-
fluence synthesis of serotonin and the catecholamines, were found in 
the brain. Changes were more pronounced during acute hepatic failure. 
The increase in brain tryptophan in particular seemed to correlate well 
xiv 
with the degree of brain dysfunction. For example, in the galactosa-
mine studies the increase was higher in the coma group than in the pre-
coma group. There is much evidence that brain tryptophan content con-
trols synthesis of serotonin, which may be involved in the regulation 
of states of consciousness. Thus, hydroxy-indole metabolism in the 
brain may be connected with the development of hepatic encephalopathy 
and the availability of tryptophan may play a crucial role. 
Brain concentrations of the aromatic amino acids in normal rats 
have been shown to depend on the relative plasma concentrations of the 
large neutral amino acids tryptophan, tyrosine, phenylalanine, methio-
nine, leucine, isoleucine, valine and threonine, since all these share 
the same transport system across the blood-brain barrier. Alterations 
in the plasma concentrations of these amino acids are characteristic 
of hepatic failure. The present study showed increased tyrosine and 
decreased leucine and isoleucine during chronic hepatic failure. This 
pattern of increased aromatic and decreased branched chain amino acids 
in the plasma . (other workers have also found increased phenylalanine 
and decreased valine), has been implicated in causing increased uptake 
of tryptophan by the brain in chronic hepatic failure, by a reduction 
in competition. However in this study the total molar concentration 
of competitors in the plasma was in fact slightly higher after porta-
caval shunting. In acute hepatic failure it was even more obvious 
that competition effects could not account for the increase in brain. 
tryptophan, since large increases were found in most of the plasma 
amino acids, including the branched chain amino acids. These findings 
led to the question of whether the actual transport system could be 


































presence of increased plasma competitors. This possibility was sub-
sequently examined. as described below. 
Several studies in normal rats have shown correlations between 
xv 
brain tryptophan content and the ratio of plasma total tryptophan to 
the sum of the competing amino acids. During hepatic failure, differ-
ent correlations were found which emphasized the importance of non-
albumin bound tryptophan, rather than total tryptophan, in affecting 
brain tryptophan. These results again suggested that extrapolations 
from normal to pathological conditions should be made with caution, 
especially when therapeutic measures are suggested such as the feeding 
of intravenous amino acids to correct plasma amino acid imbalances, 
with the aim of influencing brain amino acid uptake. This has been 
previously carried out in dogs with portacaval shunts and beneficial 
effects on both mental status as well as plasma amino acid patterns 
were obtained. These . effects were attributed to the amino acid distri-
bution in the infusion. Continuous infusion of a similar solution in 
the present chronic hepatic failure studies led to a normalization of 
both brain and plasma metabolites. However, an equal, and in the case 
of certain metabolites, even better response, was obtained with the 
control solution, containing all the ingredients but no amino acids . 
Such a control solution was not used in the earlier reported work on 
dogs. This suggested that it was the reduction of protein intake (the 
intravenously fed rats were not given food orally), and not the amino 
acid distribution in the infusion mixture, which resulted in the im-
provement observed. In acute hepatic failure the extremely high plasma 
concentrations of all amino acids measured suggested that in this condi-
tion, adding specific amino acids to the system would be of little 
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benefit. This became even more obvious when the alterations in 
trypto-
phan transport across the blood-brain barrier durinq acute hepat
i c 
failure were analyzed. Thus, in general, it appears that hepatic
 
encephalopathy of differing aetiologies may result in widely diff
er-
ing plasma amino acid patterns, which should be determined in ind
ividual 
cases before considering infusion of amino acid solutions. 
Possible alterations in the blood-brain barrier transport of 
tryptophan during hepatic failure were investigated using a sing
le 
injection, dual isotope technique. 
14c-Tryptophan was injected to-
gether with a reference substance 3tt-water into the internal car
otid 
artery and the rat decapitated after 15 seconds. The 
14c/3H ratio was 
determined in samples of the cortex as well as the injected solu
tion, 
and by assuming a constant value for the cerebral blood flow, th
e 
influx was calculated. With this method the extraction by brain
 of 
substances from the injectate, during a single capillary pass of
 the 
bolus through the brain, was examined. A range of tryptophan co
ncen-
trations was used in orqer to enable calculation of the kinetic 
constants characterizing the transport mechanism. Influx of try
pto-
phan was also determined in the presence of competing amino acid
s, by 
the addition of competitors to the injectate. 
Tryptophan influx in rats after hepatic devascularization was 
found to be about twice that of normal rats at all concentration
s test-
ed. In both normal rats and those with acute hepatic failure, t
he 
transport system was found to consist of two components which we
re 
mathematically resolved. In each case one component was a low c
apacity 
saturable system which obeyed Michaelis-Menton kinetics and the 
other 

















proportion to concentration over the range tested. In acute hepa
tic 
failure the kinetics were altered so that the influx by both com-
ponents was increased, but especially by the high capacity system
. 
It was calculated that during hepatic failure, tryptophan entry w
ould 
be higher than normal even when the high levels of competing amino
 
acids were taken into account. The high plasma competitor concen
tra-
tions during acute hepatic failure, in addition to the alterations
 in 
transport kinetics, result in a greatly reduced contribution by th
e 
saturable component to total influx, and thus markedly reduce sen
si-
tivity to the effects of further increases in competition. Trypto
-
phan influx was found to correlate significantly with brain trypto
phan 
content. Thus, these findings could explain the increase in brain
 
tryptophan content in the presence of high plasma competitors duri
ng 
acute hepatic failure. 
The alterations in transport appeared to be selective, which 
suggested that transport of other substrates might be normal or d
iffer-
ently affected in hepatic failure. These studies indicate that m
ore 
attention should be paid to precursor availability in the brain b
e-
cause of the importance of blood-brain barrier transport for seve
ral 
metabolic pathways. The study of possible alterations in blood-b
rain 
barrier transport may be worthwhile in other pathological conditio
ns 
involving brain malfunction. 
The interrelationships between the various changes in metabolites
 
and their transport are discussed in detail, compared with observ
ations 
in other metabolic comas, and a hypothesis put forward describing
 
possible events. in the development of hepatic encephalopathy, 
~k".~~.:;;;;;~~~~~~~~~~~~:;:;:;:;;:;:~~:;;;;.;;;;;
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INTRODUCTION 
Hepatic encephalopathy refers to the disturbance of cerebral 
function often associated with advanced chronic or acute hepatic 
failure. The neuropsychiatric symptoms cover a wide range from a 
rapidly developing syndrome of delirium, convulsions and coma in 
fulminant hepatic necrosis, to a more gradully developing intel-
lectual impairment leading to stupor and coma in patients with 
chronic liver disease. 
Morphological abnormalities are usually absent in the brains of 
patients with fulminant hepatic encephalopathy, although cerebral 
oedema has been de'scribed in some cases (Ware, D 'Agostino &. Combes, 
1971). On the other hand, encephalopathy resulting from chronic 
liver disease is often associated with abnormalities in protoplasmic 
astrocytes in the brain (Cavanagh, 1974) -. However, the absence of 
morphologic changes in acute hepatic failure and the fact that the 
coma in both acute and chronic conditions is potentially rapidly 
and fully reversible, suggest that neither clinical syndrome is based 
on fixed structural abnormalities of the brain. In addition, the 
varied manifestations of hepatic encephalopathy indicate widespread 
and progressive impairment of the central nervous system and do not 
seem to point to particular cerebral structures that may be involved. 
Generally therefore, hepatic encephalopathy is considered to be a 
metabolic, i.e. a biochemical disturbance of cerebral function. The 
variability of the clinical and pathological symptoms also suggests 
1 
that several factors may be involved in the pathogenesis of the syndrome; 
and a multifactorial approach may be required in order to recognize 
and allow for possible interdependence and synergistic effects of 
these factors. 
2 
Disturbances of consciousness may result from various alterations 
in the normal biochemical functioning of the central nervous system. 
These include modifications in the excitatory and inhibitory substances 
and their relationship to each other, alterations in either the pro-
duction or use of the brain's energy supply, and changes in the ionic 
distribution and pH, i.e. in the internal surroundings of the brain. 
These may all eventually lead to altered neuronal membrane permea-
bility and thus altered neuronal activity. 
This thesis describes studies of some neurochemical factors that 
may be involved in the pathogenesis of hepatic encephalopathy, using 
various models of acute and chronic hepatic failure. Particular 
attention was paid to substances involved in brain neurotransmission, 
namely neurotransmitters and related metabolites, and the availability 
of precursors. 
The finding of reduced cerebral metabolic rates of glucose and 
oxygen in human hepatic coma (Plum & Posner, 1972: Maiolo, Porro, 
Galli, Sessa & Polli, 1971) suggested that cerebral energy metabolism 
was impaired in these patients. However, the available studies did 
not clarify whether the decreased energy metabolism of the brain was 
a primary event or resulted from decreased neuronal activity secondary 
to a disturbance of function or excitability. Lowry (1975) has pointed 
out that normally work and fuel consumption are tightly coupled in the 
brain, and therefore neuronal activity must control energy expenditure 
and not vice versa. Several findings indicate that this is also true 
in states of unconsciousness. In a study of various experimental 
comatose states, Derr & Zieve (1973) showed that the aden
ylate 
energy charge remained constant, and therefore concluded 
that the 
decreased oxygen consumption observed was a consequence o
f decreased 
use of ATP. It has now been established that there is no
 shortage 
3 
of energy intermediates in experiMental hepatic coma (Bie
buyck, 
Funovics, Dedrick, Scherer & Fischer, 1974; Zieve, Nicolo
ff & Doizaki, 
1975), and the primary event in brain malfunction during 
hepatic 
failure is thought to be failure of transmission rather th
an energy 
failure. This has also been suggested for other metaboli
c comas such 
as those due to uraemia (V. d. Noort, Eckel, Brine & Hrdl
icka, 1970; 
Berghof, Mathaus, Otto, Ulrich, Held & Gottstein, 1970; R
askin & Fish-
man, 1976) and hypoglycaemia (Hinzen & Mliller, 1971; Ferr
endelli & 
Chang, 1973; Ferrendelli, 1975; Norberg, Ljunggren & Sies
jo, 1975). 
For this reason attention has been focused on brain neuro
transmit-
ter metabolism in hepatic encephalopathy. Altered brain 
concentrations 
of the neurotransmitters noradrenaline and serotonin (dec
reased and 
increased respectively), are characteristic findings in e
xperimental 
hepatic encephalopathy (Knell, Davidson, Williams, Kantam
aneni & 
Curzon, 1974; Dodsworth, James, Cummings & Fischer, 1974)
. There is 
also evidence of increased serotonin turnover as indicate
d by increased 
concentrations of the major metabolite 5-hydroxyindoleac
etic acid in 
brain and cerebrospinal fluid. Noradrenaline appears to 
have both 
inhibitory and excitatory effects on various regions of t
he brain, but 
it generally produces arousal while serotonin is more con
sistently 
inhibitory (Fischer & Baldessarini, 1976). 
While the biogenic amines undoubtedly play an important r
ole in 
brain function, the neurons containing these substances r
epresent only 
4 
a fraction of the total in the central nervous system (Snyder, Young, 
Bennet & Mulder, 1973). Therefore it is probable that the amines 
account for transmission at only a small proportion of central nervous 
synapses and that other systems are present which use different neuro-
transmitters. Many putative neurotransmitters have been proposed 
(Table 1). The amino acid candidates in particular have fulfilled 
many of the criteria for neurotransmitter function (Snyder & Young, 
1975; Davidson, 1976; De Feudis, 1975). Although a neurotransmitter 
function for some of these substances may be difficult to envisage on 
account of their widespread distribution in the central nervous system 
and involvement in intermediary metabolism, functional compartmenta-
tion, as has been demonstrated for glutamate, may enable separation 
of their various functions. These amino acids may also act as 
modulators of neuronal function mediated by the recognized, more 
localized neurotransmitters (Barchas, Akil, Elliott, Holman & Watson, 
1978; Schrier & Thompson, 1974). 
Several of the putative amino acid neurotransmitters are metabo-
lites of ammonia, which has featured prominently in the discussion of 
the pathogenesis of hepatic coma. These are glutamate and aspartate, 
which have excitatory action, and GABA, which is inhibitory. Changes 
in brain concentrations of glutamate and aspartate as well as in 
ammonia and glutamine have been found in studies of hepatic encepha-
lopathy. 
Many theories of hepatic coma have evolved around substances re-
lated to neurotransrnission. In addition, several other substances have 
been implicated. Some of these hypotheses have been summarized in 
Table 2. As described in the General Discussion, several of the 
TABLE 1 






















































































































































































































































































































































































































































































































































































































































































































































































































































neurochemical changes observed may be interdependent, resulting in 
a series of events which eventually lead to an imbalance in the 
neuroregulators, and consequent changes at the neuronal cell membrane. 
The synthesis of the neurotransmitters acetycholine, serotonin 
and the catecholamines (noradrenaline and dopamine) is dependent on 
. the availability of the respective precursors choline, tryptophan and 
tyrosine, which are originally obtained from the blood. In the case 
of serotonin and acetylcholine, the synthesis rate is in fact regu-
lated by brain precursor concentrations, due to the low K of the m 
rate-limiting enzyme for the substrate (Wurtrnan & Fernstrom, 1976). 
This means that serotonin synthesis may be controlled by tryptophan 
uptake which, in turn, is strongly influenced by the proportions of 
other plasma neutral amino acids competing for the same transport 
mechanism. Thus, it has been shown that serotonin synthesis rates are 
determined by plasma amino acid patterns via competition effects 
(Wurtrnan & Fernstrom, 1974). In addition, changing brain phenylala-
nine and tryptophan content may affect catecholamine synthesis by 
inhibiting the decarboxylation of dopa (Andrews, Patrick & Barchas, 
1978). For these reasons much attention has been paid to the ab-
normalities in plasma amino acids both in absolute concentrations as 
well as distribution, found in the various forms of hepatic failure. 
It has been suggested that these abnormal patterns can promote the 
development of coma by causing abnormal uptake patterns of amino 
acids into the brain (Munro, Fernstrom & Wurtman, 1975; Soeters & 
Fischer, 1976). 
When considering the effects of plasma amino acids on brain 
transport during hepatic encephalopathy,one assumption that has been 
7 
8 
made is that the transport mechanisms are unchanged in hepatic failure. 
This may be far from the truth. A few studies have shown that the 
characteristics of the blood-brain barrier may be altered during 
hepatic failure (Livingstone, Hinchey & Goresky, 1974; Cremer, 
Lai & Sarna, 1977; Escourreau, James & Fischer, 1977). The finding 
that patients with liver disease have increased cerebral sensitivity 
to the effects of drugs and other insults such as infection, hypoxia 
and electrolyte disturbances (Schenker, Breen & Hoyumpa, 1974), could 
also suggest increased permeability of the blood-brain barrier. As 
the investigations of metabolite changes during hepatic encephalopathy 
for this thesis progressed, the results suggested that altered brain 
transport mechanisms could be involved. Therefore, studies of amino 
acid uptake in normal and encephalopathic conditions were included 
and are described in a separate section of the thesis. 
The experimental models used to study hepatic encephalopathy have 
mostly involved surgery or the administration of chemicals. Chronic 
hepatic failure has been produced by performing a portacaval shunt 
in rats and dogs. The resulting changes in concentrations of amino acids 
and other metabolites seen in blood and brain, and of certain morpholog-
ical changes in the brain, are similar to those present in patients with 
chronic liver disease. In addition, shunting of blood past the liver 
often occurs in these patients and appears to be a prerequisite for 
cerebral dysfunction (Sherlock, 1961). Therefore the portacaval 
shunted animal seems a suitable model for study of this condition. 
In another model, rats with portacaval shunts were subjected 
to an acute ammonia challenge (Hindfelt, Plum & Duffy, 1977). These 
experiments were aimed at mimicking the situation in patients with 
portal shunting who suffer from superimposed ammonia toxicity result-
ing from acute gastrointestinal bleeding or a sudden increase in 
protein intake. 
9 
Many studies have been made of metabolite changes in ammonia-
induced coma in rats (Hindfelt & Siesjo, 197la,b; Hindfelt, 1972; 
Schenker, McCandless, Brophy & Lewis, 1967) but their relevance to 
hepatic coma can be questioned. Acute ammonia intoxication in ex-
perimental animals produces a hyperkinetic state (often with convul-
sions) with rapid turnover of metabolites and increased brain oxida-
tive metabolism (Hawkins, Miller, Nielson & Veech, 1973). In addition, 
ammonia intoxication does not reproduce all the metabolic features of 
hepatic coma; for example brain serotonin, which is increased in 
hepatic coma, is unchanged in animals given large doses of ammonia 
(Walker, Speeg, Levinson & Schenker, 1971). 
Experimental acute hepatic failure has been produced by total 
hepatectomy or by hepatic devascularization in dogs and rats. The 
two-stage ligation method, consisting of a portacaval shunt followed 
two days later by ligation of the hepatic artery, overcame many pro-
blems associated with other models such as total hepatectomy (death 
from bleeding diathesis) or simultaneous occlusion of the hepatic 
arterial and portal venous blood supply (death from shock) (Turcotte, 
Mattson & Child, 1967). In addition, the symptoms and biochemical 
abnormalities produced by this method more closely resembled changes 
seen in hepatic coma in man, than any of the previous models (Mattson, 
lob, Sloan, Coon, Turcotte & Child, 1968). 
Chemical methods of inducing acute hepatic failure have the 
advantage of involving much less trauma than surgical methods. The 
selective hepatotoxin galactosarnine has recently been used to cause 
acute hepatic necrosis and appears to have several advantages. 
Therefore this method as well as surgical methods were used to pro-
duce hepatic failure in the present studies. 
This thesis describes investigations of altered neurotransmitter 
metabolism and related changes in brain and plasma metabolites, in 
chronic and acute hepatic encephalopathy. The effects of altering 
plasma amino acid patterns by intravenous infusion were examined. 
Finally, the possibility of an altered blood-brain barrier in hepatic 






Metabolite changes were studied in two main groups of rats, 
namely those with chronic and acute hepatic failure. Chronic hepatic 
failure was studied four weeks after portacaval shunting while acute 
hepatic failure was produced either by portacaval shunt (pcs) followed 
by hepatic artery ligation (hal), or by intravenous injection of 
galactosamine-HCl (galN). These models are described in part C of 
this section. The findings in each condition were compared to the 
corresponding controls (sham-operated rats) and in some cases, normal 
rats. Intravenous feeding therapy was carried out in the chronic 
hepatic failure group. 
Figure 1 summarizes the various conditions examined and indicates 
the time intervals between events. 
Various clinical parameters and metabolites were studied. Clini-
cal parameters included: behaviour, food consumption, and weight 
change; and during acute hepatic failure: body temperature and blood 
glucose. In the brain, concentrations of cyclic AMP, ammonia, glucose 
and various amino acids (Table 3) were measured. Plasma insulin, 
glucagon, glucose and amino acids were determined, and the relation-
ships with brain metabolites investigated. In the acute hepatic 
failure series, brain water content was also measured to test for 
brain oedema. 
In a separate study, the transport of tryptophan across the 
blood-brain barrier was investigated. Tryptophan uptake was measured 






























































































































































































































































































































































































































































































acids, in both normal rats and rats with hepatic fai l ure. The 
kinetic constants characterizing the system were calculated from the 
results and used to r,redict brain influx rates. 
. 
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All the rats used were adult Long-Evans males, weighing 300-
350g and bred in the South African Mining Industries Research Centre 
for Heart Disease and Organ Transplantation at the University of Cape 
Town Medical School. The rats were housed under conditions of con-
trolled temperature, humidity and lighting. The food consisted of 
commercial rat pellets (Epol, P. o. Box 497, Cape Town, South Africa) 
and contained: 20% protein, 4.3% fibre, 0.86% calcium, 0.72% phos-
phorus, 0.51% methionine, 1.20% lysine, and 7.0% fat, with added 
trace-elements and vitamins. Water and food were continuously avail-
able unless otherwise stated. 
REAGENTS 
The following enzymes and co-factors were obtained from Boehringer 
Mannheim GmbH Biochemica, Mannheim, West Germany: glucose-6-phosphate 
dehydrogenase (EC 1.1.1. 49) , glutamate dehydrogenase (EC 1. 4 .1. 3) , 
glutamate-oxalacetate transaminase (EC 2.6.1.1), hexokinase (EC 2.7.1.1), 
malate dehydrogenase (EC 1.1.1.37), ADP, ATP, 8-NAD+, S-NADP+, S-NADH, 
and S-NADPH. L-glutaminase (EC 3.5.1.2) was obtained from Sigma Chemical 
Corporation, St. Louis, U.S.A. [ 14c]-Tryptophan and [3H]-water, and 
all the reagents for the cyclic AMP assay, were obtained from the 
Radiochemical Centre, Amersham, England. [ 14c]-n-Butanol was bought 
from New England Nuclear, 549 Albany St., Boston, Massachusetts, U.S.A. 
Scintillation cocktails Insta-gel and Dimilume-30, and tissue solubil-
izer Soluene-350 were bought from Packard Instrument Company Inc., 
2200 Warrenville Road, Downers Grove, Illinois, U.S.A. 
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Dextrostix reagent strips were from Ames Company, Division of 
Miles Laboratory Ltd., Buckinghamshire, England. Heparin B.P. was 
obtained from The Boots Company (S.A.) (Pty) Ltd., 111 Garmor House, 
121 Plein St., P.O. Box 1559 7A, Cape Town 8000, South Africa, and 
Trasylol (brand of aprotinin) from Bayer Pharmaceuticals (S.A.) (Pty) 
Ltd., P. 0. Box 2953, 16 Milner Street, Metro Industria, Milnerton, 
Cape Town 8000, South Africa. Halothane was purchased from I.C.I. 
South Africa (Pharmaceuticals) Ltd., Leyds Streets, Braamfontein, 
Johannesburg 1500/1, South Africa. The intravenous solutions Normal 
Saline and Plasmalyte B were obtained from Baxter Laboratories, Inc., 
Deerfield, Illinois, U.S.A. Dextrose (50%) was obtained from Saphar 
Laboratories, P.O. Box 568, Durham Avenue, Salt River, Cape Town 8000, 
South Africa. The F080 amino acid mixture was obtained from McGaw 
Laboratories, Division of American Hospital Supply Corporation, 
Glendale, California, U.S.A. Oxygen was obtained from Afrox Ltd., 
P. 0. Box 51, Jellico Avenue, Epping Industria, Cape Town 8000, South 
Africa. Substrates and other chemical reagents were of the highest 
available grade and were bought from Sigma Chemical Corporation or 
BDH Chemicals Ltd., Poole, England. 
I 
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C. GENERAL PROCEDURES 
Methods specific to particular sections are described in the 
relevant sections. 
SAMPLING OF BLOOD AND BRAIN 
For sampling, the rat was placed in position on the freeze-blowing 
apparatus (described below), and blood removed from the femoral artery 
into a heparinized syringe, immediately before sampling the brain. One 
ml of blood was immediately added to a pre-weighed tube containing two 
ml HCl04 and extracted for glucpse determination. One ml was trans-
ferred to a centrifuge tube containing 0.1 ml aprotinin, mixed thoroughly 
and centrifuged at 10 000 g for 15 minutes to obtain the plasma max 
(for determination of glucagon). The remaining blood was centrifuged 
in the same way and all the plasma stored at -20° until analysis. 
Brain was sampled by using the rapid freeze-blowing technique 
(Veech, Harris, Veloso & Veech, 1973). The apparatus used was made 
by Precision Medical Industries Inc., 105 Poquito Rd., Shalimar, 
Florida 32579, U.S.A. With this technique, two hollow stainless steel 
probes are driven into the cranial cavity of the rat held in a re-
straining cage, and pressurized gas entering one probe blows the supra-
tentorial part of the brain through the other probe into a thin cavity 
between two aluminum discs precooled in liquid N2. In this way brain 
samples of 0.5 to 1.0 g can be removed and frozen within 0.5 seconds. 
The frozen tissue was rapidly removed to a mortar containing liquid 
N2, and transferred into precooled polyethylene tubes with screw 
caps for storage in liquid N2 until extraction. 
" ' 
It has been shown that this method is superior to decapita tion 
or whole-animal freezing for preventing post-mortem enzyme activity 
and therefore metabolite changes in brain samples (Nahorski & Rogers, 
l R 
1973; Veech et al., 1973). In addition, no prior surgery or anaes-
thesia is required as with the method of exposing the brain and apply-
ing liquid nitrogen directly to the surface. Thus, the relationship 
between plasma and brain metabolites can be accurately correlated with 
the state of consciousness in vivo. One disadvantage is that specific 
regions of the brain cannot be analyzed. Since there is evidence that 
several amino acids and putative neurotransmitters, e.g. glutamine, 
glutamate and serotonin, are not homogenously distributed throughout 
the brain (Liebschutz, Airoldi, Brownstein, Chinn & Wurtman, 1977; 
Saavedra, 1977), results from total supratentorial brain samples may 
be less meaningful for these substrates or their precursors. In 
addition, the lower areas of the brain, in particular the cerebellum 
and lower midbrain, are not obtained. 
For certain procedures the use of anaesthesia is unavoidable even 
when brain samples are obtained by freeze-blowing, for example, when 
catheters must be placed to obtain blood samples prior to sampling the 
brain. 
In some experiments the rat was anaesthetized if necessary, the 
skull opened at room temperature, and the brain rapidly removed and 
placed in liquid nitrogen. In these experiments only those metabolites 
were measured which do not undergo changes during the sampling period, 
as compared to brain samples obtained by freeze-blowing. Blood samples 
were taken from the abdominal aorta in these cases. 
. 
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In the galactosamine studies, samples of liver, kidney and spleen 
were taken from some animals and kept in isotonic formalin buffered 
to pH 7, for later histological evaluation. 
EXTRACTION OF TISSUE 
Frozen brain was ground to a fine powder using a pre-cooled pestle 
and mortar under intermittent irrigation with liquid N2. The N2 was 
allowed to evaporate and the dry brain powder rapidly weighed out into 
a tared pre-cooled polyethylene centrifuge tube. Six volumes of ice-
cold 8% HCl04 were added. After digesting for 15 minutes on ice and 
thorough mixing, the extract was centrifuged at 20 000 g for 15 max 
minutes at 4°C, in a RC-5 Sorval centrifuge. The supernatant fluid was 
poured off and neutralized to pH 6-7 with cold, freshly prepared 15% 
KOH/15% K2C03 (about 0.25 ml per ml of extract). More alkaline condi-
tions were avoided as this may result in loss of NH4+ from the extract. 
The precipitate KCl04 was removed by centrifuging as before and the 
supernatant used for determination of metabolites. Blood (one ml) was 
similarly extracted with two ml 8% HC104 and the extract neutralized 
as above. Weight of the brain powder and blood, and volumes of the 
extract before and after neutralization were noted for calculation of 
the dilution factor as follows: 
Dilution factor = weight tissue
 x 0.8 + HCl04 
weight brain powder 






1 . Enzymatic Methods 
The metabolites ammonia, aspartate, glutamine, glutamate and 
glucose were measured spectrophotometrically using nicotinamide adenine 
dinucleotides with appropriate cofactors and enzymes (Biebuyck, Lund 
& Krebs, 1972; Bergmeyer, 1974). These techniques involve the oxida-






The substrate to be determined is involved in a reaction with an 
associated change in the redox state of either NAD or NADP using NAD-
or NADP-dependent dehydrogenases. Since the reduced form of these 
nucleotides absorbs light at a wavelength of 340 nm while the oxidized 
form shows no absorption between 300 and 400 nm, the reaction results 
in an increase or decrease in absorption of light at 340 run which is 
measured spectrophotometrically. If conditions are chosen so that 
the reaction goes to completion in the desired direction, the observed 
change in absorption is proportional to the concentration of substrate 
in the cuvette. The equilibrium of the reaction can be influenced by 
variation of the conditions, such as pH, addition of excess substrate 
or enzyme, the presence of cofactors such as ADP, and the use of trap-
ping agents, e.g. hydrazine hydrate, to remove products of the reaction. 
Measurements were made in glass cuvettes with a light path length 
of one cm. The substrate concentration in the tissue extract was cal-





total volume in cuvette 
volume of extract used 
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where ~Eis the change in absorbance in the sample cuvette after sub-
traction of the absorbance change in the reagent blank cuvette, and 
6.3 is the extinction coefficient of NADH and NADPH at 340 run in 
(Recent investigations [Bergmeyer, 1975) have 
established this more accurate value for the extinction coefficient; 
previously the value of 6.22 was used.) Multiplication of the concen-
tration in the tissue extract by the dilution factor gave the sub-
strate concentration in the brain per g wet weight tissue. 
All determinations were carried out in duplicate, using a Zeiss 
PMQ III spectrophotometer with an automatic amplification unit. Stand-
ards were included in all assays. The reagent blank used was obtained 
by neutralizing 8% HCl04 as in the tissue extraction procedure and using 
the same volume of supernatant as for the tissue samples. 
Ammonia. NH4+ was measured using glutamate dehydrogenase (Kirsten, 
Gerez & Kirsten, 1963): 
NH4+ + a-ketoglutarate + NADH ~glutamate+ NAD+ + H20 
Excess a-ketoglutarate and enzyme shift the equilibrium to the right. 
ADP was added to overcome inhibition of glutamate dehydrogenase by ATP 
and GTP in the sample extract (Levitzki, 1970; Lund, 1971). Special 
precautions were taken to prevent ammonia contamination from the air 
in reagents and glassware. Only water that had been freshly double 
distilled was used. (Distilled water from various sources was found 
to be seriously contaminated with ammonia, in one case the ammonia 
concentration was twice that of normal brain extract.) The cuvettes 
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were soaked in chromic acid solution and only removed just before use. 
They were thoroughly rinsed with deionized water to remove all traces 
of acid and then rinsed several times with double distilled water. All 
reagents were freshly made up except the buffer and glutamate dehydro-
genase solution which were stored at 4°C in tightly stoppered con-
tainers. Brain samples were always assayed for ammonia immediately 
after extraction, since freezing and thawing of the extract was found 
to lead to losses. Ammonia concentration in the blank cuvette was 
usually about 0.005 rnM (mostly due to ammonia contamination of the KOH 
and K2C03 used to make up the neutralizing solution). 
Aspartate. Aspartate was determined in a two-step reaction 
(Bergmeyer, Bernt, Mollering & Pfleiderer, 1974): 
glutamate oxalacetate 
(1) L-aspartate + a-ketoglutarate transaminase 




The absorbance was measured five minutes after the addition of rnalate 
dehydrogenase, the glutamate oxalacetate transaminase added, and the 
second reading taken 10 to 20 minutes later. 
Glucose. Glucose was determined in a two-step reaction (modified 
from Bergmeyer, Bernt, Schmidt & Stork, 1974): 
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(1) Glucose+ ATP hexokinase glucose-6-phosphate + ADP 
(2) Glucose-6-phosphate + NADP+ glucose-6-phosphate 
dehydrogenase 
6-phosphogluconate 
+ NADPH + H+ 
The first reading was taken 3 to 5 minutes after addition of glucose-6-
phosphate dehydrogenase to allow for conversion of any glucose-6-phos-
phate present. Then the hexokinase was added and the second reading 
taken after a further five minutes. 
Glutamine and glutamate. Glutamate was measured with glutamate 
dehydrogenase (modified from Bernt & Bergmeyer, 1974). 
glutamate + 
L-glutamate + H20 + NAD+ a-ketoglutarate + NADH + NH4 
dehydrogenase 
To determine glutamine, the glutamine in a portion of tissue extract 
was first converted to glutamate by incubation with glutaminase (Lund, 
1974) : 
L-glutamine + H20 glutaminase) L-glutamate + NH3 
An aliquot of this reaction mixture was then assayed for glutamate, 
which represented the sum of glutamine and glutamate. The glutamate 
content of the extract was determined by assaying the extract directly 
and the glutamine determined by subtraction, i.e. 
glutamine in extract= (glutamate present after hydrolysis) -
(glutamate in extract). 
2 . Non-enzymatic Methods 
Tryptophan. Free tryptophan was assayed in brain tissue extract 
and in plasma. In plasma, tryptophan is largely bound to albumin. 
(This is still regarded as free tryptophan however, since it is in 
equilibrium with the unbound tryptophan and does not form part of 
protein.) Both the total and unbound tryptophan concentrations in 
plasma were determined. 
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Separation of Unbound From Bound Tryptophan. Plasma ultrafiltrate 
was obtained by centrifuging 0.5 ml fresh plasma in Arnicon 24-CF 50 
Centriflo cones at 800 g for 15 minutes at room temperature (Knott max 
& Curzon, 1972). (Speeds higher than 1000 g result in damage to the 
cone membrane.) These Centriflo cones have a 50 000 molecular weight 
cut-off point and therefore exclude albumin. A fraction of the filter-
able plasma components including the unbound tryptophan passes through 
the membrane. It has been suggested that this method may disturb the 
relationship between bound and unbound tryptophan by concentrating 
the albumin within the cone (Madras, Cohen, Messina, Munro & Wurtrnan, 
1974). However, since unbound tryptophan is removed just as readily 
as the other filterable plasma components, the filtration procedure 
does not affect the binding equilibrium, even though an increase in 
the concentration of albumin and bound tryptophan occurs inside the 
cone. This can be seen from the following: 
[albumin]+ [unbound tryp] [bound tryp] 
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The equilibrium constant 
[bound tryp] = K = [alb][unb tryp] 
If half of the solute and half of the unbound tryptophan is removed, 
the concentration of albumin and bound tryptophan inside the cone is 
doubled, while there is no net change in unbound tryptophan concentra-
tion, i.e. 




[alb] x [unb] 
Thus there is no net change in K. This was confirmed for the present 
studies by experiments in which plasma was centrifuged for various 
lengths of time. No differences in unbound tryptophan concentration 
in the ultrafiltrate were obtained. 
The alternative method of using equilibrium dialysis for 3.5 hours 
(Madras et al., 1974) has the disadvantages of being more tedious and 
possibly leading to artifical increases in the unbound tryptophan con-
centration (Hutson, Knott & Curzon, 1976). 
Since the binding of tryptophan to albumin is pH sensitive 
(McMenamy & Oncley, 1958), blood was centrifuged immediately after 
collection before pH changes could occur due to loss of CO2. Freezing 
of the plasma was found to lead to significant elevations in the levels 
of unbound tryptophan, therefore the ultrafiltrate was separated on the 
same day, at room temperature, before storing the ultrafiltrate and 
plasma at -20°C. The tryptophan was assayed within five days after 
collection of the sample. After use, the cones were rinsed with 
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distilled water, soaked overnight in 5% NaCl solution, rinsed with 
distilled water, and stored in 10\ ethanol . They could be re-used 
up to 10 times. 
Assay of Tryptophan. The free tryptophan is condensed with for-
maldehyde and oxidized by ferric chloride in acid conditions to form 
a highly fluorescent derivative, norharman. The norharman produced by 
the sample is measured spectrophotometrically and the concentration 





Of the naturally occurring tryptophan derivatives tested, only trypta-
mine produces any appreciable fluorescence with this method (Denckla & 
Dewey, 1967). However, since endogenous levels of tryptamine in rat 
brain are about 100 times lower than tryptophan (Eccleston, Aschcroft, 
Crawford & Loose, 1966) and the fluorescence produced by tryptamine is 
10 times lower than that produced by the same concentration of trypto-
phan (Denckla & Dewey, 1967), the method can be considered to be highly 
specific for tryptophan. 
In the original method described by Denckla and Dewey (1967) tri-
chloroacetic acid was used, which was found to cause several problems. 
. 
Incqbation with this acid at the high temperatures necessary for the 
reaction, resulted in decomposition to chloroform leading to blowing 
out of stoppers and loss of fluid, or the presence of an insoluble 
layer when screw-capped tubes were used. Therefore perchloric acid 
was used (Eccleston, 1973) and the incubation carried out in glass 
tubes with teflon-lined caps. A hot-air oven at 105°C was used in 
preference to a waterbath for incubation, since temperatures below 
99°C seriously affect the yield (Denckla & Dewey, 1967) and higher 
temperatures were difficult to maintain in a waterbath. 
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The incubation mixture contained 1-8 nmoles tryptophan (from 
standards or samples), 1.5 x 10-4 M FeCl3, 0.3% HCHO and 10% HC104 in 
a total volume of 3 ml. A range of six standards was included with 
each assay. Norharman standards were initially included to ensure 
that there was no loss during incubation. Plasma samples were allowed 
to stand for 10 minutes after addition of the HCl04 to denature the 
albumin and release the bound tryptophan, and then centrifuged at 
13 000 g for 10 minutes before adding the other reagents. Incuba-max 
tion was carried out at 105°C for three hours. The fluorescence was 
measured in a Perkin Elmer MPF 43A spectrofluorimeter at an excitation 
maximum of 373 run and an emission maximum of 452. nm. The readings of 
the standards were used to calculate a calibration line by linear re-
gression and the sample concentrations determined from this line. Over 
the range of standards used, the intensity of fluorescence increased 
linearly with increase in concentration of norharman or tryptophan,with 
a correlation coefficient of 0.998 or greater (Figure 2) . 
·. 
FIGURE 2 
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A range of tryptophan standards (0 to 250 nmol/ml in 0.1 M NH40H) 
was incubated with FeC1 3 and formaldehyde in perchloric acid as 
described in the text, and the resulting fluorescence measured at 
excitation maximum 373 nm and emission maximum 452 nm. The corre-
lation coefficient r = 0.999. 
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Other amino acids. These were measured on a Beckman 120 C auto-
matic amino acid analyzer. Plasma was deproteinized with 10% salicyl-
sulphonic acid and 50 to 200 µl of the supernatant applied to the 
chromatographic columns. Neutralized brain extract (1 ml) was freeze-
dried and reconstituted with 0.2 M citrate buffer pH 2.2 before amino 
acid analysis. 
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Cyclic AMP. Cyclic AMP was determined using a protein binding 
assay (Cyclic AMP Assay Kit, Arnersham) according to the method of 
Tovey, Oldham & Whelan (1974) as modified from the original method of 
Gillman (1970). This assay is based on the competition between un-
labeled cyclic AMP in the sample and a fixed quantity of added tritium-
labeled compound for binding to a protein which has a high specificity 
and affinity for cyclic AMP. The amount of labeled protein-cyclic AMP 
complex formed is inversely related to the amount of unlabeled cyclic 
AMP present in the assay sample. Thus, measurement of the protein-
bound radioactivity enables the amount of unlabeled cyclic AMP in the 
sample to be calculated. Separation of the protein-bound cyclic AMP 
from the unbound nucleotide is achieved by adsorption of the free 
nucleotide on to charcoal, followed by centrifugation. An aliquot of 
the supernatant is then removed for liquid scintillation counting. The 
concentration of unlabeled cyclic AMP is determined from a linear 
standard plot, obtained by plotting Co/Cx versus concentration of un-
labeled standard cyclic AMP, where Co= counts bound in the absence of 
unlabeled compound, and Cx = counts bound in the presence of x pico-
moles of standard. A new standard line was determined each time the 
assay was performed, to check on the stability of the binding protein. 
This method gave high precision and reproducibility. Initial 
unsuccessful attempts were made with the Assay Kit from Boehringer 
Mannheim GmbH in which millipore filters are used to ad3~rb the 
protein-cyclic AMP complex. However, only negligible radioactivity 
was retained on the filters; this finding was confirmed by other 
users of the same method. 
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Insulin and glucagon. Standard radioimmunoassay techniques were 
used to measure plasma insulin (Weinkove, Weinkove & Pimstone, 1974) 
and glucagon (Unger, Aquilar-Parada, Mliller & Eisentraut, 1970). These 
assays were carried out by the Endocrine Laboratories of the Depart-
ment of Medicine, University of Cape Town Medical School. 
STATISTICAL ANALYSIS 
Differences between means were tested .for significance by using 
Student's t-test or the paired t-test where applicable (Snedecor & 
Cochran, 1967). Correlation coefficients were tested against the null 
hypothesis that .r = O. Calculations were carried out on a Tektronix 
calculator, provided with programs for statistical evaluations. Suit-
able programs were written for all other calculations. 
D. DESCRIPTION OF ANIMAL MODELS 
Although plasma samples may readily be obtained from patients 
with encephalopathy from acute or chronic liver disease, ·brain meta-
bolites can obviously not be measured until after death. Such post-
mortem measurements do not reflect the true in vivo situation. Cere-
brospinal fluid metabolites have been measured during hepatic en-
cephalopathy (Record, Chase, Curzon & Murray-Lyon, 1974: Lal, Young 
& Sourkes, 1975: Ono, Hutson, Dombro, Levi, Livingston & Zeppa, 
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1978) but there is some doubt about whether these are true indications 
of brain concentrations (Moir, Aschcroft, Crawford & Guldberg, 1970: 
Young, Etienne & Sourkes, 1976). Therefore, in order to study the 
cerebral effects of chronic and acute liver disease, suitable animal 
models are necessary. 
Requirements for a suitable model of hepatic encephalopathy in-
clude: 
(a) The method used should cause, as far as possible, selective 
liver damage. 
(b) The liver damage produced should be reproducible. 
(c) The time of onset of coma and death should be within a 
narrowly defined range. 
(d) The clinical symptoms and brain and plasma metabolite changes 
should be similar to those observed in patients with hepatic 
failure. 
(e) Ideally the liver damage and associated encephalopathy should 
be potentially reversible. 
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In general, surgical methods can be used to cause specific liver damage 
but usually involve considerable trauma and the damage caused is ir-
reversible. Chemical methods are less traumatic and simpler to use, 
but may involve tissues other than liver and are often less predictable. 
Table 4 gives examples of various methods used. 
The portacaval shunted dog and rat have been widely used to study 
chronic hepatic failure. The biochemical changes occurring after 
portacaval shunting in these animals are very similar to those found 
in patients with chronic hepatic encephalopathy. Experimental acute 
hepatic failure has been produced by surgical procedures such as 
hepatectomy or hepatic devascularization, i.e. portacaval shunt plus 
hepatic artery ligation, usually in two steps to reduce trauma. The 
response depends somewhat on the animal species used. This process, 
as with portacaval shunt alone, results in metabolite changes also 
seen in acute hepatic failure patients. The surgical trauma involved, 
however, remains a serious disadvantage of this method even when sham-
operated controls are used. In a recent study the selective hepatotoxin 
galactosamine was used to induce liver necrosis and fulminant hepatic 
failure in rabbits (Blitzer et al., 1977). In these experiments, 
death was preceded by a period of clinically obvious coma, which is 
not always evident after portacaval shunt plus hepatic artery ligation. 
Therefore galactosamine-induced hepatic necrosis seemed to be a 
suitable alternative to surgically induced liver failure for examining 
acute hepatic encephalopathy. 
In this section the various rat models used to study hepatic 
encephalopathy are described. Chronic hepatic failure was examined in 
rats four weeks after portacaval shunting, while acute hepatic failure 
TABLE 4 
STUDIES OF CHRONIC AND ACUTE HEPATIC FAILURE 
1. CHRONIC HEPATIC FAILURE 
Studies in man: Wu et al., 1955; Iber et al., 1957; Ning 
et al., 1967; Sherwin et al., 1974; Fischer et al., 1974; 
Maddrey et al., 1976; Ono et al., 1978. 
Studies in animals with portacaval shunts: 
Dogs: Fischer et al., 1975; Aguirre et al., 1974; Soeters 
et al., 1976b. 
Rats: Curzon et al., 1975b; James et al., 1976; Cununings 
et al., 1976a; Hindfelt et al., 1977. 
2. ACUTE HEPATIC FAILURE 
Studies in man: Record et al., 1976; Knell et al., 1974; 
Fischer et al., 1976. 

























Tyce et al., 1967 
Tyce et al., 1967; 
McMenamy et al., 1965 
Biebuyck et al., 1974 
Cununings et al., 1976b 
Dodsworth et al., 1974 
Mattson et al., 1968 
Iob et al., 1970 
Curzon et al., 1973b 
Buxton et al., 1974 
Miller et al., 1976 
Blitzer et al., 1978 
Chirito et al., 1977 
Aguirre et al., 1974 
Cacciatore et al., 1973 
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was produced either by portacaval shunt plus hepatic artery ligation 
or by galactosamine treatment. 
1. CHRONIC HEPATIC FAILURE 
PORTACAVAL SHUNT 
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The rats were anaesthetised and an end-to-side portacaval shunt 
constructed as described by Lee & Fisher (1961) and Lee, Arnot, Engel-
brecht & Terblanche (1973). Using clean, but not sterile, surgical 
technique, the abdomen was opened and the intestines retracted lateral-
ly to expose the vena cava and portal vein. These vessels were oc-
cluded after mobilisation, using rubber shod hemostats. An elliptical 
opening was made in the vena cava, the portal vein was severed after 
ligation of the end proximal to the liver, and an anastomosis was per-
formed with No. 7-0 braided silk attached to two three-eighths circle 
taper needles, using over-and-over stitches. The portal vein was com-
pletely occluded from 10 to 12 minutes. The patency of the shunt 
after four weeks was checked in four rats by performing a spleno-
portograrn (performed by Dr. R. Hickman, Department of Surgery). 
Sham-operated rats of the same weight served as controls. These 
rats were similarly anaesthetised and a laparotomy performed; the 
inferior vena cava and portal vein were isolated, simultaneously oc-
cluded for 12 minutes, and then released . 
. All rats recovered from the operation within 10 minutes. 
POST-OPERATIVE HANDLING 
The rats were housed for four weeks in individual metabolic cages 
which were constructed so that food consumption could be accurately 
monitored. The powdered food was supplied at the end of a narrow 
tunnel so that no food could be carried back into the main cage. 
Any food dropped in the tunnel fell through a grid into a trough, 
enabling all uneaten food to be weighed. 
Each sham-operated rat was paired with a shunted rat and given 
the amount of food consumed by the shunted rat during the previous 24 
hours. The rats were weighed twice weekly. At the end of the four 
week period the rats were anaesthetised with halothane (1.5% v/v in 
oxygen) and blood and brain samples obtained. The blood was taken 
from the abdominal aorta and the brain removed rapidly at room tem-
perature. The samples were then treated as described under General 
Procedures. 
WEIGHT LOSS AND BEHAVIOUR 
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The shunted rats lost about 10% of their pre-operative weight 
during the first 2-3 days after the operation. They continued to eat 
less food than normal rats and did not regain their pre-operative 
weight although w~ight loss became very slight or ceased after the 
first week. These findings were subsequently confirmed by others 
(Rossouw, Labadarios, Vinik & De Villiers, 1978). At the time of 
sampling there was no difference in mean percentage weight loss be-
tween the shunted rats and pairfed controls: 
portacaval shunt 
control 
-11.3 ± 2.3 (S.E.M.) (8 rats) 
-11.4 ± 1.4 (S.E.M.) (8 rats) 
Behaviourally the two groups of rats could not be differentiated. 
2. ACUTE HEPATIC FAILURE: SURGICALLY INDUCED 
The procedure of using a two-stage interruption of hepatic blood 
supply to induce acute hepatic coma was first described by Rappaport, 
McDonald & Barowy (1953) using dogs. The animals were subjected to 
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a side-to-side portacaval shunt and the hepatic artery was ligated 
24-48 hours later. Later work, using an end-to-side anastomosis 
followed by ligation of the hepatic artery one to ten days later, 
showed that coma only developed if the ligation occurred within 72 
hours after shunting (Giges, Dein, Sborov, Seligson & Howard, 1953; 
Turcotte et al., 1967). The dogs became comatose 16-24 hours after 
ligation. The degree of hepatic insufficiency and number of animals 
dying from hepatic coma could be altered by varying the time interval 
between the two stages. With a 24 hour interval nearly 100% mortality 
from coma resulted. With longer time intervals the percentage of 
animals in coma decreased, possibly due to a compensatory increase in 
the collateral arterial blood supply occurring after construction of 
the portacaval shunt (Mattson & Turcotte, 1969). 
The surgical mortality rate obtained with the two-stage ligation 
method was much lower than that obtained with other methods such as 
total hepatectomy or simultaneous occlusion of the hepatic arterial 
and portal venous blood supply (Mattson & Turcotte, 1969). In addi-
tion, many of the symptoms and biochemical abnormalities produced 
closely resembled changes seen in hepatic coma in man. 
Similar results were obtained in pigs after portacaval anastomo-
sis followed immediately by hepatic artery ligation (Curzon et al., 1973b; 
Buxton et al., 1974; Opolon, Lavallard, Huguet, Bidallier, Granger, Gallet 
& Bloch, 1976). After the operation, liver function was grossly 
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impaired, movements became uncoordinated and coma ensued. Most 
animals died 5~ to 8~ hours after the operation (Curzon et al., 1973b). 
In rats, acute hepatic failure has been induced by performing 
an end-to-side portacaval anastomosis followed 24 to 48 hours later by 
hepatic artery ligation (Fischer & Baldessarini, 1971; Dodsworth et al., 
1974; Funovics, Cummings, Shuman, James & Fischer, 1975). In these 
studies the rats appeared normal for about 4 hours and then became in-
creasingly somnolent and comatose, unresponsive to all but severe stim-
uli. They died in coma 6 to 12 hours after hepatic artery ligation. 
A similar method was used for the present studies. 
PROCEDURE 
The rats were subjected to a portacaval shunt or sham-operation 
as described for chronic hepatic failure. Postoperatively the rats 
were housed three to a cage with free access to food and water until 
sampling or hepatic artery ligation 65 hours after portacaval shunt. 
This time period allowed recovery from the first operation. The 
hepatic artery was ligated (Dodsworth et al., 1974) using halothane as 
anaesthetic (1.5% v/v in 02). At the same time catheters were inserted 
into the femoral vein for the administration of glucose (17 g needle, 
8 inch Deseret Intracath), and femoral artery for the removal of blood 
samples (19 g needle, 8 inch Davol catheter). Control rats were treat-
ed similarly except that the hepatic artery was not ligated. This pro-
cedure was completed within 20 minutes. Following hepatic artery 
ligation or sham-operation, the rats were placed in restraining cages 
and kept in a heated room to maintain rectal temperature at 37°C. 
Blood glucose levels were measured half hourly using Dextrostix and 
. 
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maintained between 4.5 and 6.5 rnM by giving 50% dextrose, diluted 
with normal saline, into the femoral vein. Blood glucose concentra-
tions started to decrease soon after hepatic artery ligation and un-
less additional glucose was given, decreased to below 2.5 rnM. To 
maintain normal glucose concentrations, 50-100 mg given half-hourly 
was usually sufficient. In the later stages there was often a more 
rapid decrease in blood glucose. Control rats did not require supple-
mentary glucose. At the time of brain sampling there was no differ-
ence in blood glucose concentrations between the two groups. The 
mean concentrations± S.E.M. in µmol/ml were: 
hepatic devascularization 
control 
4.91 ± 0.96 (8 rats) 
5.76 ± 0.22 (7 rats) 
The rats were sampled 4 to 7 hours after hepatic artery ligation 
when they were unresponsive to all but severe stimuli. One group of 
rats was sampled 65 hours after portacaval shunt, i.e. without 
ligation of the hepatic artery. Control rats were sampled at the 
same time after surgery as the corresponding shunted rats. The 
brains were removed by freeze-blowing or at room temperature and 
stored in liquid nitrogen until extraction. 
BODY WEIGHT LOSS 
During the two days following the shunting operation both the 






-9.8 ± 0.7 (S.E.M.) (25 rats) 
-10.4 ± 1.0 (S.E.M.) (14 rats) 
No change in behaviour was noted after portacaval shunt alone, 
or in the control rats, during the entire period of the experiment. 
After ligation of the hepatic artery, the rats behaved normally for 
the first three to four hours. Thereafter they became increasingly 
less active and unresponsive to stimuli. They were capable of being 
aroused but immediately returned to the inactive state. The EEG of 
several animals was monitored using a Cerebral Functions Monitor 
(Devices Instruments Ltd., 13-15 Broadwater Rd., Welwyn Garden City, 
Hertfordshire, England) and typical changes reported in patients 
(Kennedy, Parbhoo, MacGillivray & Sherlock, 1973) were not seen until 
immediately before death (6 to 9 hours after hepatic artery ligation) 
despite changes in behaviour. In order to avoid the secondary alter-
ations in cerebral metabolism induced by the terminal events of 
hypoxia and decreased cerebral blood flow, brain samples were taken 
during the period of altered behaviour described above. 
BRAIN OEDEMA 
The brain water content was determined in a separate series of 
rats. Portions of the brain were rapidly weighed and then heated in a 
hot-air oven until there was no further loss of weight. The% water 
was determined from the total weight loss. No evidence was found of 
brain oedema in the rats with acute hepatic failure as indicated by the 




76.82 ± 0.61 {S.E.M.) (5 rats) 
76.78 ± 1.2 {S.E.M.) (5 rats) 
40 
Oedema has been reported in rats 4-5 weeks after portacaval shunt 
{Cavanagh, 1974) as well as in patients dying of massive hepatic 
necrosis {Ware et al., 1971; Bernstein, 1976), while others found no 
increase in brain water content {Kindt, Brock, Altenau & Poll, 1977). 
In view of these findings, the results suggest that cerebral oedema is 
a sequel to and not a causative factor in the development of acute 
hepatic encephalopathy. 
3. ACUTE HEPATIC FAILURE: GALACTOSAMINE-INDUCED 
The hepatotoxin D-galactosamine {galN) has been shown to produce 
morphological and biochemical changes in the liver very similar to 
those found during human viral hepatitis (Keppler & Decker, 1969; 
Keppler, Lesch, Reutter & Decker, 1968; Reutter, Bauer, Kreisel & 
Lesch, 1971). It has been used to study metabolism and regulatory 
mechanisms of the liver cell. Because of its specificity and ability 
to cause massive liver necrosis, its use was recently suggested for 
producing a model of fulminant hepatic failure {Blitzer et al., 1977). 
In this study rabbits were injected intravenously with 4.25 mmoles/kg 
of galactosamine-HCl. Of 22 rabbits, 16 died between 22 and 41 hours 
after injection, 4 died between 48 and 89 hours, and 2 survived. In 
non-survivors a period of coma lasting 2.6 ± 4 {S.E.M.) hours preceded 
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death. Thes e results sugqcsted that gal.N mi qh t b e useful in provi ding 
an alternative model to the surgical one for studying a cute hepa tic 
coma. Therefore, the experiments described in this section we r e 
carried out. The main objectives were to establish a predictable rat 
model of acute hepatic coma, involving minimal surgical trauma, and 
to compare the metabolic changes with those found during surgically 
induced acute hepatic failure. 
BIOCHEMISTRY 
GalN is the 2-amino substituted form of galactose: 
6 CH20H 
2-amino-2-deoxy-D-galactose 
GalN cannot be detected as the free sugar in untreated animals, but 
is found as a constituent of glycoproteins and polysaccharides, e.g., 
hyaluronic acid, heparin and cerebral gangliosides, as the N-acetyl 
conjugate with other hexoses. When administered intraperitoneally or 
intravenously, galN is taken up by the liver and enters the galactose 
metabolism pathway. It is rapidly phosphorylated by liver galacto-
kinase: 
galactokinase 
1. GalN + ATP GalN-1-phosphate + ADP ---------
+--- -- UDP-galN + glucose-1-phosphate 2. GalN-1-phosphate + UDPG 
The second reaction is catalyzed by the enzyme galactose-1-phosphate: 
UDPG-uridylyltransferase which is nonspecific but has a low affinity 
for the unusual substrate. This low affinity and the limited supply 
of UDPG (derived from UTP) favour the accumulation of galN-1-phos-
phate. GalN-phosphate inhibits the enzyme UDPG-pyrophosphorylase 
which catalyzes the formation of UDPG from UTP: 
U'I'P + a-D-glucose-1-phosphate UDPG + PP. +------ 1 
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Therefore, as a result of galN-phosphate synthesis and accumulation, 
UDPG is depleted and its synthesis inhibited, further increasing the 
accumulation of galN-phosphate. UDP-galN is converted to UDP-glucosa-
mine by UDP~galactose-4'-epimerase: 
3. UDP-galN ----~ UDP-glucosamine 
UDP-glucosamine apparently does not serve as a uridylate donor (as does 
UDP-glucose which would be formed from galactose) so that UDP-hexosamine 
formation acts as a trap mechanism for uridylate. GalN-induced trapping 
of uridylate exceeds the compensatory capacity of uridylate biosynthesis 
about fourfold in the adult rat liver. Hence galN metabolism is associ-
ated with a rapid decrease in the concentrations of UDPG, UDP-galactose, 
UTP, UDP, UMP and UDP-glucuronate. Hepatic UTP levels drop to 20% of 
normal 15 minutes after an intraperitoneal injection of galN and to 7% 
after 30 minutes (Decker & Keppler, 1972). Control levels are reached 
again about 20 hours after a single dose. Only if concentrations of 
UTP or UDP-glucose remain below a critical level of about 25-30% of 
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normal for several hours will signs of cell damage appear later (Decker, 
Keppler, Rudigier & Dornsche, 1971) . 
Further metabolites UDP-N-acetyl-glucosarnine and UDP-N-acetyl-
galN accumulate after galN-adrninistration but these substances them-

















Uridylate deficiency results in depression of uracil nucleotide-
dependent biosynthesis of macromolecules such as nucleic acids, glyco-
proteins, glucolipids in rnernbranes,and glycogen, which is almost corn-
pletely exhausted in liver cells of treated animals. Organelle injury 
in viable cells results, leading to liver necrosis. Necrosis of single 
liver cells is evident at 6 hours after a single dose of galN (Koff, 
Gordon & Sabesin, 1971). After 26 hours all histologic signs of a 
spotty necrotic hepatitis are present, with an increase in hepato-
cellular fat when higher doses are used (Koff et al., 1971). The 
histologic changes are more severe 48 hours after injection and re-
semble those seen in acute liver necrosis (Keppler et al., 1968). 
In surviving animals the liver morphology returns to normal within 
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· 7 to 12 days. Repeated injections of galN can lead to hepatic cirrho-
sis in 6 months (Lesch, Keppler, Reutter, Rudigier, Oehlert & Decker, 
1970). 
No damage to other organs has been observed in rats except for 
frequent haemorrh<1gcs ·in gut and stomach, probably due to prothrornbin 
deficiency (Keppler et al., 1968). 
PROCEDURE 
The rats were anaesthetised with halothane in oxygen and the 
femoral vein cannulated with a Bardi-Cath catheter (17 gauge needle). 
The galN solution was injected very slowly to prevent osmotic shock. 
Some rats were given a second dose 3-12 hours later and these were 
placed in restraining cages and the femoral line kept open by a very 
slow 0.9% sodium chloride infusion (0.6 ml/hour) until the second 
dose had been given. Control rats were given an equal volume of 0.9% 
sodium chloride solution. After dosing, the catheter was removed and 
the animals housed three to a cage with free access to food and water. 
The dose of galN given ranged from 1 to 2~ g/kg body weight in a 
volume of 1-2 ml. GalN (as the hydrochloride salt) was dissolved in 
0.1 M NaOH solution and brought to pH 7.4 with 1.0 M NaOH solution. 
The solution was injected at room temperature . 
. 
Metabolite concentrations were determined in samples obtained 
from rats given 2 g/kg galN in two doses three to six hours apart. 
These rats were divided into two groups based on their behaviour at 
the time of sampling, i.e. a "precoma" and a "coma" group (defined 
below) . The results from the two groups ~,ere combined except where 
stated otherwise. At the time of sampling (some animals required 
light anaesthesia with halothane) four ml blood was sampled from the 
abdominal aorta through a large needle. The skull was then opened 
and the brain rapidly removed and placed in liquid nitrogen. The 
blood and brain samples were treated as described under General 
Procedures. Samples of liver, kidney and spleen were taken from 
several animals and kept in formalin buffered to pH 7 for routine 
histological evaluation. 
CLINICAL FEATURES 
The rats recovered rapidly after dosing and remained normally 
active for the first 24 hours, exc·ept for a loss in weight of about 
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10 g. Thereafter they showed signs of increasing drowsiness; they 
developed staring fur, their food intake decreased, and they continued 
to lose weight. They became progressively less responsive to stimuli 
until they lapsed into a clearly distinguishable coma 30 to 60 hours 
after the first galN dose. Death occurred 1-2 hours later. (For 
sampling purposes, coma was defined as the completely unresponsive con-
dition. Rats responsive to severe stimuli only, and expected to become 
comatose during the next few hours, were defined as precomatose.) There 
was a large variation in time of response which was partly related to 
the amount of galN given and the weight of the rat. The most consistent 
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response was obtained by giving 2 g/kg in 2 doses 3-6 hours apart to 
rats weighing 340 to 350 g. (It has been shown that for liver cell 
damage to occur, the hepatic uridylate concentrations must be de-
pressed below 30% of normal for several hours [Decker & Keppler, 1974]. 
This could be the reason for the improved response when divided doses 
were given.) Of 29 rats given 2 g/kg in 2 doses 3-6 hours apart, 16 
rats (55%) became comatose between 30 and 48 hours after the first in-
jection, 11 rats (38%) between 48 and 60 hours, and 2 rats (7%) re-
covered completely from the treatment. Younger rats were more re-
sistant to the drug probably because of higher rates of hepatic uri~ 
dylate biosynthesis (Keppler & Decker, 1971). For example, when 6 
rats weighing 245-255 g were given 2 g/kg galN, only one became coma-
tose. The other 5 rats recovered completely although all lost about 
15 g weight during the first 48 hours and 3 showed signs of drowsiness. 
HISTOLOGY 
At the time of sampling the livers appeared pale and faintly 
speckled. Light microscopic examination showed massive cell necrosis, 
inflammation, haemorrhage, and fatty infiltration, with no evidence of 
mitochondrial activity. These findings agree with those previously 
reported (Keppler et al., 1968: Koff et al., 1971). No abnormality 
was seen in kidney or spleen tissue. In some rats there was evidence 




Chronic hepatic failure induced by portacaval shunting results 
in many biochemical changes also seen in human chronic hepatic 
encephalopathy. Another manifestation of both the experimental and 
the human condition is an increase in brain astrocytes showing the 
Alzheimer Type II change. For these reasons the portacaval-shunted 
rat has been widely studied as a model of chronic hepatic enceph-
alopathy. Whether it truly represents the syndrome of confusion, 
stupor and delirium observed in humans, is uncertain, since, cer-
tainly in this study, there were no obvious behavioural abnormalities 
in the shunted rats. Sophisticated behavioural monitoring may be 
the only way to answer this question. 
The surgical model of inducing acute hepatic failure similarly 
results in metabolite changes, including hypoglycaemia,also seen in 
acute hepatic failure patients. In addition these rats showed clear 
signs of brain dysfunction, although a completely unresponsive state 
was not reached in most cases. The surgical trauma involved however 
remains a serious disadvantage of this method even when sham-operated 
controls are used. The use of galactosamine therefore appeared to be 
promising. The surgical manipulation was minimal in comparison to 
portacaval shunting plus hepatic artery ligation, and since the method 
was a completely different one it was interesting to see if similar 
biochemical and behavioural results would be obtained. The biochemical 
alterations were in fact very similar in the two models (see next two 
sections) indicating that these changes were due to liver failure and 
not the result of either surgical manipulation or the drug treatment. 
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Another advantage of using galactosamine was that the rats 
lapsed into a distinguishable coma before death. A disadvantage of 
the method was the wide variation in time of response which prevented 
adequate monitoring of physiological parameters such as temperature 
and blood glucose in the terminal stages. Intermittent monitoring 
of the EEG by means of implanted electrodes may be one way of follow-
ing the mental state and approaching coma in this model. 
RESULTS SECTION I 
NEUROTRANSMIT!'ERS: RELATED TO AMMONIA METABOLISM 
Ammonium ion has long been a favourite candidate as the primary 
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aetiologic agent in the development of hepatic encephalopathy. During 
liver disease with encephalopathy, ammonia concentrations are in-
creased in the blood and cerebrospinal fluid (McDermott, 1958; Caesar, 
1962; Plum & Hindfelt, 1976). Patients with liver damage are espe-
cially sensitive to the cerebral toxic effects of ammonia and often 
show intolerance of protein ingestion (Breen & Schenker, 1972). This 
evidence favoured the role of ammonia and its metabolism in the patho-
genesis of hepatic coma. However, it is now generally believed that 
ammonia, although toxic to the brain, is not entirely or even primar-
ily responsible for the development of hepatic coma. The correlation 
between ammonia blood levels and grade of hepatic encephalopathy is 
often poor and blood ammonia concentrations may be normal during 
severe encephalopathy (Phear, Sherlock & Summerskill, 1955; Summer-
skill, Wolfe & Davidson, 1957). 
Brain metabolism of ammonia occurs by the formation of glutamate 
and glutarnine according to the reactions: 
a.-ketoglutarate + NH4+ + NADH ~g_l_u_t_a_m_a_t_e~~--,. g
lutamate+ NAD+ 
dehydrogenase 
glutamate + ATP 
glutamine 
synthetase 
glutamine + ADP + p. 1 
A number of basic cerebral mechanisms were suggested for ammonia 
toxicity. The first and most widely accepted hypothesis was that NH4+ 
impaired brain energy metabolism and thus led to a decrease in the 
available high energy phosphates (Bessman & Bessman, 1955; Breen & 
Schenker, 1974). Increased glutamine synthesis due to elevated NH4+ 
levels may hypothetically interfere with brain energy metabolism by 
various mechanisms: 
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a. a-Ketoglutarate may be diverted from the Krebs cycle at such 
a rate that substrate depletion occurs within the cycle, 
resulting in a slower rate of oxidation. 
b. NADH availability for oxidation in the electron transport 
chain may be decreased, thereby lowering oxygen consumption 
and energy production. 
c. 1be amidation of glutamate to glutamine is ATP-consuming, 
increasing the energy demands of the tissue. 
The hypothesis that NH4+ causes encephalopathy by interference with 
brain energy metabolism as outlined above is no longer tenable for 
various reasons: it has been established that there is no shortage of 
high energy intermediates in experimental hepatic coma (Biebuyck et al., 
1974); no distinctive abnormality of glucose oxidative metabolism could 
be found in dogs in hepatic coma after hepatectomy (Zieve et al., 1975); 
and NH4+ intoxication does not lead to depletion of a-ketoglutarate or 
cause primary energy failure (Hindfelt et al., 1977; Hindfelt & Siesjo, 
1971a; Hawkins et al., 1973). In addition, synthesis of glutamine 
appears to use a small pool of glutamate that is rapidly turning over 
rather than the larger pool derived from a-ketoglutarate in the Krebs 
cycle (Berl & Clarke, 1969). Regional brain depletion of ATP and 
creatine phosphate has been reported (Schenker et al., 1967; Zieve, 
Zieve & Gilsdorf, 1972) and implicated in the development of coma 
(Schenker et al., 1974). However, the interpretation of these results 
has been complicated by the various methods used for sampling brain 
tissue and investigating brain high-energy phosphates. 
Other possibly toxic effects of ammonia have been suggested such 
as inhibition of the synthesis of acetylcholine by inhibition of 
pyruvate decarboxylase and depletion of ATP, thus diminishing acetyl 
CoA. However, in ammonia-intoxicated animals no changes in these 
metabolites have been noted (Schenker et al., 1967). A third sug-
gestion is that the ammonium ion exerts a direct toxic effect on the 
neuronal membrane by competition with K+ (Skou, 1962). In vitro 
auunonia decreases ATP-ase activity and could. therefore disturb 
energy-dependent Na-K flux across the membrane (Skou, 1962). This 
possibility is so far untested. 
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During hepatic failure, changes have also been found in several 
amino acids associated with the metabolism of ammonia, specifically 
glutarnine, glutamate, aspartate, y-aminobutyrate (GABA) and a-keto-
glutararnate (see Figure 3 for interrelationships). Glutamine is in-
creased in plasma, cerebrospinal fluid and brain during hepatic enceph-
alopathy in man and experimental animals (Hourani, Hamlin & Reynolds, 
1971; Biebuyck et al., 1974; Record, Buxton, Chase, Curzon, Murray-
Lyon & Williams, 1976). In contrast to ammonia, a fairly good correla-
tion between glutamine and the degree of encephalopathy has been re-
ported (Hourani et al., 1971). Glutamate and aspartate were decreased 
during acute hepatic failure in dogs (Mattson et al., 1968) and rats 
(Biebuyck et al., 1974). Glutamate was decreased three weeks after 
portacaval shunting in the rat (Hindfelt et al., 1977). Similar 
changes have been found in ammonia-induced coma in rats (Hindfelt & 
Siesjo, 1971a; Schenker et al., 1967). In fulminant hepatic failure 
FIGURE 3 
INTERRELATIONSHIPS BETWEEN AMMONIA AND 
THE GLUCOSE-DERIVE.D AMINO ACIDS 
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methionine 
su lphoxi mine 
in man aspartate was decreased in the brains of some patients (Record 
et al., 1976). 
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These changes are of great interest in view of the postulated 
neurotransmitter roles of several of the amino acids associated with 
the metabolism of ammonia, namely GABA, glutamate and aspartate (Curti.s 
& Johnston, 1970; Hebb, 1970; Snyder, Young, Bennett & Mulder, 1973; 
DeFeudis, 1975; Davidson, 1976). These amino acids, as well as glycine 
and taurine, are unique among amino acids in that they all have 
specialized high-affinity uptake systems in mammalian brain in addition 
to being transported by relatively nonspecific low-affinity transport 
systems as are the other amino acids (Iversen, 1971; Logan & Snyder, 
1972). Since similar high-affinity systems are found for the neuro-
transmitter amines, this is strongly suggestive that these systems 
may play a role in terminating the actions of the amino acids after 
their synaptic release, as with the catecholamines at adrenergic synapses. 
a-Ketoglutaramate is derived from glutamine by the removal of an 
amine group (see Figure 3). Its concentration is increased in the 
cerebrospinal fluid of patients with encephalopathy (Vergara, Plum & 
Duffy, 1974) and the suggestion was made that it could exert a toxic 
effect by competition with glutamate for post-synaptic receptors. The 
finding that methionine sulphoximine, which inhibits glutamine synthe-
tase (see Figure 3), could reduce ammonia toxicity in mice (Warren & 
Schenker, 1964), seemed to fit . in with this suggestion. However, when 
a-ketoglutaramate was perfused into cerebral lateral ventricles of rats, 
coma was not produced, although depressed nocturnal locomotor activity 
resulted (Duffy, Vergara & Plum, 1974). More recently it was found 
that a-ketoglutaramate neither alters cerebral cortical synaptic 
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activity nor impairs the metabolism of cerebral tissue slices and is 
therefore probably a nontoxic byproduct (Plum, 1978). 
Attention was recently focused on a completely different sub-
stance, cyclic AMP, which seems to be involved in neurotransmission 
in various ways, and which was found to be greatly increased during 
anaesthesia (Biebuyck, Dedrick & Scherer, 1975). 
The changes in brain concentrations of ammonia and the ammonia-
related putative neurotransmitter amino acids as well as cyclic AMP, 
observed during hepatic failure, are discussed in this section. 
RESULTS 
Table 5 shows the concentrations of brain NH4+ and its metabolites 
in rats four weeks after portacaval shunt and in controls. There were 
significant increases in NH4+ (2.5-fold) and glutamine (nearly 3-fold) 
after portacaval shunt. A small but significant decrease was found 
in aspartate. No changes were found in concentrations of GABA or 
glutamate. In an earlier study of the portacaval shunted rat similar 
results were found; however, in this study there were decreases in 
glutamate but not aspartate (Hindfelt et al., 1977). On the other 
hand, aspartate was decreased during ammonia-induced precoma and coma 
in rats with portacaval shunts (Hindfelt et al., 1977). 
The concentrations of brain ammonia and metabolites after porta-
caval shunt alone, after hepatic devascularization, and in control 
rats, are presented in Table 6, while results from the galN study are 
shown in Table 7. (Since there was no difference in these metabolites 
between the coma and precoma groups, the two groups were combined for 
this table.) 
TABLE 5 
CHANGES IN BRAIN AMMONIA AND ITS METABOLITES DURING CHRONIC HEPATIC 
FAILURE 
All rats were sampled four weeks after portacaval shunt (pcs) or 
sham-operation (control). The results are expressed in µmol/g wet 
weight tissue as the mean± S.E.M. with the number of rats in 
parenthesis. Results significantly different from control are indi-
cated by *p<0.01, **p<0.001. 
Control Pcs 
NH4+ 0.40 ± 0.04 (7) 0.97 ± 0.10 (9) ** 
Glutamine 5.85 ± 0.30 (11) 15.9 ± 1.0 (13) ** 
Glutamate 10.5 ± 0.4 (11) 10.1 ± 0.4 (13) 
Aspartate 2.50 ± 0.08 (8) 2.16 ± 0.07 (4)* 






















































































































































































































































































































































































































































































































































































































































































































































































































































































BRAIN AMMONIA AND METABOLITES DURING GALACTOSAMINE-INDUCED ACUTE 
HEPATIC ENCEPHALOPATHY 
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Brain samples were taken 30-60 hours after the first galactosamine 
injection when the animals were unresponsive, or after sodium chloride 
injection (controls). The results are expressed in µmol/g wet weight 
tissue as the mean± S.E.M. with the number of rats in parenthesis. 
Results significantly different from control are indicated by *p<0.01; 
**p<O. 001. 
Control EncephaloEath:t: 
NH4+ 0.43 ± 0.04 (6) 1.18 ± 0.15 (20)** 
Glutamine 5.35 ± 0.30 (18) 13.90 ± 0.98 (21)** 
Glutamate 10.39 ± 0.36 (11) 9.39 ± 0.30 (21)* 
Aspartate 2.80 ± 0.26 (8) 2.50 ± 0.07 (19) 
GABA 2.51 ± 0.11 (15) 2.54 ± 0.12 (21) 
Significant increases in NH4+ and glutamine were found 65 hours 
after portacaval shunt alone before the onset of any obvious signs 
of encephalopathy, while hepatic artery ligation produced further 
increases in these two substances to 8-fold and 3-fold normal re-
spectively. Very similar results were obtained in galN-induced 
hepatic encephalopathy (Table 7) although the increase in NH4+ was 
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not as great (3-fold). These results agree with previous reports of 
increased brain ammonia and glutamine during acute hepatic failure in 
the rat (Biebuyck et al., 1974) and increased glutamine in man (Record 
et al., 1976). Portacaval shunt alone resulted in no other significant 
changes in anunonia-related metabolites. Changes in brain aspartate 
and glutamate concentrations during acute hepatic failure were con-
flicting in the two models. After hepatic devascularization there was 
a 31% decrease in aspartate but no significant change in glutamate 
(Table 6). In contrast, galN treatment resulted in slightly decreased 
glutamate but unchanged aspartate (Table 7). Biebuyck et al. (i974), 
using the devascularization method of producing acute hepatic failure, 
found a decrease both in aspartate and in glutamate concentrations. 
Both substances were decreased during acute hepatic failure in dogs 
(Mattson et al., 1968) while glutamate was significantly increased and 
aspartate unchanged in patients with fulminant hepatic fai·lure (Record 
et al., 1976). From all these results and those found during chronic 
hepatic failure, it is apparent that although changes in either one or 
both of these substances is often associated with hepatic failure, 
these are not consistent in the various studies (see Table 8). 
A significant increase was also seen in GABA in the rats with 
hepatic devascularization, which has not been previously reported. No 
TABLE 8 
SUMMARY OF CHANGES FOUND IN BRAIN ASPARTATE AND GLUTAMATE DURING 
HEPATIC FAILURE 
Species Condition Aspartate Glutamate Reference 
Rat 4 weeks pcs + unchanged Present study 
Rat 3-8 weeks pcs unchanged + Hindfelt et al., 
Rat 8 weeks pcs + + + Hindfelt et al., 
NHr./ 
Rat Hep. devasc. + unchanged Present study 
Rat GalN-necrosis unchanged + Present study 
Rat Hep. devasc. + + Biebuyck et al. , 






Man1 Fulminant unchanged + Record et al., 1976 
hepatic failure 
1Brain samples obtained within one hour of death. 
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change was found in a similar study (Biebuyck et al., 1974) or in the 
galN model. Therefore, the possibility was considered that the change 
observed was the result of the delay in brain freezing since some of 
the rats were not sampled by freeze-blowing. Post-mortem increases 
in GABA have been ~eported when samples were not frozen within 60 
seconds (Minard & Mushahwar, 1966; Alderman & Shellenberger, 1974), 
although others found no change even when brains were dissected on a 
cold stage (Nicklas & Berl, 1973). In the present studies, when 
values were compared from test and control animals all sampled at room 
temperature, a significant increase was still obtained (Table 9). 
When only rapidly sampled brains from test and control animals were 
compared the difference was only significant at the level of p = 0.19. 
No significant difference was obtained when rapidly sampled and slowly 
sampled brains were compared in each group. Thus, although the present 
results must be interpreted with caution, they do suggest that possible 
changes in GABA during hepatic encephalopathy cannot be ruled out. 
The changes in brain concentrations of ammonia and the amino acids 
in the various models of acute and chronic hepatic failure compared 
to control rats are shown in Figure 4. It can be seen that qualita-
tively similar results are obtained in both chronic and acute hepatic 
failure. The similarity of the changes produced by the two entirely 
different models of acute hepatic encephalopathy is striking. 
CYCLIC AMP (cAMP) 
cAMP was measured only in rats sampled by freeze-blowing since 
rapid post-mortem increases occur (Breckenridge, 1974; Nahorski & 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































found between control rats and those with portacaval shunt alone or 
hepatic devascularization (Table 10). These findings confirm those 
of Biebuyck et al. (1974) in a similar rat model of acute hepatic 
failure. 
DISCUSSION 
Increased brain ammonia was a prominent feature of all the forms 
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of hepatic failure studied. The increase was greater in acute hepatic 
failure where brain dysfunction was more obvious than in chronic 
hepatic failure. However, during galN-induced encephalopathy where 
the rats clearly became comatose, brain ammonia concentrations were 
not as high as after hepatic devascularization, supporting earlier 
reports that the correlation with the development of encephalopathy 
is not exact. From other evidence it is clear that NH4+ per se is 
not the main cause of encephalopathy. However, since it is known to 
be toxic to the brain, and hepatic failure is closely associated with 
changes in brain concentrations of ammonia itself as well as its 
metabolites, its possible involvement in this condition cannot be 
ignored. Ammonia may affect the pools of its metabolites which have 
neuroregulatory functions,and thus influence brain activity. 
The brain metabolite showing the next largest increase during 
hepatic failure was glutamine, which showed changes that paralleled 
those of NH4+. The size of the increase observed correlated roughly, 
although not absolutely, with the extent of brain dysfunction (higher 
concentrations were seen after hepatic artery ligation than after 
portacaval shunt alone,but in the galN series the coma group showed 
similar increases to the precoma group). Altered glutamine 
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TABLE 10 
BRAIN CYCLIC AMP DURING ACUTE HEPATIC FAILURE 
The experimental details are as described in Table 6 except that all 
brains were sampled by freeze-blowing. cAMP concentrations are given 
in nmol/g wet weight tissue as the mean± S.E.M. with the number of 
rats in parenthesis. The differences between the means were not 
found to be significant. 
Pcs group Hepatic devascularization group 
Sham-operation (8) 
1.55 ± 0.36 
Pcs (8) 
1. 26 ± 0.13 
Sham-operation (8) Hep. devasc. (11) 
1.13 ± 0.05 1.37 ± 0.29 
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concentrations could contribute to the development of encephalopathy 
in several ways. Under normal conditions glutamine may regulate the 
level of glutamate and consequently also of GABA (Shank & Aprison, 
1977). The observation that glutaminase is an allosteric enzyme that 
is activated by phosphate, ammonia and nucleoside triphosphates, and 
inhibited by glutamate, suggests that the conversion of glutamine to 
glutamate is normally under fine metabolic control (Cooper, Bloom & 
Roth, 1978). Glutamine itself does not appear to have neurotransmitter 
activity. When glutamine was applied iontophoretically to nerve cells 
(Curtis & Crawford, 1969) or to brain slices (Bradford & Mcillwain, 
1966), it was found to be inactive. However, some reports suggest 
that glutamine may have CNS depressant effects. Cerebral glutamine 
levels decreased during stimulation of the mammalian CNS and parenteral 
glutamine tended to suppress certain features of cerebral excitation 
(Dobkin, 1972). Inhibition of glutamine synthesis with methionine 
sulphoximine can produce seizures (Sellinger & Weiler, 1963). A role 
for glutamine as a possible "false neurotransmitter" in hepatic coma 
has been suggested (Baldessarini & York, 1974). These authors found 
that glutamine was taken up by isolated nerve endings from rat brain 
and could inhibit glutamate transport. The possibility was suggested 
that glutamine could interfere with normal neurotransmission by 
accumulating in nerve endings in which glutamate is an excitatory 
neurotransmitter. The reports that glutamine itself is electro-
physiologically inert supports this idea as do the findings that 
inhibition of glutamine synthetase with methionine sulphoximine 
can reduce the toxicity of ammonia in mice, while leading to increased 
levels of brain ammonia but decreased levels of glutamine (Warren & 
Schenker, 1964). Even if glutamine metabolism is primarily localized 
in glial cells (discussed below) it is possible that excesses might 
be secondarily taken up by nerve terminals and accumulate there at 
the expense of other amino acids such as glutamate to act as a 
relatively inactive or "false neurotransmitter" (Baldessarini & York, 
1974). Finally, glutamine may be involved in changes in blood-brain 
barrier function as described in the General Discussion. 
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Glutamate and aspartate occur in uniquely high concentrations in 
the . brain. Their function as excitatory neurotransmitters has received 
much support (Johnson, 1972; Snyder et al., 1973; Curtis & Crawford, 
1969; Bradford, 1970; Krnjevic, 1970) but has not been clearly 
established. There is much evidence that glutamate is an excitatory 
transmitter in invertebrate systems but similar evidence for mammalian 
systems is deficient. Because glutamate and aspartate are also in-
volved in intermediary metabolism it is extremely difficult to dissoci-
ate this role from the role in transmission. These amino acids are 
not restricted to a particular type of neuron as are acetylcholine 
and noradrenaline, although they are unequally distributed throughout 
the brain (Liebschutz et al., 1977). High affinity uptake systems 
have been shown to exist for glutamate and aspartate (Logan & Snyder, 
1972) and when applied externally to nerve cells they exert powerful 
stimulatory effects on neuronal activity (Krnjevic & Phillis, 1963). 
However, some evidence suggests that this depolarising response 
represents a nonspecific receptivity of the neurons to those agents 
and is therefore not indicative of transmitter function (Cooper et al., 
1978). Others have suggested a "neuromodulator" rather than a "neuro-
transmitter" role for these and other neuroactive amino acids (Florey, 
1967; Schrier & Thompson, 1974). Neuromodulators are described as 
compounds which amplify or dampen neuronal activity while neuro-
transmitters convey information between adjacent nerve cells (Barchas 
et al., 1978; Florey, 1967). Neuromodulators could be released from 
neurons or glia and set the "tone" of local synaptic activity by 
altering the effectiveness of a neurotransmitter (e.g. by affecting 
transmitter synthesis, release, receptor interactions, reuptake, or 
metabolism). Whatever the true functions of glutamate and aspartate, 
it is clear that changes in the concentrations of these substances 
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may have important effects on brain function. As Table 8 shows, 
alterations during hepatic failure usually involve a decrease in 
either glutamate or aspartate or both. The close metabolic relation-
ship between these two substances (Figure 3) may account for the find-
ing that in one model of acute hepatic failure glutamate only was de-
creased while in the other it was aspartate. 
It has been established that there exist at least two pools of 
glutamate; a small pool thought to be glial, and a larger one that is 
neuronal (Benjamin & Quastel, 1974; Hosli & Hosli, 1976). It is not 
known with any certainty how the pools relate to the various activities 
of this amino acid. Synthesis of GABA is thought to occur in the 
larger compartment which preferentially uses glucose as a substrate. 
Glutamine synthesis occurs in the smaller, possibly glial, compartment. 
Much evidence has been presented that the metabolism of glutamine is 
associated with glial cells (Benjamin & Quastel, 1972). It has been 
suggested that the glutamate is released from neurons on electrical 
stimulation, is taken up by the glia and converted into glutamine. 
Glutamine is taken up by the neurons where presumably annnonia is 
. " .. 
released and glutamate reformed. Several findings support this 
suggestion: 
1. 15N from an administered ammonium salt is preferentially 
incorporated into the "small" glutamate pool that is con-
verted into glutamine (Hindfelt, 1975). 
2. The main pool of glutamine in the brain is found to be 
located in the glia while the major pools of glutamate, 
aspartate, glycine and serine are found in the neurons 
(Benjamin & Quastel, 1972). 
3. Glutamine synthetase has been found to be localized in 
glial cells while none could be found in neuronal cell 
bodies, endothelial cells or choroid epithelium (Martinez-
Hernandez, Bell & Norenberg, 1977). 
4. Cultured glial cells can take up glutamate and aspartate 
(Hosli & Hosli, 1976; Schrier & Thompson, 1974). 
Thus glial cells may play a role in modulating neuronal excitability 
in the CNS by regulating the extracellular level of neurotransmitters 
(Schrier & Thompson, 1976). In this respect it is interesting that 
an abundance of glial cells showing the Type II Alzheimer change is 
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a very frequent morphological finding in chronic hepatic encephalopathy 
(Cavanagh, 1974; Schenker et al., 1974) in the absence of any other 
morphological changes. If the ammonia removing functions pf glutamine 
synthesis were compartmented in the glia, proliferation and dilation 
of these cells might be a response to consistently elevated ammonia 
levels. Because of their situation in close proximity to or surrounding 
the cerebral capillaries, glial cells are the first to be exposed to 
ammonia as it passes into the brain . 
The decarboxylated form of glutamate, GABA, is also found in 
large quantities in the brain (in µmole amounts compared to the nmole 
amounts of the monoamines). In addition, GABA is found in no other 
tissue but the CNS and retina. Like the monoamines it has a discrete 
distribution within the CNS. There is good evidence that GABA func-
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tions as an inhibitory transmitter in crustacea and a similar role ha s 
been postulated for it in mammalian systems. Considered as a whole 
the evidence which now favours GABA in this role is impressive although 
not conclusive (Curtis & Watkins, 1965; Hebb, 1970; Iversen & Kelly, 
1975; Cooper et al., 1978; Krnjevic, 1970). Studies on GABA uptake 
showed that the amino acid was selectively taken up only into certain 
nerve terminals, which suggested that these terminals represented 
those normally storing and using GABA as a transmitter (Iversen & Bloom, 
1972). In addition to being a post-synaptic inhibitory transmitter, 
it has been postulated that GABA is involved in the production of 
presynaptic inhibition by depolarising nerve terminals and thereby 
preventing release of transmitter (Davidson, 1976). In view of these 
findings, the increase in concentration found after hepatic devas-
cularization in the present study is interesting. However, as dis-
cussed in the Results section, it is not certain whether the observed 
increase was a true in vivo effect. 
Changes in total brain content of metabolites in abnormal con-
ditions may not accurately reflect changes in function of the various 
systems due to compartmentation of the metabolites into functionally 
separate pools. Thus, localized changes, either at the regional or 
cellular level, may be more significant in determining brain function. 
In addition, the brain undoubtedly has many homeostatic mechanisms for 
the maintenance of neurotransmitter concentrations, and therefore it 
would seem that at least in the cases of GABA and glutamate, changes 
in the activities of these systems would not necessarily lead to 
substantial changes in total concentrations within the brain. Infor-
mation about functional turnover is needed before conclusions may 
be drawn about their activities (Davidson, 1976; Cooper et al., 1978). 
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The same remarks might apply to the study of cyclic AMP which is 
becoming increasingly important in consideration of CNS transmission. 
In addition to its role as a "second messenger" (Greengard, 1976) it 
has recently been suggested that cAMP may function as a synaptic 
modulator involving glial cells (Iversen, 1974). According to this 
hypothesis cAMP released from the glial cells surrounding the Purkinje 
neurons may mediate the well-known inhibitory effects of noradrenaline 
on these neurons. This would involve the release of and an external 
site of action for cAMP which in other systems is thought of as a 
strictly intracellular messenger. In addition it means that the glia 
would be capable of responding to a neurotransmitter substance, a con-
cept that has not been previously considered. 
The uniform elevation of brain cAMP during anaesthesia caused by 
several diverse anaesthetic agents (Biebuyck et al., 1975) prompted 
the study of cAMP in another form of unconsciousness. It is of interest 
therefore that no significant changes in brain cAMP content were found 
during hepatic failure. As indicated above, however, this finding 
does not rule out any changes in activity of cAMP in this condition. 
RESULTS SECTION II 
NEUROTRANSMITTERS: RELATED TO PLASMA/BRAIN 
AMINO ACID RELATIONSHIPS 
Alterations in brain concentrations of the neurotransmitters 
serotonin and the catecholamines are common findings in all forms of 
hepatic encephalopathy (Cummings, Soeters, James, Keane & Fischer, 
1976a; Cummings, James, Soeters, Keane, Foster & Fischer, 1976b; 
Dodsworth et al., 1974; Curzon et al., 1975a). Concentrations of the 
precursors for these neurotransmitters, the essential aromatic amino 
acids tryptophan, tyrosine and phenylalanine, are also changed, both 
in brain and blood, during hepatic failure (Rosen, Soeters, James, 
Hodgman & Fischer, 1978; Curzon, ~ntamaneni, Winch, Rojas-Bueno, 
Murray-Lyon & Williams, 1973b). Changes in serotonin metabolism 
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have been especially consistent. Portacaval shunting in the rat re-
sulted in large increases in brain tryptophan and 5-hydroxyindoleacetic 
acid (5-HIAA, the major product of serotonin catabolism) and smaller 
but significant increases in serotonin (Cummings et al., 1976a; Curzon 
et al., 1975a; Baldessarini & Fischer, 1973; James et al., 1976; 
Rosen et al., 1978). Similar changes have been found during acute 
hepatic failure in the rat (Fischer, James & Baldessarini, 1972; Tyce, 
Flock & Owen, 1967; Cummings et al., 1976b) and the pig (Curzon et al., 
1973b). These findings, and the known toxicity of oral tryptophan in 
hepatic failure (Ogihara, Mozai & Hirai, 1966; Condon, 1971), led to 
the suggestion that changes in hydroxyindole metabolism in the brain 
are involved in the development of hepatic encephalopathy (Curzon 
et al., 1975a; Baldessarini & Fischer, 1973; Cummings et al., 1976a,b). 
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In the brain, serotonin synthesis appears to be regulated by the 
availability of free tryptophan, due to the low K of the rate-limiting m . 
enzyme in the synthetic pathway, tryptophan hydroxylase, which appears 
to be normally unsaturated with tryptophan (Friedman, Kappelman & 
Kaufman, 1972). The systemic administration of tryptophan increases 
whole brain concentrations of serotonin up to a maximum (Fernstrom 
& Wurtman, 1971a; Moir & Eccleston, 1968). Many drugs and changes in 
physiological variables produce parallel changes in brain tryptophan 
content and serotonin turnover, as estimated from changes in steady-
state 5-HIAA concentrations (Tagliamonte, Tagliamonte, Perez-Cruet, 
Stern & Gessa, 1971; Guerinot, Doitou & Bohuon, 1974; Perez-Cruet, 
Tagliamonte, Tagliamonte & Gessa, 1971; Messing, Fisher, Phebus & 
Lytle, 1976; Colmenares, Wurtman & Fernstrom, 1975; Curzon, Joseph & 
Knott, 1972; Baldessarini & Fischer, 1973). Thus, changes in brain 
tryptophan concentrations may have important effects on brain serotonin 
levels. 
Synthesis of the catecholamines, noradrenaline and dopamine, does 
not appear to be limited by availability of the precursor tyrosine, 
although it may have some influence (Wurtman, Larin, Mostafapour & 
Fernstrom, 1974). However, high concentrations of tryptophan and 
phenylalanine may inhibit catecholamine synthesis by competition 
(Curtius, Baerlocher & Vollmin, 1972; Andrews et al., 1978). 
The aromatic amino acids are transported into the brain by a 
mechanism that is shared with the other large neutral amino acids leu-
cine, isoleucine, valine, methionine, and threonine (Oldendorf, 1971b; 
Oldendorf & Szabo, 1976) and competition among these has been shown to 
affect influx of individual amino acids (Fernstrom & Faller, 1975; 
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Perez-Cruet, Chase & Murphy, 1974; Etienne, Young & Sourkes, 1976). 
For example, a good correlation between the brain content of any one 
of the neutral amino acids and the ratio of its plasma concentration 
to the sum of the other competing neutral amino acids has been shown 
in individual normal rats (Fernstrom & Faller, 1978; Ashley & Anderson, 
1975). Evidence of these competition effects led to suggestions that 
alterations in plasma amino acid patterns found during hepatic failure 
might be involved in causing altered brain amino acid concentrations 
and thus disturb brain neurotransmitter metabolism. Chronic liver 
disease both in man and experimental animals is characterized by a 
plasma pattern with high phenylalanine, methionine, tyrosine, and 
sometimes tryptophan,and lowered branched chain amino acids valine, 
leucine, and isoleucine (Fischer et al., 1974, 1975; James et al., 
1976; Sherwin et al., 1974; Hirayama, 1971; Maddrey et al., 1976). It 
was suggested that the decreased branched chain amino acids (presumably 
resulting from decreased insulin degradation due to shunting of blood 
past the liver) could increase brain tryptophan content by decreasing 
competition for transport (Munro et al., 1975). High insulin concen-
trations would stimulate entry of the branched chain amino acids into 
muscle tissue where these are primarily catabolized. The aromatic 
amino acids on the other hand, are catabolized by the liver and would 
accumulate during hepatic failure. Some evidence for increased plasma 
insulin during chronic hepatic failure has been presented (Creutzfeldt, 
Frerichs & Sickinger, 1970; Marco, Diego, Villanueva, Diaz-Fierros, 
Valverde & Segovia, 1973). Others have suggested that it is the low 
insulin to glucagon ratio which promotes the abnormal plasma amino 
acid pattern (Soeters & Fischer, 1976). High glucagon levels have 
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been found during chronic hepatic failure in man (Sherwin et al., 
1974) and after portacaval shunt in the dog (Soeters, Weir, Ebeid & 
Fischer, 1976a). The hypothesis was supported by the finding that 
administration of branched chain amino acids to dogs with portacaval 
shunts led to improved mental status as well as normalized plasma 
amino acids (Fischer, Funovics, Aguirre, James, Keane, Wesdorp, 
Yoshimura & Westman, 1975). One objection, however, is that in most 
studies the decreases in the branched chain amino acids were very 
small in comparison to the increases in phenylalanine and tyrosine 
which are also competitors of tryptophan transport. Indeed it has 
been reported that phenylalanine and tyrosine are stronger competitors 
of tryptophan transport in vivo than the branched chain amino acids 
(Daniel, Love, Moorhouse & Pratt, 1975b). 
An entirely different situation exists during acute hepatic 
failure. Recent studies have revealed qualitative and quantitative 
differences in the plasma amino acids in animals with encephalopathy 
from acute and chronic liver disease (Record et al., 1976; Rosen, 
Yoshimura, Hodgman & Fischer, 1977). Acute hepatic failure led to 
large elevations in most of the plasma amino acids studied (McMenamy, 
Vang & Drapanas, 1965; Record et al., 1976). In contrast to the 
consistent reports of decreased branched chain amino acids in chronic 
hepatic failure, the findings in acute hepatic failure have been con-
flicting. In fulminant hepatic failure in man the branched chain amino 
acids were found to be decreased (Knell, Pratt, Curzon & Williams, 
1972) or normal (Record et al., 1976) while in experimental acute 
hepatic failure in the pig they were unchanged (Bu~ton et al., 1974). 
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Another factor which appears to influence tryptophan uptake in 
many circumstances is the concentration of unbound tryptophan in the 
plasma (Tagliamonte, Biggio, Vargui & Gessa, 1973b; Curzon, Knott, 
Murray-Lyon, Record & Williams, 1975b). Tryptophan is unique among 
free plasma amino acids in that it is reversibly bound to albumin, 
normally 80-90% (McMenamy & Oncley, 1958). Many physiological factors 
affect the binding constant, several of them mediated by changes in 
the plasma free fatty acids which release tryptophan from its binding 
sites (Curzon & Knott, 1974b; Curzon, Friedel, Kantamaneni, Greenwood 
& Lader, 1974; Lipsett, Madras:, Wurtman & Munro, 1973). Unbound 
tryptophan levels are often increased in hepatic failure and changes 
in brain tryptophan have been correlated with unbound tryptophan levels 
in man (Knell et al., 1974) and animals (Curzon et al., 1973b; Buxton 
et al., 1974) with acute hepatic failure. However, its relationship 
with brain does not appear to be simple (Madras et al., 1974) and it 
is most likely that several factors are acting together to regulate 
tryptophan transport into the brain. 
In this section of the thesis, studies of plasma and brain amino 
acid concentrations and their relationships (with particular respect 
to brain tryptophan content) during hepatic failure, are described. 
INFLUENCE OF DIET 
Plasma and brain tryptophan and brain serotonin concentrations 
have been shown to vary diurnally (Hery, Rouer & Glowinski, 1972; 
Wurtman & Fernstrom, 1972) primarily due to food intake (Wurtman & 
Fernstrom, 1974). Therefore, attempts were made to sample the rats 
in each group, including the controls, at the same time of day. 
The chronic hepatic failure rats were pair-fed with controls to 
eliminate food intake differences, and were sampled between 8 and 10 
a.m. 
In the acute hepatic failure studies, the rats were sampled 65 
hours after portacaval shunt, between 8 and 10 a.m., or during the 
afternoon 4-7 hours after ligation of the hepatic artery. The 
latter group had no access to food after hepatic artery ligation, 
their blood glucose concentrations being maintained by dextrose in-
fusion. In addition, one experimental group of rats was deprived of 
all food after portacaval shunt, and allowed access to water only, 
until after hepatic artery ligation when blood glucose maintenance 
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was begun. The aim of this experiment was to determine if dietary 
differences between the shunted rats and controls (due to decreased 
food intake by the shunted rats) could be responsible for the changes 
observed in brain and plasma metabolites. The results showed that 
changes in brain and plasma metabolites did not depend on whether rats 
were fed or starved between shunting and ligation. 
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RESULTS 
1. BRAIN AMINO ACIDS 
Four weeks after portacaval shunt, concentrations of the aromatic 
amino acids tryptophan, tyrosine and phenylalanine were significantly 
increased in the brain by 60 to 107% (Table 11). Similar changes have 
been previously reported in the portacaval shunted rat (Curzon et al., 
1975a; James et al., 1976; Cummings et al., 1976a). The other neutral 
amino acids measured were unchanged during chronic hepatic failure. 
In the hepatic devascularization series (Table 12, Figure 5) only 
tryptophan was increased 65 hours after portacaval shunt alone, while 
ligation of the hepatic artery produced a further increase in tryptophan 
to nearly 2-fold and also large increases in tyrosine (5-fold) and 
phenylalanine (3-fold). In addition, brain alanine content was doubled. 
Galactosamine-induced acute hepatic encephalopathy led to very 
similar brain changes (Table 13). Tryptophan was nearly doubled, 
tyrosine increased 6-fold and phenylalanine doubled in the coma group. 
In addition, concentrations of methionine, isoleucine, leucine and 
glycine showed significant increases, which were not seen in the 
surgical model. In Figure 6 the changes in the precoma and coma groups 
are compared to the control values. All significant changes seen 
were more marked during coma than precoma (with the exception of 
leucine) • 
Thus, both forms of acute hepatic encephalopathy were character-
ised by brain increases in the essential aromatic amino acids which 
became more pronounced as brain dysfunction increased. 
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TABLE 11 
BRAIN AMINO ACIDS DURING CHRONIC HEPATIC FAILURE 
All rats were sampled four weeks after portacaval shunt (pcs) or sham-
operation (control). The results are expressed in µmol/g wet weight 
tissue as the mean± S.E.M. with the number of rats in parenthesis. 
Results significantly different from control are indicated by 
*p<0.05, **p<0.001. 
Control Pcs 
Tryptophan 0.024 ± 0.002 (11) 0.051 ± 0.003 (13)** 
Tyrosine 0.084 ± 0.009 (11) 0.17 ± 0.02 (8)** 
Phenylalanine 0.097 ± 0.020 (11) 0.16 ± 0.02 (8)* 
Methionine 0.054 ± 0.012 (7) 0.053 ± 0.005 (7) 
Valine 0.092 ± 0.011 (10) 0.098 ± 0.010 (6) 
Leucine 0.11 ± 0.01 (11) 0.12 ± 0.01 (9) 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































EFFECT OF GALACTOSAMINE-INDUCED HEPATIC ENCEPHALOPATHY ON BRAIN 
AMINO ACIDS 
Samples were taken 30-60 hours after the first galactosamine in-
jection when the animals were either in a precomatose or comatose 
state (see Experimental Section for definitions). The results are 
expressed as the mean± S.E.M. in µmol/g wet weight tissue with the 
number of rats in parenthesis. Results significantly different from 
control values are indicated by *p<0.05, **p<0.01; significant dif-
ferences between the precoma and coma groups by +p<0.05. 
Control Precoma Coma 
Tryptophan 0.033 ± 0.001 (8) 0.043 ± 0.006 (8) * 0.061 ± 0.004 
Tyrosine 0.086 ± 0.010 (7) 0.40 ± 0.06 (8) ** 0.56 ± 0.05 
Phenylalanine 0.11 ± 0.01 (6) 0.15 ± 0.03 ( 8) 0.22 ± 0.04 
Methionine 0.037 ± 0.010 (6) 0.049 ± 0.010 (5) 0.14 ± 0.02 
Valine 0.16 ± 0.03 (6) 0.17 ± 0.02 (8) 0.19 ± 0.01 
Leucine 0.11 ± 0.01 (7) 0.15 ± 0.01 (8)* 0.15 ± 0.01 
Isoleucine 0.063 ± 0.010 (7) 0.060 ± 0.010 (8) 0.080 ± 0.010 
Glycine 0.84 ± 0.11 (7) 1. 2 ± 0.2 (8) * 1.4 ± 0.1 












BRAIN NEUTRAL AMINO ACIDS DURING GALACTOSAMINE-INDUCED 
























Trp Tyr Phe Met Val lie Leu 
The rats were sampled 30-60 hours after the first galactosamine 
injection when the rats were either in a precomatose or a comatose 
state, as described in the Experimental Section. The bars represent 
percentage of control, with the results significantly different from 
control values indicated by *p<0 .05 and **p<0.01. 
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Increased brain tryptophan has been observed during experimental 
acute hepatic failure in animals (Curzon et al., 1973b; Mattson et al., 
1968; Tyce et al., 1967; Cummings et al., 1976b) and fulminant hepatic 
failure in man (Record et al., 1976). Increases in other nonessential 
and essential amino acids, including the branched chain amino acids, 
were reported in the dog after hepatic devascularization (Mattson 
et al., 1968) and in patients with fulminant hepatic failure (Record 
et al., 1976). 
DISCUSSION 
In all three conditions studied, particularly striking increases 
were seen in brain concentrations of the aromatic amino acids tryptophan 
and tyrosine, which are neurotransmitter precursors, and phenylalanine, 
which may also influence neurotransmitter synthesis in the brain (Cur-
tius et al., 1972; Bagchi & Zarycki, 1973). Acute hepatic failure 
resulted in much larger increases than chronic hepatic failure. The 
three branched-chain amino acids on the other hand, which share the 
blood-brain barrier transport system with the aromatic amino acids, 
were unaltered except during galactosamine coma when isoleucine and 
leucine were raised. 
The increase in brain tryptophan content is of special signifi-
cance because there is considerable evidence that brain tryptophan 
availability is a major factor regulating the rate of serotonin syn-
thesis in the central nervous system (see Figure 7). In vitro deter-
mination of the K of the first enzyme of the pathway, tryptophan 
m 
hydroxylase, suggested that the enzyme is unsaturated with substrate 
at normal cerebral tryptophan concentrations in the presence of the 
FIGURE 7 
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natural cofactor, tetrahydrobiopterin (Friedman et al., 1972). The 
~ for tryptophan was found to be about 50 µM which is in the range 
of normal brain tryptophan concentrations (Costa & Meek, 1974). This 
implies that an increase in the concentration of tryptophan available 
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to the enzyme would be reflected in an increase in the synthesis of 
5-hydroxytryptophan. Since there is no evidence that the decarboxyla-
tion of 5-hydroxytryptophan to serotonin is rate-limiting, and there 
is normally a considerably greater activity of aromatic-L-amino acid 
decarboxylase than of tryptophan hydroxylase in brain tissue (Ichiyama, 
Nakamura, Nishizuka & Hayaishi, 1968) this would lead to an increase 
in the synthesis of serotonin. In vivo studies support this view; an 
increase in cerebral tryptophan concentration has been shown to lead 
to an increase in the rate of serotonin synthesis as indicated by 
increased serotonin and 5-HIAA concentrations (Carlsson, 1974; Gessa 
& Tagliamonte, 1974; Curzon et al., 1975a; Bender, 1976). Some evi-
dence suggests that factors other than tryptophan availability affect 
serotonin synthesis in the brain (Bender, 1976; Mandell, 1978) and 
feed-back inhibition has been suggested (Macon, Sokoloff & Glowinski, 
1971; Hamon, Bourgoin & Glowinski, 1973) but this has not been demon-
strated in vivo and the validity of the experiments have been questioned 
on technical grounds (Green & Graham-Smith, 1976). It is somewhat 
surprising that the synthesis of a substance of importance for brain 
function should be influenced by the many factors which can alter brain 
tryptophan concentration and indeed Graham-Smith (1974) has suggested 
that these factors may normally have little influence on the amount of 
brain serotonin at receptor sites. Evidence that brain serotonin 
exists in two or more pools (Shields & Eccleston, 1973; Lane & Aprison, 
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1978) implies the possibility that total brain serotonin and func-
tional brain serotonin are not related. In addition, tryptophan 
availability for serotonin synthesis may depend not only on total brain 
tryptophan concentrations but also on the neuronal membrane transport 
system which may be limiting for serotonin synthesis in some circum-
stances (Mandell, 1978). 
Some indirect evidence for the importance of tryptophan availabil-
ity to serotonin synthesis and function has been presented. Changes in 
sensitivity to pain, which has been linked to changes in brain sero-
tonin concentrations, have also been correlated with changes in brain 
tryptophan (Tenin, 1967; Lytle, Messing, Fisher & Phebus, 1975). Ad-
ministration of tryptophan has also been shown to modify sleep (Hartmann, 
Chung & Chien, 1971) as well as the secretion of prolactin and gonado-
tropins in humans (Macindoe & Turkington, 1973). Both these body 
functions have been shown to be influenced by serotoninergic neurons. 
The role of serotoninergic mechanisms in central nervous system 
function is stili a matter of much discussion, and the exact relation-
ship of central indoleamines to the diverse cerebral activities and 
pathophysiology of several diseases with which they have been linked 
is not clear (see Chase & Murphy, 1973; Holman, Elliott & Barchas, 1975). 
Considerable biochemical evidence supports a special relationship be-
tween serotoninergic mechanisms and the maintenance of non-REM sleep 
(Jouvet, 1969, 1972; Pujol, Buguet, Froment, Jones & Jouvet, 1978; 
Holman et al., 1975). In a recent review Gillin, Mendelson, Sitaram & 
Wyatt (1978) reported that much of the evidence suggests that sero-
tonin is involved in regulation of states of consciousness. Work by 
Jouvet (1974) has shown that serotonin is inhibitory and noradrenaline 
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excitatory in the central arousal system (reticular activating system) 
of cats. Therefore the finding of increased brain serotonin and 5-HIAA 
during acute and chronic hepatic encephalopathy (Cummings et al., 
1976a,b; Curzon et al., 1973b; Tyce et al., 1967) stimulated interest 
in 5-hydroxyindole metabolism in hepatic failure. The importance of 
the changes found in 5-HIAA concentrations was recently emphasized when 
it was reported that serotonin is only metabolized to 5-HIAA after re-
lease into the synapse and reuptake, strongly suggesting that changes 
in 5-HIAA concentrations do imply changes in the functional concentra-
tions of serotonin (Reinhard & Wurtrnan, 1977). Further evidence for 
the importance of tryptophan metabolism in hepatic encephalopathy was 
obtained from experiments with portacaval shunted rats given tryptophan 
(Bloxarn, Curzon, Kantamaneni & Tricklebank, 1977). These rats showed 
impaired ambulatory behaviour compared to controls. 
In the present study, brain tryptophan was increased 47% 65 hours 
after portacaval shunt before ligation of the hepatic artery and any 
obvious signs of encephalopathy. After the onset of encephalopathy 
4-7 hours after hepatic artery ligation, the level had increased 86% 
as compared to controls. Similarly, in the galactosarnine model trypto-
phan was increased 30% in the precoma group and 85% in the coma group. 
Thus increasing brain tryptophan was a characteristic feature during 
the development of encephalopathy. The increased concentrations ob-
served after shunting alone, where brain dysfunction was not apparent, 
may indicate that tryptophan is associated with the development of 
encephalopathy only in combination with other changes, or after a 
critical level in the brain has been reached. Alternatively, brain 
damage may be present in this condition but not so as to cause 
noticeable changes in behaviour of the rat. The early stages of coma 
as defined in patients involve impairment of several brain functions 
that must be specifically tested for and which would not be obvious 
in the rat. 
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Metabolites of tryptophan may also influence a completely differ-
ent system in the brain, namely that of glucose metabolism. Treatment 
of rats with either 5-hydroxytryptophan or an inhibitor of monoamine 
oxidase (both leading to increased brain serotonin) or both, seemed to 
impair the transport of glucose from plasma to brain, and significantly 
reduced the utilization of glucose in brain tissue (Wong & Tyce, 1978). 
Possible relationships between aromatic amino acids and other metabolic 
pathways are discussed further in the General Discussion. 
Brain concentrations of noradrenaline, which has mostly excitatory 
effects in the central nervous system (Baldessarini, 1972), are de-
creased in acute hepatic coma (Dodsworth et al., 1974). As with sero-
tonin, the changes found in brain aromatic amino acids may be related 
to this finding. The influence of brain tryptophan on serotonin bio-
synthesis is in marked contrast to the relationship between tyrosine 
and brain catecholamine synthesis, which appears to be regulated 
mainly by endproduct inhibition (Costa & Meek, 1974; Baldessarini & 
Karobath, 1973). Since the rate-limiting enzyme, tyrosine hydroxylase 
(see Figure 8) is almost completely saturated when the concentration 
of the substrate is in the normal range (McGeer, McGeer & Wada, 1971), 
changes in brain concentrations of tyrosine would not be expected to 
affect catecholamine synthesis. However, some evidence has been 
presented that tyrosine can and may control the rates of catecholamine 
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synthesis (Wurtman & Fernstrom, 1975). Thus, the effects of increased 
brain tyrosine cannot be predicted at this stage. 
The high phenylalanine concentrations found during hepatic en-
cephalopathy may compete with tyrosine and inhibit tyrosine hydroxyla-
tion (Curtius et al., 1972); however, the increases observed in brain 
tyrosine (which were even greater than phenylalanine, Figures 5 and 6) 
would be expected to overcome this effect. On the other hand, the 
nonspecificity of the next enzyme in the biosynthetic pathway, 
aromatic-L-amino acid decarboxylase, may lead to inhibition of 
catecholamine synthesis at this step by the high concentrations of 
phenylalanine, tryptophan, 5-hydroxytryptophan and serotonin (Andrews 
et al., 1978; Cooper et al., 1978). Such inhibition may result in the 
decreased brain noradrenaline concentrations found during acute 
hepatic failure (Dodsworth et al., 1974). 
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2. PLASMA AMINO ACIDS 
Plasma unbound and total tryptophan concentrations were unchanged 
four weeks after portacaval shunt (Table 14). Of the other aromatic 
amino acids, only tyrosine was increased (190% of control value). Two 
of the branched chain amino acids, leucine and isoleucine, were 
significantly decreased to 73% of control values. These changes have 
been previously seen three to four weeks after portacaval shunt in the 
rat; however, earlier reports of increased unbound tryptophan or phen-
ylalanine were not confirmed (Curzon et al., 1975a; James et al., 1976; 
Cummings et al., 1976a). 
In marked contrast to the chronic condition were the plasma 
changes during acute hepatic failure. In the surgical model (Table 15, 
Figure 9) plasma concentrations of tyrosine and phenylalanine had 
doubled 65 hours after portacaval shunt alone. After ligation of the 
hepatic artery there were striking increases in all the amino acids 
measured, with the exception of total tryptophan which was decreased 
to 81% of control. Unbound tryptophan had doubled while the other 
aromatic amino acids tyrosine and phenylalanine were increased 
7-fold and 6-fold respectively. Methionine showed a similar increase. 
The branched chain amino acid concentrations had doubled. The non-
essential amino acids serine, glycine and threonine were increased 
three- to five-fold and alanine showed a 10-fold increase. 
Changes during galN-induced hepatic encephalopathy (Table 16) 
were very similar to those seen after hepatic devascularization with 
even greater decreases (in the case of total tryptophan) and increases 
(in the case of all the other amino acids). No significant differences 
were found between the plasma amino acids in the precoma and coma 
94 
TABLE 14 
PLASMA AMINO ACIDS DURING CHRONIC HEPATIC FAILURE 
All rats were sampled four weeks after portacaval shunt (pcs) or sham-
operation (control). The results are expressed in µmol/ml plasma as 
the mean± S.E.M. with the number of rats in parenthesis. Results 
significantly different from control are indicated by *p<0.02, **p<0.01. 
Control (12) Pcs (12) 
Tryptophan - unbound 0.012 ± 0.002 0.011 ± 0.003 
Tryptophan - total 0.20 ± 0.01 0.18 ± 0.02 
Tyrosine 0.051 ± 0.010 0.097 ± 0.010** 
Phenylalanine 0.073 ± 0.010 0.091 ± 0.010 
Methionine 0.047 ± 0.004 0.056 ± 0.011 
Valine 0.17 ± 0.01 0.16 ± 0.02 
Leucine 0.15 ± 0.01 0.11 ± 0.01* 
Isoleucine 0.069 ± 0.005 0.051 ± 0.005* 
Glycine 0.34 ± 0.03 0.32 ± 0.03 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLASMA AMINO ACIDS DURING GALACTOSAMINE-INDUCED HEPATIC ENCEPHALOPATHY 
The experimental details are as given in Table 13. The precoma and 
coma groups were grouped together for this analysis. The results are 
expressed as mean± S.E.M. in µmol/ml with the number of rats in 
parenthesis. Results significantly different from control are indi-
cated by *p<0.01, **p<0.001. 
Control Encephalopathy 
Tryptophan-unbound 0.018 ± 0.002 (12) 0.038 ± 0.006 (12)** 
Tryptophan-total 0.20 ± 0.01 (12) 0.14 ± 0.01 (13)** 
Tyrosine 0.063 ± 0.010 (8) 0.86 ± 0.13 (15) ** 
Phenylalanine 0.080 ± O.Oll (8) 0.35 ± 0.06 (15)** 
Methionine 0.043 ± 0.005 (9) 0.39 ± 0.05 (15)** 
Valine 0.16 ± 0.01 (9) 0.55 ± 0.05 (15)** 
Leucine 0.15 ± 0.01 (9) 0.47 ± 0.06 (15)** 
Isoleucine 0.068 ± 0.010 (9) 0.24 ± 0.03 (15)** 
Glycine 0.29 ± 0.03 (9) 1.1 ± 0.2 (15)* 
Alanine 0.24 ± 0.02 (9) 1.8 ± 0.4 (14)** 
groups; therefore these results were grouped together. Figure 10 
shows the plasma neutral amino acids after hepatic devascularization 
and galN-induced encephalopathy as compared to control values. The 
similarity in the plasma changes between the two models is striking 
and again supports the assumption that these changes are due to a 
failing liver, and not the method used to produce it. 
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Large increases in unbound tryptophan and the aromatic and 
straight-chain amino acids have been previously observed during acute 
hepatic failure in man (Knell et al., 1974; Record et al., 1974, 
1976) and experimental animals (McMenamy et al., 1965; Iob, Mattson, 
Sloan, Coon, Turcotte & Child, 1970; Buxton et al., 1974). Reports 
of total tryptophan changes have been inconsistent. Some authors 
found increases (Fischer et al., 1976), and others found no change 
(Cummings et al., 1976b; Buxton et al., 1974; Knell et al., 1974; 
Record et al., 1976), or decreases (Curzon et al., 1973b). 
PLASMA INSULIN AND GLUCAGON DURING ACUTE HEPATIC FAILURE 
Plasma insulin concentrations in both models of acute hepatic 
failure were not significantly different from those in control 
rats (Table 17). However, glucagon concentrations had increased 
6-fold after hepatic devascularization and 4-fold in the rats 
treated with galN, resulting in a greatly decreased insulin to 
glucagon ratio. 
Slightly elevated circulating insulin levels have been found in 
association with cirrhosis (Creutzfeld et al., 1970; Marco et al., 
1973). In agreement with the above findings a much larger increase 
in plasma glucagon than insulin was found after portacaval shunt 
100 









































































































































































































































































































































PLASMA INSULIN AND GLUCAGON DURING ACUTE HEPATIC FAILURE 
Refer to Tables 12 and 13 for experimental details. The results are 
expressed in ng/ml as the mean± S.E.M. with the number of rats in 
parenthesis. Results significantly different from control values 




1.3 ± 0.3 (9) 
0.41 ± 0.19 (9) 
Hep. devasc;. 
1.8 ± 0.2 (9) 
2. 5 ± 0. 2 (9) * 
GalN 
0. 4 5 ± 0. 09 ( 5) 
1.7 ±0.1 (3)* 
alone in dogs (Soeters et al., 1976a). The plasma insulin/glucagon 
ratio was also decreased in patients with spontaneous or surgical 
portacaval shunting (Sherwin et al., 1974). Similarly, rats with 
portacaval shunts had lower plasma insulin and higher plasma 
glucagon concentrations than control rats (Rossouw et al., 1978). 
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No information seems to be available about changes in these hormones 
during acute hepatic failure. 
DISCUSSION 
The high concentrations of the plasma amino acids found during 
acute hepatic failure in patients have been attributed to release 
from the necrotic liver as well as catabolism in peripheral muscle. 
The striking rise of methionine, phenylalanine and tyrosine sug-
gested a hepatic origin. The large increases in plasma amino acids 
observed after hepatectomy in the dog and rat (McMenamy et al., 
1965; Tyce et al., 1967) indicate that voluntary muscle may contribute 
to these increases during acute hepatic failure. In the present study, 
the amino acid profile, including the 10-fold increase in alanine, as 
well as the decreased insulin/glucagon ratio, suggested a catabolic 
state. Inability of the liver to extract alanine would further in-
crease its plasma concentrations. (Increased branched chain amino acids 
are also found in other clinical conditions associated with increased 
protein catabolism [Felig, 1975; Ruderman, 1975]). Since the liver is 
not being perfused by either the portal vein or the hepatic artery 
after the devascularization procedure, in this model the liver cannot 
be releasing large quantities of amino acids. The larger increases 
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observed in plasma amino acids during galactosamine-induced necrosis 
may be due to additional free amino acids originating from the liver. 
The high unbound tryptophan concentrations found in the plasma 
are characteristic of acute hepatic failure. These may be caused by 
the high plasma free fatty acids found during hepatic failure (Ono 
et al., 1978) which release tryptophan from. albumin, and low albumin 
concentrations (James et al., 1976; Ono et al., 1978) due to decreased 
synthesis by the failing liver. The increased unbound tryptophan 
could possibly lead to increased uptake by various tissues thus 
causing decreased concentrations of total tryptophan in the plasma. 
Only small chanqes in plasma amino acids were observed during 
chronic hepatic failure. Others have suggested that the decreased 
branched chain amino acids during this condition are caused by in-
creased uptake by mu:;cle, which is largely responsible for their 
metabolism (Ruderman, 1975), and possibly by adipose tissue where 
increased incorporation into fatty acids may occur (Soeters & Fischer, 
1976). 
The possible effects of the plasma amino acid changes on brain 
amino acids is discussed in part 3 of this section. 
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3. PLASMA/BRAIN AMINO ACID RELATIONSHIPS 
Figures 11 and 12 show the changes in plasma and brain amino 
acids as compared to control values, during chronic and acute hepatic 
failure, respectively. The pattern in the two models of acute hepatic 
failure is very similar. Increases in plasma aromatic amino acids 
(including unbound but not total tryptophan) were associated with 
increases in brain concentrations. Plasma methionine and branched-
chain amino acid increases on the other hand, were not accompanied 
by significant brain increases with the exception of leucine and 
methionine during galN hepatic failure. Thus these essential neutral 
amino acids competing for one transport mechanism are divided into 
two groups, those associated with neurotransmitter metabolism (the 
aromatic amino acids), which showed parallel increases in plasma 
and brain, and the others which are not involved in neurotransmitter 
metabolism and increased largely in the plasma. 
During chronic hepatic failure, plasma and brain changes were 
much smaller. However, a parallel change in plasma and brain was 
seen in the case of tyrosine. 
The ratio of unbound plasma tryptophan to brain tryptophan was 
similar in acute hepatic failure rats and controls. lbis finding, 
together with the significant decrease in total plasma tryptophan 
suggested that unbound tryptophan was a more important factor in 
determining brain concentrations than total tryptophan in these rats. 
The influence of plasma amino acids on brain tryptophan was further 
examined by testing for correlation between brain tryptophan and 
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All rats were sampled four weeks after portacaval shunt or sham-
106 
operation (controls). The results are expressed as percentage of 
control, as shown by the bars. Results significantly different from 
control values are indicated by *p<0.05 and **p<0.01. 
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For legend to FIGURE 12, see over. 



















































































































































































































































































































































































































































total tryptophan to the competing amino acids tyrosine, phenylalanine, 
methionine, leucine, isoleucine, and valine, i.e. 
(a) Brain tryptophan vs. unbound -tryptophan 
(b) Brain tryptophan vs. total tryptophan 
(c) Brain tryptophan vs. unbound tryptophan f sum competitors 
(d) Brain tryptophan vs. total tryptophan f sum competitors 
(Figure 13 and 14). 
The values of the sums of the competitors and ratios in the 
various groups are given in Table 18. The sum of competitors in-
creased in all conditions, including chronic hepatic failure. Due 
to the large increase in competing amino acids the unbound tryptophan 
f sum ratio was significantly decreased during acute hepatic failure, 
in spite of the increase in unbound tryptophan. The total tryptophan 
f sum ratio, as expected from the lowered total tryptophan, showed a 
large decrease. 
No significant correlations were obtained during chronic hepatic 
failure, when testing either shunted or control groups or both groups 
together (Figure 13). 
During acute hepatic failure (Figure 14) there was a significant 
positive correlation between brain tryptophan and unbound tryptophan 
(Figure 14A) and a negative correlation between brain tryptophan and 
plasma total tryptophan (Figure 14B) when all rats were examined to-
gether. Similarly, a negative correlation was obtained between brain 
tryptophan and the total tryptophan to sum of competitors ratio (Figure 
l4D). There was no significant correlation between brain tryptophan and 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































These results contrast with those of Fernstrom, Hirsch & Faller 
(1976) who found that in normal rats correlations involving total 
tryptophan were more positive than those involving unbound tryptophan. 
This discrepancy suggests that extrapolations from normal to patho-
logical conditions, as have been made to account for increased 
brain tryptophan in hepatic encephalopathy, must be made with caution, 
since new variables may be present. 
DISCUSSION 
Tryptophan plays a unique role in amino acid metabolism. It is 
the least abundant amino acid in mammals and may be a limiting factor 
in protein synthesis, especially in young animals (Munro, 1974). 
Tryptophan is also the only plasma amino acid which is bound to 
albumin (McMenamy, Lund & Oncley, 1957; McArthur & Dawkins, 1969). 
Much work has been done to study the regulation of tryptophan uptake 
into the brain. The two main factors involved are firstly, competition 
with other neutral amino acids for the same uptake carrier mechanism, 
and secondly, the proportion of tryptophan bound to plasma albumin. 
The effect of competing amino acids on tryptophan transport into the 
brain has been extensively studied in normal rats in experiments where 
fluctuations in plasma amino acids remained within physiological 
limits (Fernstrom & Wurtman, 1971b, 1972; Fernstrom et al., 1976; 
Colmenares, Wurtman & Fernstrom, 1975; Perez-Cruet, Chase & Murphy, 
1974). When a diet consisting only of carbohydrate or fat and/or 
protein lacking the amino acids phenylalanine, tyrosine, leucine, 
isoleucine, and valine was fed to rats, a rise in brain tryptophan 
















,---....:+....;+;.....1•..._ __ ~_ 
Plasma 
+ .... -._..1....+ __ ..... 
Plasma 
(T+P +L+l+V) Tryptophan r,,., /, 

















However, if normal protein was included no rise was seen. This was 
I H i 
explained as being due to the relatively low proportion of trypto-
phan in normal dietary protein. After a protein meal the competing 
amino acids in the plasma show a greater rise than tryptophan and thus 
there is no increase in tryptophan uptake. These diet-induced 
changes in brain tryptophan and hence serotonin concentrations 
were summarized as shown in the diagram above (from Fernstrom & Wurtman, 
1972). Similar results were obtained when feeding various amino 
acid mixtures to rats (Gessa, Biggio, Fadda, Corsini & Tagliamonte, 
1974). If only phenylalanine, tyrosine, leucine, isoleucine, 
methionine, histidine or all the essential amino acids excluding 
tryptophan were fed, there was a decrease in brain tryptophan. 
If a mixture of amino acids without those listed was given, no 
decrease was observed. 
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Injection of neutral amino acids (histidine, isoleucine, leucine, 
methionine, phenylalanine, tyrosine, valine) in the normal physiological 
range was shown to decrease brain uptake of tryptophan (Etienne et al., 
1976). These experiments are strong evidence that competition plays 
an important role in the regulation of tryptophan uptake in normal 
rats. 
The second factor which is thought to influence this process 
is the extent to which tryptophan is bound to albumin in the plasma. 
Unbound tryptophan has been found to influence brain tryptophan in 
many circumstances, for example: 
(a) after food intake or insulin injection (Perez-Cruet et al., 
1974; Curzon & Knott, 1974b), 
(b) during food deprivation (Knott, Joseph & Curzon, 1973), 
(c) during immobilization stress (Knott et al., 1973), 
(d) during treatment with drugs affecting tryptophan binding 
(Guerinot et al., 1974; Tagliamonte, Biggio, Vargiu & Gessa, 
1973a; Gessa et al., 1974), 
(e) in early life (Bourgoin, Faivre-Bauman, Benda, Glowinski & 
Hamon, 1974), 
(f) in acute experimental hepatic failure in pigs (Curzon et al., 
1973b; Buxton et al., 1974). 
. 
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However, increases in plasma unbound tryptophan do not always lead 
to increased tryptophan in the brain (Madras et al., 1973, 1974). In 
addition, food intake leads to an increase in brain tryptophan even 
though the resulting insulin secretion causes decreased plasma unbound 
tryptophan levels (by lowering free fatty acids which release trypto-
phan from its binding sites on albumin) (Madras et al., 1973, 1974; 
Curzon, Friedel & Knott, 1973a; Curzon et al., 1974; Curzon & Knott, 
1974a). Some of the conditions listed may also be associated with 
changes in the competing amino acids, for example fenfluramine and 
probenecid, as well as increasing plasma unbound tryptophan, cause a 
decrease in plasma tyrosine (Tagliamonte et al., 1971). This matter 
is further complicated by the various methods used to separate unbound 
from bound tryptophan. This must be done under carefully controlled 
conditions since factors such as pH, temperature and the presence of 
heparin may affect the binding constant. For example, it has been 
suggested that in vitro lipolysis in serum after collection, can 
lead to high unbound tryptophan levels which would not be indicative 
of the true in vivo situation (Hutson et al., 1976; see also Fernstrom, 
Munro & Wurtman, 1977). 
Significant correlations have been obtained between brain trypto-
phan content and 
(a) plasma total tryptophan concentrations (Fernstrom et al., 
1976)# 
(b) plasma unbound tryptophan concentrations (Knott & Curzon, 
1972; Tagliamonte, Biggio, Vargiu & Gessa, 1973b) 9 
(c) the ratio of plasma total tryptophan to the sum of the 
competing amino acids (Fernstrom et al., 1976) Y 
. ' 
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(d) the ratio of plasma unbound tryptophan to the sum of the 
competing amino acids (Perez-Cruet et al., 1974). 
The relative importance of the effects of competition by other amino 
acids and unbound tryptophan concentrations in regulating normal brain 
tryptophan transport is controversial at present, but it seems that 
both these factors play a role in the process, their individual im-
portance depending on specific conditions. Dynamic factors, such as 
rapid re-equilibrium between free and unbound tryptophan in the brain, 
may alter the relative importance of the factors influencing brain 
uptake, during passage of blood through the brain. 
Much attention has been paid to tryptophan transport and its 
regulation in the investigation of chronic and acute hepatic failure, 
because brain tryptophan is thought to be involved in the aetiology 
of hepatic encephalopathy. Hypotheses have been put forward impli-
cating plasma amino acid changes in the increase in brain tryptophan 
content (Munro et al., 1975; Soeters & Fischer, 1976). The results 
in the present study indicated that during hepatic failure, plasma 
competing amino acid and unbound tryptophan changes do not explain 
the increases in brain tryptophan observed, and additional factors 
must be considered. During chronic hepatic failure, changes in the 
plasma concentrations of the competing amino acids (an increase in 
tyro~ine and decreases in leucine and isoleucine) resulted in no 
significant alteration in the total molar sum of the competing amino 
acids (portacaval shunt: 0.59 ± 0.04, control: 0.54 ± 0.03, Table 18) 
due to the large increase in tyrosine and small decreases in the 
other two amino acids. Thus it seemed very unlikely that these 
changes resulted in reduced competition for tryptophan uptake and 
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thus caused the approximate doubling of brain tryptophan content 
observed. Therefore, these experiments did not support the hypothesis 
that altered plasma amino acid patterns lead to increased brain trypto-
phan by lowering competition for transport during chronic hepatic 
failure (Munro et al., 1975; Soeters & Fischer, 1976). Nor could the 
increase in brain tryptophan be attributed to any change in plasma 
tryptophan, since both unbound and total tryptophan were unchanged 
and no correlation was obtained between plasma and brain changes. 
Thus, at this stage, there seemed to be no explanation for the high 
brain tryptophan content without considering possibilities of de-
creased utilization by and removal from the brain. 
As indicated by a few earlier studies of acute hepatic failure , 
the picture presented by the plasma amino acid concentrations, with 
several-fold increases in all amino acids except tryptophan, was very 
different from that found during the chronic condition. It is clear 
that the altered plasma amino acids could not have been responsible 
for the increased brain tryptophan; in fact, if dependent only on 
competition effects, brain tryptophan should have been decreased. 
Unbound plasma tryptophan showed a similar increase to brain tryptophan 
which suggests that it had a greater influence. However, whether the 
increase in unbound tryptophan was sufficient to overcome the effect of 
the very high competing amino acid concentrations (it seemed unlikely 
from earlier evidence, that these would have no effect at all) remained 
an open question. 
Therefore, as with chronic hepatic failure, changes in plasma 
amino acids could not satisfactorily account for the increased brain 
tryptophan content. This finding directed attention to another aspect 
1 7.l 
of tryptophan transport, namely the uptake mechanism itself. Studies 
showing competition between the neutral amino acids for transport 
across the blood-brain barrier were all performed in normal rats 
(Fernstrom et al., 1976; Etienne et al., 1976; Oldendorf & Szabo, 
1976) and the hypotheses attempting to explain brain tryptophan 
changes in terms of plasma amino acid patterns were based on these 
findings. However, it had not been established that the carrier 
mechanisms remained unaltered during pathological conditions such 
as hepatic failure. 
In the light of the above results, it seemed possible that 
during chronic and acute hepatic failure the transport system was 
altered, resulting in different uptake patterns from normal. For 
example, the affinities of the transport carrier for various substrates 
such as tryptophan might have been increased, or the blood-brain 
barrier might have become generally more permeable. The experiments 
investigating these possibilities are described in Results Section III. 
4. EFFECTS OF INTRAVENOUS INFUSION OF AMINO ACIDS ON 
BRAIN AND PLASMA METABOLITES 
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Intravenous infusion of special amino acid mixtures to dogs with 
portacaval shunts and patients with chronic hepatic failure has been 
shown to have beneficial effects in several studies (Fischer et al., 
1975; Soeters, Ebeid, Hodgman, James, Yoshimura, Westman & Fischer, 
1976b; Fischer et al., 1976). These amino acid mixtures were specially 
formulated to correct the abnormal plasma amino acid pattern found in 
chronic hepatic failure, thus possibly influencing brain uptake of 
neurotransmitter precursors. A further stimulus to attempts to formu-
late specific amino acid mixtures for intravenous use in hepatic failure 
was the well-known intolerance of protein by patients with severe liver 
disease, especially if given orally. For example, a milk diet is 
tolerated better by these patients than a similar amount of protein 
given as meat which has a higher content of aromatic amino acids 
phenylalanine, tyrosine and tryptophan (Condon, 1971). Simi.larly, 
the infusion of various amino acid mixtures in amounts sufficient to 
provide adequate nutrition in hepatic failure results in a worsening 
of encephalopathy associated with a markedly abnormal plasma amino 
acid pattern (Fischer et al., 1974). In dogs with portacaval shunts, 
survival could also be related to various diets, the shortest survival 
correlating with a greater dietary intake of aromatic amino acids 
(Condon, 1971) • 
In the experiments by Fischer et al. (1975) and Soeters et al. 
(197Gb), dogs with portacaval shunts, showing symptoms of hepatic 
encephalopathy, were given various intravenous amino acid mixtures. 
While administration of a commercially available synthetic amino acid 
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mixture led to increased encephalopathy and high mortality, a specially 
formulated mixture was associated with 100% survival and improvement 
of mental status, as well as normalization of plasma amino acids. 
This mixture, FOBO, contained reduced concentrations of aromatic 
and increased concentrations of branched chain amino acids, compared 
to the commercially available mixtures. 
Patients with chronic hepatic failure showed a similar 
favourable response to FOBO administration, associated with decreased 
plasma aromatic and increased branched chain amino acid levels 
(Fischer et al., 1976). 
In these studies the normalization of plasma amino acids and 
improvement in mental status was attributed to the amino acids 
and their proportions in the solution given. However, a control 
solution containing all the ingredients but no amino acids was not 
used. 
a. ACUTE HEPATIC FAILURE 
Preliminary experiments, in which rats were infused with the 
amino acid solution FOBO after hepatic devascularization, showed no 
improvement in brain or plasma metabolites, and in fact shortened 
the survival time compared to untreated rats. In view of the very 
high plasma amino acid concentrations, including the branched 
chain amino acids, found in the rats with acute hepatic failure, 
these results were not unexpected. Therefore these experiments 
were not taken further in the acute hepatic failure condition. 
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b. CHRONIC HEPATIC FAILURE 
The previously reported work on the effects of intravenous amino 
acids in hepatic failure was carried out in dogs with portacaval shunts 
and patients with chronic hepatic failure. No similar work had been 
done with rats with portacaval shunts. Therefore, even though the 
plasma amino acid changes found in the present study could not account 
for the brain amino acid abnormalities (as described in part 3 of this 
section), it was thought that the effects of continuous intravenous 
infusion of amino acids might be of interest, not only as a possible 
therapeutic measure but also to shed more light on plasma/brain amino 
acid relationships in chronic hepatic failure. 
This section describes investigations of plasma and brain meta-
bolite changes after continuous intravenous infusion of solutions with 
and without amino acids, to rats four weeks after portacaval shunting. 
PROCEDURE 
Portacaval shunts and sham-operations were performed as described 
in the Experimental Section. Rats were fed intravenously for four days 
before sampling at four weeks after portacaval shunt or sham-operation. 
The intravenous solutions were administered to unrestrained rats 
according to the procedure of Steiger, Vars & Dudrick (1972). Using 
halothane as anaesthetic (1.5% in oxygen), a catheter (19 gauge needle, 
Deseret Intracath) was inserted into the jugular vein over the clavicle, 
advanced into the superior vena cava as far as the right atrium and 
secured with two silk sutures. The free end of the catheter was passed 
subcutaneously to exit through the skin of the midscapular area where 
it was held in position by a specially constructed harness. 
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The intravenous catheter was connected by means of Portex plastic 
tubing to a sterile swivel infusion apparatus (Model 192-03 Cannula 
Feed-through Swivel, Lehigh Valley Electronics Inc., Fogelsville, 
Pennsylvania, USA) which allowed the animal complete freedom of move-
ment. 
The intravenous solution was infused from a glass syringe at a 
continuous rate of about 35 ml per 24 hours by a constant infusion 
pump (B. Braun Melsungen) fixed above the cage. No additional food 
or water was given. 
This technique allowed total parenteral nutrition for prolonged 
periods. Preliminary experiments with normal rats showed that it was 
well tolerated for at least five days. The composition of the solutions 
used is given in Table 19. 
RESULTS 
Intravenous feeding of amino acids and dextrose or dextrose alone 
resulted in a striking return towards normal of nearly all the brain 
metabolites that were altered in the rat four weeks after portacaval 
shunt (Table 20). After FOBO plus dextrose infusion, ammonia concentra-
tions, although reduced, were still significantly greater than normal, 
while aspartate, which was decreased in untreated portacaval shunted 
rats, was even further decreased by FOBO + dextrose (Figure 15). 
Dextrose alone had a greater effect on ammonia and glutamine, and 
raised aspartate, so that all these metabolites were statistically in 
the normal range in this group of rats. 
Similar effects were seen on the brain neutral amino acids (Table 
20, Figure 16). The high tryptophan, tyrosine and phenylalanine were 
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TABLE 19 
COMPOSITION OF SOLUTIONS USED FOR INTRAVENOUS INFUSION 
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* F080 is an experimental amino acid solution designed for hepatic 
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THE EFFECT OF INTRAVENOUS INFUSION ON BRAIN AMMONIA AND METABOLITES 
FOUR WEEKS AFTER PORTACAVAL SHUNT. 
NO INFUSION 
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All rats were sampled four weeks after portacaval shunt (pcs) or sham 
operation. Three groups of rats are shown: pcs fed normally, pcs in-
fused with F080 + dextrose solution, and pcs infused with dextrose only 
solution (see Table 19 for composition of solutions). The infused rats 
were treated for four days before sampling (see Procedure section for 
further details). The results are shown as percentage of control (nor-
rnally fed sham-operated rats) as indicated by the bars. Results sig-
nificantly different from control values are indicated by *p<0.05, 

















THE EFFECT OF INTRAVENOUS INFUSION ON BRAIN NEUTRAL AMINO ACIDS 
FOUR WEEKS AFTER PORTACAVAL SHUNT 
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See Figure 15 for details. The bars indicate percentage of control 
values. Results significantly different from control are indicated 




normalized by the infusion although tyrosine was still significantly 
greater than normal after F080 + dextrose. This solution also in-
creased brain isoleucine and leucine, possibly the result of the high 
plasma concentrations of these amino acids. All the amino acids were 
in the normal range after infusion of dextrose alone. 
The effect of IV infusions on plasma amino acids is shown in 
Figure 17, while absolute values are given in Table 21. The two 
solutions had essentially similar effects in that the reduced branched 
chain amino acids were increased to normal or higher (with F080 + 
dextrose) while the other amino acid altered after portacaval shunt, 
tyrosine, was not normalized and remained significantly higher than 
in control rats. F080 + dextrose infusion caused very high branched 
chain amino acid concentrations (200 to 240% of normal) which was to 
be expected from the amounts of these amino acids in the solution; 
however, infusion of dextrose alone also normalized these amino 
acids and even caused significantly higher isoleucine concentrations 
when compared to control rats. Methionine was increased by infusion 
of F080 + dextrose while alanine was increased by both solutions. 
DISCUSSION 
The above experiments show a striking return to normal of most 
brain metabolites after infusion of either amino acids plus dextrose or 
dextrose alone. This was accompanied by normalization of the lowered 
plasma leucine and isoleucine. The finding that the dextrose solution 
was at least as effective as the amino acid combination in correcting 
brain metabolite abnormalities suggested that factors other than the 
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See Figure 15 for details. The bars indicate percentage of control. 
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solution were involved. Since these rats were not being fed orally, 
one possibility is that the total absence of protein intake (which has 
been associated with the development of encephalopathy in patients), 
results in normalization of brain metabolites. In the rats given F080 
there would be a reduction of protein intake from about 2.4 g per day 
if normally fed, to about 1.3 g per day in the intravenous solution, and 
this may be sufficient to result in improvement. The exact mechanism 
remains an open question since, as previously discussed, the plasma 
amino acid abnormalities in rats with portacaval shunts are very small 
and in fact, the amino acid showing the greatest change from normal, 
tyrosine, was not normalized by intravenous infusion and therefore 
does not appear to be associated with the changes occurring in the 
brain. 
Subsequent to carrying out the above experiments, similar work 
using F080 has been published (Rosen et al., 1978). In this study 
rats with portacaval shunts were used and the normalization of plasma 
amino acid abnormalities was accompanied by decreased brain tyrosine 
and phenylalanine although a relationship with brain tryptophan was 
not observed. However, as with the earlier experiments using dogs, 
no animals were given the infusion without the amino acids. 
There has been considerable interest in the use of keto analogues 
of essential amino acids in liver and kidney disease (Walser, 1976; 
Maddrey, Weber & Walser, 1974; Maddrey et al., 1976; Richards, 1978). 
a-Keto acids can replace the corresponding amino acids in the diet 
of rats, with the exception of lysine and threonine (Richards, 1972). 
In theory, a-keto acids could offset both hyperarnrnonaemia and protein 







by combining with amino group donors to yield essential amino acids. 
Amination of these acids has been observed in tissues other than 
liver, such as muscle, and this suggests that normal liver function 
may not be a prerequisite for the utilization of these compounds for 
protein synthesis. Studies on patients with chronic portal-systemic 
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encephalopathy have supported this suggestion (Maddrey et al., 1976). 
In these patients, given keto analogues of five essential amino acids 
either parenterally or orally, the principal source of the nitrogen for 
conversion of the keto acids appeared to be glutamine. Plasma glycine 
and tyrosine concentrations returned toward normal during administra-
tion; no change was observed in arterial blood ammonia but there was 
a pronounced decrease in glutamine. No toxicity was found and clini-
cal improvement occurred in 8 of 11 patients. An additional advantage 
of administering keto analogues of essential amino acids is that the 
branched chain keto acids may themselves promote protein synthesis, 
particularly in muscle (Sapir & Walser, 1977). The usefulness of the 
essential amino acid analogues in the treatment of hepatic failure has 
yet to be established. However, in view of the present results and 
many earlier experiments showing the detrimental effects of administer-
ing protein during hepatic failure, the possibilities of providing a 
nitrogen-free source of the essential amino acids should possibly re-
ceive more attention. 
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RESULTS SECTION III 
BLOOD-BRAIN BARRIER: TRYPTOPHAN TRANSPORT 
DURING HEPATIC ENCEPHALOPATHY 
The fate of tryptophan in the brain depends both on its concentra-
tion within specific regions of specific neurons where it is metabolized 
(mostly to protein and to a much lesser extent to serotonin), and on the 
true fluxes of its transport into brain, into specific neurons and 
finally into subcellular regions. Although other processes such as 
metabolism are undoubtedly important in determining the concentration 
and distribution of tryptophan in the brain, there is much evidence 
that transport is one of the main determinants. Since serotonin- if 
not protein synthesis appears to be limited by tryptophan availability 
(Carlsson, 1974; Friedman et al., 1972; Barondes, 1974), rates of trans-
port may be important in regulating these processes (Lajtha, 1974; Pard-
ridge, 1977). Of the various transport steps, entry from the plasma is 
believed to be rate-limiting since the predicted maximal velocity of tryp-
tophan entry into brain cells is much higher than the rate of influx 
through the blood-brain barrier (Bauman, Bourgoin, Benda, Glowinski & 
Hamon, 1974; Parfitt & Graham-Smith, 1974) and extracellular fluid con-
centrations of all amino acids are much lower than cell concentrations 
(Bito, Davson, Levin, Murray & Snider, 1966; McGale, Pye, Stonier, Hutch-
inson & Aber, 1977). In addition, indirect evidence is provided by exper-
iments showing that changes in the factors known to affect blood-brain 
barrier transport of tryptophan (such as competition by plasma amino 
acids and the plasma concentration of unbound tryptophan), result in 
predictable changes in serotonin concentrations and turnover in whole 
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brain, as well as in regions with large numbers of serotoninergic 
neurons (Colmenares et al., 1975; Fernstrom & Wurtman, 197la,b, 1972; 
Gessa & Tagliamonte, 1974; Tagliamonte et al., 1973b: Curzon & Knott, 
1974a,b; Curzon, Joseph & Knott, 1972). Therefore the study of blood-
brain barrier transport is vitally important for a greater understand-
ing of changes in brain tryptophan and serotonin metabolism. 
The site of the blood-brain barrier is believed to be the tight 
junctions between endothelial cells of the brain capillaries (Oldendorf, 
1975; Pardridge, 1977) (Figure 18). These cells have no open clefts 
between them as do capillaries elsewhere in the body. There is also a 
marked absence of pinocytotic vesicles. Therefore, since substances 
must pass through two capillary cell walls to reach brain extracellular 
fluid, passage through the blood-brain barrier depends on either lipid 
solubility or mediation by carriers present in the capillary cell mem-
branes. Most substrates pass by means of facilitated diffusion, i.e. 
the process is equilibrative (not concentrative), Na+- and energy-
independent, and stereospecific. Depending on the kinetic constants 
characterizing each system, different substrates transported by the 
same system may compete with each other for entry. Influx of substrates 
is therefore affected by the concentration of the substrate as well as 
the concentrations of the competitive inhibitors and the kinetic con-
stants characterizing the system. When penetration is high, influx into 
the brain is also affected by cerebral blood flow, since at higher 
blood flows extraction of the substrate will be less complete. 
In vivo studies of amino acid transport showed that most amino acids 
could be assigned to one of three carriers, one for the acidic amino 
acids glutamate and aspartate, one for the basic amino acids arginine, 
FIGURE 18 
DIAGRAM OF MAJOR DIFFERENCES BETWEEN A 
GENERAL (NONNEURONAL) CAPILLARY AND A BRAIN CAPILLARY 
GENERAL 
CAPILLARY 






In the general capillary, small molecules can equilibrate between the 
moving extracellular fluid (plasma) and the stationary extracellular 
fluid outside by diffusion through the intercellular cleft. Pinocyto-
sis is a relatively inefficient mechanism of permeability but probably 
is independent of molecular size and can pass even very large macro-
molecules. In the brain capillary, these nonspecific routes of ex-
change are missing; the intercellular clefts are sealed shut by tight 
junctions, there is markedly reduced pinocytosis and no fenestrae. 
Transcapillary exchange must accordingly take place through the cells 
of the capillary wall, the major barrier of which is the plasma mem-
brane (inner and outer) of the capillary endothelial cells. This trans-
capillary exchange is therefore dependent on lipid solubility of the 
substrate and carrier mediated transport. 
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lysine and ornithine, and one for the neutral amino acids (Oldendorf, 
1971b; Oldendorf & Szabo, 1976; Richter & Wainer, 1971). The essential 
amino acids were taken up to a much larger extent than the nonessential 
amino acids. Tryptophan transport is mediated by the neutral system 
which also carries tyrosine, phenylalanine, valine, leucine, isoleucine, 
methionine and threonine at similar influx rates. 
Findings described in the previous section of the thesis, which 
indicated that plasma competition effects could not account for the 
brain amino acid changes observed during hepatic failure, prompted an 
investigation of possible alterations in the transport mechanism for 
tryptophan. In these studies the term transport is defined as the 
movement of an amino acid from blood to brain without suggesting any net 
increase in the quantity of amino acid in the brain and without con-
sideration of the numerous compartments and membrane barriers that 




Methods used to study blood-brain barrier transport involve either 
steady-state or single injection techniques. With the steady-state 
method, a steady level of radiolabeled test-substance is maintained 
in the circulation and the radioactivity in brain relative to that in 
plasma is measured at various times (Daniel, Donaldson & Pratt, 1975a). 
The single-injection technique involves the injection of test sub-
stance together with a reference which is either completely nondif-
fusible and indicates dilution of the injectate in blood (Crone, 1963, 
1965; Yudilevitch & De Rose, 1971), or highly permeable in which case 
it is measured in brain tissue and indicates the amount of injectate 
reaching the portion of brain tested (Oldendorf, 197la,b). The results 
obtained with the various methods agree fairly well with each other 
(Banos, Daniel, Moorhouse & Pratt, 1975; Pardridge & Oldendorf, 1975a). 
The method first described by Oldendorf was used for the present ex-
periments because it was the simplest and could be used in rats. In 
this method the 14c-amino acid is injected together with the reference 
3H-water into the common carotid of the rat (Figure 19). The injected 
bolus is assumed to remain unmixed with blood constituents during its 
passage through the brain. A known amount of 3tt-water and an unknown 
fraction of 14c-amino acid enter the brain. The solution is washed 
out of the brain by the circulation before the rat is decapitated 15 
seconds after injection. A sample of brain tissue and of injectate are 





penetrates copi llary 
Ext. Carotid 
ARTERIAL INFLOW 
Contains 3HOH and 
14C- test substance 
20% 
' 
Unknown traction ot 
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VENOUS OUTFLOW 
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is corned out of brain 
by blood flow within 
15 sec 
DIAGRAM OF METHOD USED IN DETERMINING BRAIN INFLUX OF A 14C-AMINO 
ACID FROM A SINGLE CAPILLARY PASS 
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The mixture of a 14c-labeled test substance and 3H-water is injected 
rapidly into the rat common carotid artery and the rat is decapitated 
15 seconds later. The test substance c14c) remaining in brain is re-
lated to the reference ( 3H) remaining. The mixture is washed out of 
the brain before decapitation. From Oldendorf (1971b). 
BUI = E X 100 
where E (fractional extraction) 
14c/3H brain tissue 
14c/ 3H injectate 
Several assumptions have to be made when using this procedure as 
originally described: 
a) The rate of efflux of the test substance and the reference 
141 
from the brain tissue must be the same during the time of the 
experiment. 
b) The injectate must be completely removed from the brain 
capillaries and not recirculated during the time before de-
capitation. Oldendorf found a background BUI of 1-2% after 
15 seconds (Oldendorf & Szabo, 1976) due almost entirely to 
incomplete brain-blood compartment washout with only a minor 
contribution from systemically recirculating radioisotope. 
Therefore when testing substrates with high BUI's such as the 
neutral amino acids, this background can be ignored. In order 
to test the above two assumptions under the conditions used, 
tryptophan transport was measured at 5, 10 and 15 seconds. 
The BUI's obtained were 19.0 ± 0.94, 17.9 ± 2.9, 15.7 ± 3.9 
(means± S.E.M. of three determinations) respectively. The 
higher values at shorter times suggest that brain washout was 
less complete; however the differences between the results 
were not significant. 
c) There must be no variation in cerebral blood flow. This is 
necessary since the extraction is affected by blood flow 
according to the equation (Kety, 1951); 
E = 1 -PS/F e 
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where PS = capillary permeability coefficient x surface area 
F = cerebral blood flow 
Blood flow in turn is affected by physiological parameters 
such as body temperature and blood gases (Hagerdal, Harp & 
Siesjo, 1975; Borgstrom, Johannsson & Siesjo, 1975). Therefore 
these parameters should remain unchanged during the experiment. 
In the presence study halothane anaesthesia was used instead of 
pentobarbital (as originally described by Oldendorf) which 
causes a profound reduction in cerebral blood flow, body 
temperature as well as increased circulating CO2 and de-
creased o2 (Nilsson & Siesjo, 1975). With halothane anaesthesia 
respiratory depression was minimal and body temperature main-
tained above 37°C for the duration of the experiment. 
In addition, in order to compare different experimental 
groups, it is necessary that blood flow is constant in all 
conditions examined. Cerebral blood flow has been measured 
in rats with portacaval shunts and found to be indistinguish-
able from controls (Gjedde, Lockwood, Duffy & Plum, 1978; 
Eklof, Holmin, Johannsson & Siesjo, 1974). The situation in 
acute hepatic failure is not clear. There have been no re-
ports of measurements of blood flow in rats with acute hepatic 
failure; however in patients a slight increase was observed 
(Maiolo et al., 1971) and in goats with CC14-induced acute 
hepatic necrosis there was a decrease (Stanley, 1978). This 
is discussed further in the Results section. 
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d) The extraction of 3H-water must be almost complete. This 
was subsequently found not to be the case. Various values 
for the fractional extraction have been reported, ranging 
from 0.5 to 0.9 at various blood flows and in different 
species (Brender, Andersen & Rafaelsen, 1975; Oldendorf & 
Braun, 1976; Raichle, Eichling & Grubb, 1974). For the 
present study the extraction of 3tt-water was separately 
determined relative to 14c-n-butanol, which is almost com-
pletely equilibrated on passage through capillaries (Crone, 
1965; Raichle, Eichling, Straatman, Welch, Larson & Ter-
Pogossian, 1976), under the same conditions as used for 
studying tryptophan transport. The mean extraction of 18 
determinations was found to be 0.545 ± 0.053 (S.E.M.). 
Therefore the BUI was calculated as 
BUI = E X 54.5 
The use of a partially diffusable reference such as water 
has the advantage that its extraction will be affected by 
unknown alterations of blood flow to a similar extent as the 
test substance. Thus if a substance has an extraction of 
0.2 at a flow of 1.5 ml.min- 1 .g-1 and changes of flow to 
1.2 or 1.8 ml.rnin.-lg- 1 were to occur, it can be calculated 
that the extraction would change to 0.21 and 0.19 respec-
tively. If, on the other hand, a perfectly diffusible 
reference were used, such as n-butanol, extractions of 
0.24, 0.20 and 0.17 would be found at blood flows of 1.2, 
1.5 and 1.8 rnl.min.-lg- 1 , respectively. 
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PROCEDURE 
Tryptophan transport was studied in normal rats, sham-operated 
controls, after portacaval shunt alone, after hepatic devasculariza-
tion (acute hepatic failure), and four weeks after portacaval shunt 
(chronic hepatic failure). The experimental procedures for these are 
fully described in the Experimental Section. In the acute hepatic 
failure condition, transport was measured three hours after ligation of 
the hepatic artery at which time the brain metabolites showed all the 
abnormalities (including increased tryptophan concentrations) found in 
rats sampled in the terminal stages preceding death. Results were 
compared to those obtained from normal rats after establishing that 
the findings in sham-operated controls were not different from normal. 
The rat was anaesthetised with 1.5% halothane in oxygen, and the 
left carotid artery exposed. After positioning the rat on a guillo-
tine, the artery was lifted slightly with a small paperclip to enable 
injection without occluding the flow of blood. Using a slightly bent 
needle (26 wire gauge, outer diameter 0.38 mm), 0.2 ml of radioactive 
solution was injected rapidly to minimise mixing with plasma. The 
artery cleared momentarily as the solution entered. Normal blood 
flow continued past the needle which was left in place until decapi-
tation 15 seconds after injection. The whole procedure from induction 
of anaesthesia to decapitation took 8-10 minutes. The brain was rapidly 
removed and two samples of about 100 mg each of the left cortex removed. 
The remaining brain tissue was stored in liquid nitrogen at -196°C 
until extraction and assay of tryptophan. The cortex samples were 
placed in scintillation counting vials containing 1 ml of tissue 
solubilizer, Soluene-350. After standing overnight at room temperature 
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to allow complete solubilization, 10 ml of liquid scintillation cock-
tail, Dimilume-30, was added to each vial and the 14c dpm/3H dpm ratio 
determined on a Packard Tri-Carb scintillation counter, using a program 
which calculated disintegrations per minute from counts per minute, from 
a previously calculated quench curve. A sample of the injected solu-
tion was treated in the same way and counted to determine the original 
14c/3H ratio. 
The Soluene-350/Dimilume-30 system was preferred to others since 
it produced less colour, and chemiluminescence was more rapidly in-
hibited due to the low pH of Dimilume (which neutralized the highly 
basic tissue solubilizer) and the presence of radical scavengers. Thus 
vials could be counted within a few hours of addition of scintillant. 
The injected solution contained 1.25 µCi of [1 4c]-tryptophan and 
5 µCi [ 3H]-water per ml, in a diluent consisting of Ringers solution 
(NaCl 147 mM, KCl 4 mM, CaCl2 2 mM) containing 4 mM HEPES (4-(2-hy-
droxyethyl)-1-piperazine-ethane sulphonic acid) as buffer, at pH 7.4. 
The solution was injected at room temperature. To examine the effects 
of increasing tryptophan concentration on transport, unlabeled trypto-
phan was added to obtain final concentrations ranging from 24 µM to 
1980 µM tryptophan. In studies assessing the influence of competing 
amino acids, solutions were made containing 24 µM [14c]-tryptophan and 
unlabeled leucine 130 µM, isoleucine 66 µM, valine 190 µM, methionine 
47 µM, phenylalanine 67 µM, and tyrosine 63 µM. 
In the preliminary experiments measuring the extraction of water 
relative to n-butanol, the solution contained 1.25 µCi of [14c]-n-
butanol and 5 µCi [3H]-water in the HEPES~Ringers buffer. 
CALCULATIONS 
The brain uptake index (BUI) was calculated as follows: 
BUI = 14c/3H brain tissue 14c/3H injectate X 54.5 
The rate of tryptophan transport from the solution was calculated 
according to the formula: 
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Influx 








cerebral blood flow 
(ml.min- 1 .g- 1 ) 
The value for the cerebral blood flow used was 1.0 ml.min- 1 .g-l since 
this was the approximate mean found in normal rats and after porta-
caval shunt (Eklof et al., 1974; Gjedde et al., 1978; · Norberg & Siesjo, 
1974). 
Mediated transport is similar in many respects to an enzymatic 
reaction. Thus, analysis of these transport data can be simplified by 
assuming that the substance outside, the carrier, and the solute inside 
the brain, are analogous to the substrate, enzyme, and product, of an 
enzymatic reaction, respectively. When the rate of influx has been 
determined over a range of concentrations, the results can be analysed 
using enzyme kinetic techniques. The K and V for transport are m max 
calculated by fitting the data to the Michaelis-Menton equation: 
V = 
where v = rate of influx 
S = substrate concentration 
V = maximal influx rate max 
Km = Michaelis constant 
The K for an enzymatic reaction provides a means by which the 
m 
degree of saturation of the catalytic sites on the enzyme can be 
estimated. 
In the presence of a competitive inhibitor the K is apparently 
m 
increased by the factor (1 +!._)where I= inhibitor and KI is the 
KI 
inhibition constant, i.e.: 
influx = 
S + K (1 + !._) 
--m Kr 
and when several competitors are present: 
influx = 
S + Km (1 + [ r 
Kr 
r 
where [ is the sum of the ratios of each competitor to its Kr. 
Kr 
For the amino acid transport system it has been shown that the Krs 
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of competing amino acids are equivalent to their Ks of transport, i.e. 
m 
they are true competitive inhibitors (Christensen, 1969). Therefore 
published values for the Ks can be used in the equation. 
m 
B. RESULTS 
KINETICS OF TRYPTOPHAN INFLUX AND ALTERATIONS DURING ACUTE HEPATIC 
FAILURE 
148 
After hepatic devascularization, the brain uptake index (BUI) and 
I 
calculated influx of tryptophan were about twice as high as in control 
rats at all concentrations of tryptophan tested (Table 22). As the 
concentration of unlabeled tryptophan was increased, the BUI decreased 
(Figure 20) to a minimum. This indicated that the transport system 
was saturable, i.e. the increasing concentration of unlabeled tryptophan 
was competing with the 14c-tryptophan (the concentration of which re-
mained constant) and inhibiting its transport. The effect on influx is 
shown in Figure 21. At lower · concentrations a hyperbolic curve char-
acteristic of saturation kinetics was observed but saturation was not 
reached even with concentrations many times those found normally. At 
the higher concentrations influx appeared to be directly proportional 
to concentration. A double reciprocal plot (Figure 22) was the next 
step in trying to explain these findings. In both normal and acute 
hepatic failure conditions the plot curved towards the origin at higher 
concentrations. This nonlinearity suggested that more than one system 
was operating (Denizeau, Wyse & Sourkes, 1976), with the influx observed 
being the sum of the various components at each concentration. The 
simplest possibilities to explain the data were the following: 
1) two saturable facilitated diffusion transport systems (one 
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500 1000 2000 
TRYPTOPHAN CONCENTRATION (µ M) 
For experimental details and calculation of the BUI see Table 22. 
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The points are the data given in Table 22 and represent the means of 
at least five determinations (line a, normal rats) or three determina-
tions (line b, acute hepatic failure). The S.E.M. is indicated by 
the vertical bars. 

















BRAIN TRYPTOPHAN INFLUX IN NORMAL RATS AND 
AFTER HEPATIC DEVASCULARIZATION 
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Influx was calculated as described in Table 22. The points represent 
the means of at least five determinations in normal rats (line a) or 
three determinations in rats with acute hepatic failure (line b). The 
vertical bars represent the S.E.M. 
1 52 
F IGURE 22 
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TRYPTOPHAN 1/CONCENTRATION (µM) 
The lines were plotted using the reciprocals of the data in Table 22. 
Line a indicates results from normal rats, line b from those with 
acute hepatic failure. 
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2) one saturable facilitated system (with low V and low K) max m 
and free (non-facilitated) diffusion. 
An approximation of the two components can be obtained by drawing 
tangents to the curves at low and high concentrations. However this 
method involves a large error which can be removed by subtracting each 
component from the other iteratively until the contribution made by 
component 1 to component 2 is negligible and vice versa (Spears, Sneyd 
& Loten, 1971). By following this procedure the data of Table 22 were 
resolved into the various components shown on Tables 23 and 24 together 
with the kinetic constants describing the systems. The close correla-
tion between the sum of the calculated components and the actual influx 
obtained indicated the completeness of the resolution. 
The high capacity component in each case was described by a pro-
portionality constant K (i.e., assuming a linear relationship) since no 
definite distinction could be made between this possibility and a 
system with very high V and K. Measurements at even higher con-
max m 
centrations would be needed to determine whether this system is 
eventually saturable or represents free diffusion. 
During acute hepatic failure the affinity constant (K) of the 
m 
low capacity component was similar to that in normal rats, while the 
transport capacity (V ) was considerably greater. The constant of max 
transport by the high capacity comronent was increased more than two-
fold. (If this component were to be described by a K and V , the K 
m max m 
would be about 80% of normal, i.e. the affinity would be increased, 
and the V more than doubled.) The contributions made by the two max 
components at various concentrations are shown in Figure 23. At 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































COMPONENTS OF BRAIN TRYPTOPHAN INFLUX 
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TRYPTOPHAN CONCENTRATION (JJM) 
The data of Table 22 were analyzed by an iterative procedure to 
separate the influx into two components as described in the text. 
Line a is drawn through the experimentally obtained points. Each 
point is the mean of at least five (normal) or three (acute hepatic 
failure) determinations with the S.E.M. indicated by the vertical 
bars. Lines band c represent the high and low capacity components, 
respectively. 
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the major fraction of tryptophan entry into the brain would be medi-
ated by the low capacity saturable component of transport in both 
conditions. 
THE EFFECT OF COMPETING AMINO ACIDS 
157 
In the above experiments tryptophan influx was measured in the 
absence of any amino acids that would normally compete with it for 
entry in vivo. This was necessary in order to obtain the kinetic 
constants for tryptophan transport. To obtain estimates of tryptophan 
influx in physiological conditions, predictions were made of the actual 
influx occurring in normal rats and during acute hepatic failure, at 
various hypothetical tryptophan concentrations, using the kinetic 
constants for tryptophan influx obtained for the two components and 
the competing amino acid concentrations found in these conditions 
(Table 26). The high capacity component would not be affected at the 
concentrations of substrates involved even if it were eventually satur-
able, due to its ·very low affinity and high capacity. Thus total 
influx was calculated as 
influx = 
I 
S + ~ (1 + I Kr 
+ KS 
These calculations showed that in normal rats about 40% of the influx 
is mediated by the high capacity component while this is increased to 
about 74% during acute hepatic failure. This means that any further 
increase in plasma competitor concentratipn would have a minor effect 
in inhibiting tryptophan transport since entry could be reduced by 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































and high plasma concentrations of competing amino acids in acute 
hepatic failure were examined by including these factors singly in the 
calculation (Table 26). Total influx at 50 µM tryptophan is reduced 
from 3.4 to 1.9 nmol.min- 1.g-1 by the high plasma competitors (when the 
kinetic constants are held normal). The altered kinetic constants on 
. 7 2 1 . - 1 - 1 the other hand, increase total influx from 3.4 to . nrno .min .. g . 
The combined effects result in a net increase of influx from 3.4 to 
· -1 -1 4.6 nmol.min .. g . 
In order to test these predictions in vivo, competing amino acids 
were added to the injected solution to obtain concentrations approxi-
mating those normally found in rat plasma. This resulted in a reduc-
. · -1 -1 · 1 tion of tryptophan influx from 4.02 to 1.69 nrnol.min .. g in norma 
rats and from 7.85 to 3.31 in rats after hepatic devascularization 
(Table 27). The values obtained corresponded well with those predicted 
from calculations of the influx where the inhibitory effect of the 
competitors on transport by the low capacity component was taken into 
account, thus confirming the validity of the method of calculation and 
the kinetic constants obtained. 
CORRELATION WITH BRAIN TRYPTOPHAN CONTENT 
Tryptophan influx was found to be increased when measured after 
portacaval shunt alone although not as much as after both portacaval 
shunt and hepatic artery ligation (Table 29). A significant correlation 
was found between brain tryptophan content and influx from 24 µM trypto-
phan solution in the three groups of rats: normal, portacaval shunt 
alone and acute hepatic failure (Table 29, Figure 24), providing 
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TABLE 26 
INDIVIDUAL EFFECTS OF ALTERED TRANSPORT KINETICS AND ALTERED COMPETITOR 
CONCENTRATIONS ON TRYPTOPHAN TRANSPORT 
Influx was calculated (equation in Table 25) using combinations of 
kinetic constants and plasma competing amino acid concentrations 
found in normal rats (Table 23, Table 28) and during acute hepatic 
failure (Table 24, Table 28). 
1) Normal kinetic constants 
+ normal competitors 
2) Normal kinetic constants 
+ high competitors 
3) High kinetic constants 
+ normal competitors 
4) High kinetic constants 
+ high competitors 
Predicted Influx (nmol.min- 1 .g- 1) 
at 50 µM Tryptophan 
Low component High component Total 
2.1 1.3 3.4 
0.6 1.3 1.9 
3.8 3.4 7.2 
1.1 3.4 4.5 
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TABLE 27 
EFFECT OF COMPETING AMINO ACIDS ON TRYPTOPHAN INFLUX 
Influx was determined as described in the Procedure section. The 
solution used to measure influx in the presence of competitors con-
tained tyrosine 63 µM, phenylalanine 67 µM, methionine 47 µM, leucine 
130 µM, isoleucine 66 µM, valine 190 µM, in addition to tryptophan 
22 µM. The results are expressed as the mean± S.E.M. with the 
number of determinations in parenthesis. 
Normal 
Tryptophan (22 µM} 4.02 ± 0.26 (16} 
Tryptophan (22 µM} 1.69 ± 0.07 (5) 
+ competitors 
Predicted influx with 1.58 
competitors* 
* calculated using the equation: influx = 








S + Kin ( 1 + z:!_ } 
Kin 
+ KS 
where the constants for tryptophan were those in Tables 23 and 24, the 
Ks for the amino acids those given in Table 25, and the concentrations 
m 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CORRELATION OF BRAIN TRYPTOPHAN CONTENT AND INFLUX 
60 



















2 4 6 8 10 
TRYPTOPHAN INFLUX (nmolxmin-1 xg-1) 
Brain tryptophan content was compared to tryptophan influx in normal 
rats ( •); after portacaval shunt alone ( C) and after hepatic 
devascularization ( £). The correlation c o efficient r = 0.64 (p <0.001). 
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evidence of the importance of blood-brain barrier transport of trypto-
phan for total brain tryptophan content. 
TRYPTOPHAN INFLUX IN CHRONIC HEPATIC FAILURE 
When measured four weeks after portacaval shunt, tryptophan influx 
from a 22 µM solution showed a 32% increase from normal. The mean 
value obtained from 5 determinations was 5.3 ± 0.4 (S.E .M .) nrnol.min-1.g-l 
(p < 0.05, when compared to normal). This value is similar to that 
seen 65 hours after shunting (5.9 ± 0.3 nrnol.min- 1.g- 1). 
CEREBRAL BLOOD FLOW 
Reports in the literature about changes in cerebral blood flow 
during hepatic encephalopathy have been conflicting. A decrease was 
found in patients with chronic hepatic failure (Maiolo, 1971) but not 
in rats with portacaval shunts (Gjedde et al., 1978; Eklof et al., 
1974). In patients with acute hepatic failure, there was a slight in-
crease (Maiolo et al., 1971) but a decrease in goats in coma from 
CCl4-poisoning (Stanley, 1978). The present studies were carried out 
three hours after hepatic artery ligation before the terminal stage 
preceding death. Since these rats were still conscious it was con-
sidered unlikely that blood flow would be altered. In order to account 
for the doubling of tryptophan transport observed, blood flow would have 
h d d f · -1 -1 a to ecrease rom 1 to 0.44 ml.min .. g . In addition, as explained 
in the Methods section, any change in blood flow would also have affected 
the 3H-water reference and a decrease would therefore have to be 
even greater in order to explain the results. These considerations, 
as well as the finding of increased tryptophan transport after 
portacaval shunt alone, when there is no change in cerebral blood 
flow (Gjedde et al., 1978) suggested that alterations in cerebral 
blood flow could not be significantly involved in producing the 






Many experiments have shown that alterations in plasma concen-
trations of the neutral amino acids tyrosine, phenylalanine, leucine, 
isoleucine and valine, relative to tryptophan, influence brain trypto-
phan content in normal rats (Fernstrom & Wurtman, 1972; Etienne et al., 
1976; Perez-Cruet et al., 1974). Thus the concept arose that competition 
influences tryptophan transport and thereby overall uptake. With this 
in mind, it was suggested that the decreased plasma branched chain amino 
acid concentrations found during chronic hepatic failure were responsi-
ble for causing increased brain tryptophan content (Munro et al., 1975; 
James et al., 1976; Soeters & Fischer, 1976). However, concentrations 
of phenylalanine and tyrosine, also competitors of tryptophan trans-
port, were increased in this condition, casting some doubt on this 
hypothesis (Daniel, Love, Moorhouse & Pratt, 1975b; Lal et al., 1975). 
In fact when influx from an arbitrarily chosen tryptophan concentration 
of 50 µMis calculated using data from James et al. (1976) and kinetic 
constants found in the present studies in normal rats, influx is un-
changed in the rats four weeks after portacaval shunt compared to the 
normal rats (both about 2.9 runol •. min- 1 .g- 1 ). Similarly when using 
the plasma amino acid concentrations obtained four weeks after porta-
caval shunting, described in Results Section II, influx in shunted rats 
is not altered (3.3 nmol.min- 1 .g- 1 ) from normal (3.4 runol.min- 1 .g- 1). 
In the acute hepatic failure series it is even more obvious that the 
increase in brain tryptophan content cannot be attributed to decreased 
competition for passage into brain since all the competitors are in-
creased. The finding of altered brain tryptophan transport during 
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hepatic failure described in this section is therefore of great 
significance when considering the factors contributing to the increased 
brain tryptophan content, as well as abnormalities in other brain amino 
acid and hence neurotransmitter concentrations. 
SELECTIVE CHANGES IN BARRIER TRANSPORT 
Dual component transport systems have been described for several 
substrates in brain tissue, e.g. tryptophan uptake into synaptosomes 
(Baumann et al., 1974), glutamate and aspartate transport into 
synaptosomes of cerebral cortex (Logan & Snyder, 1972), glucose and 
choline transport across the blood-brain barrier (Pardridge & Oldendorf, 
1975b; Cornford, Braun & Oldendorf, 1978). The finding that tryptophan 
transport across the blood-brain barrier contains several components is 
consistent with these reports. over the range of concentrations tested, 
the data did not show saturation of the high capacity system, thus it 
was impossible to distinguish between the possibilities of non-facili-
tated diffusion or a facilitated transport carrier with a high V and max 
a low affinity. Therefore, the increased transport observed during 
acute hepatic failure may have been due to either a general increase 
in permeability of the blood-brain barrier or more selective altera-
tions in the transport carrier. Earlier studies showing different 
alterations in the different carrier systems for blood-brain barrier 
transport during hepatic failure indicate selective changes rather than 
a generalized breakdown. For example, transport of D-glucose was unal-
tered 1-4 weeks after portacaval shunt while that of the basic amino acid 
arginine and the monocarboxylic acids pyruvate and butyrate was decreased 
(Cremer et al., 1977; James, Escourrou & Fischer, 1978; Sarna, Bradbury, 
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Cremer, Lai & Teal, 1979). These substrates are transported by differ-
ent carrier systems from the neutral amino acid system that transports 
tryptophan. On the other hand, barrier permeability to normally non-
permeable substances such as [ 51 cr]-EDTA was unchanged (Sarna, Bradbury 
& Cavanagh, 1977). If there was a generalized breakdown of the blood-
brain barrier under these circumstances one would expect the transport 
of other small molecules to be increased. 
When considering tryptophan transport on its own it may seem 
irrelevant whether the high capacity component is due to free diffusion 
or facilitated diffusion, since at physiological concentrations influx 
is proportional to concentration. However, one important difference 
between the two possibilities is that a facilitated mechanism is likely 
to be stereo- and group-specific while free diffusion has no such 
limitations except possibly those associated with physico-chemical pro-
perties such as lipid solubility. Therefore this distinction between 
free and facilitated diffusion is important in the physiological 
situation, although difficult to make in many cases (Denizeau et al., 
1976). 
CONSEQUENCES OF TWO TRANSPORT COMPONENTS 
The presence of a high capacity component which permits entry of 
tryptophan in direct proportion to concentration may be especially 
significant for total influx rates, since the effect of this is to 
diminish the importance of competition among the neutral amino acids, 
which affects the low capacity component only. This is clear from 
Table 25 in which calculated rates of tryptophan entry by each component 
are shown at concentrations of tryptophan in the physiological range, 
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in the presence of competing amino acids. It can be seen that by taking 
the competing amino acids into account, the predicted contribution by 
the high capacity component in normal rats is about 40%. This supports 
the concept that competition may influence tryptophan transport, by 
affecting the low capacity component. However, the effect of the 
unsaturated component is to permit some transport to occur in direct 
proportion to the concentration of non-albumin bound tryptophan. Thus, 
regardless of the concentrations of other neutral amino acids, trypto-
phan entry could never be reduced by more than 60% of normal. Rats 
with hepatic devascularization (and probably to a lesser extent rats 
with portacaval shunt alone), are even less sensitive to alterations 
in the concentration of other neutral amino acids. In these rats, a 
remarkable 74% of tryptophan influx appears to be mediated by the high 
capacity component and therefore tryptophan entry into the brain could 
never be reduced by more than 26%. It is important to realize that 
the effect of increasing competition on total influx becomes increas-
ingly less significant as the concentrations of competitors increase, 
due to the corresponding decrease in the contribution made by the 
saturable component to total influx. For example, in normal rats, 
increasing competition from zero to approximately normal, decreased 
influx by about 58% (Table 27) while increasing competition from normal 
to high levels was predicted to decrease influx by 44% (Table 26). Thus, 
in the situation of acute hepatic failure, the very high concentrations 
of plasma competitors, as well as the altered kinetic constants, result 
in a very low contribution by the saturable component to total influx, 
and therefore great resistance to the effects of further increases in 
competition. 
From these estimates it seems that adding more competing amino 
acids to a circulation already flooded with amino acids, to further 
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inhibit tryptophan entry and thus lower brain tryptophan content, would 
be of little benefit, even though a reduction of as little as 26% may 
be important. In chronic failure the situation is different since 
here the plasma amino acid concentrations are not far from normal. The 
kinetics of transport are likely to have altered less significantly than 
during acute hepatic failure, judging from the lesser increase in influx 
observed. Thus even if the abnormal plasma amino acid pattern is not 
responsible for the increased brain tryptophan content, some signifi-
cant reduction in influx may be achieved by increasing circulating 
competitor concentrations. Beneficial results have been obtained from 
infusing amino acid mixtures high in concentrations of branched chain 
amino acids to dogs and rats with portacaval shunts (Fischer et al., 
1975; Rosen et al., 1978). However it was not clearly established that 
the improvements observed were due specifically to the amino acids 
present in the intravenous solution administered (see Section II). 
It is possible that merely normalizing plasma amino acids may not be 
sufficient; higher competitor concentrations may be necessary to 
overcome the effect of the altered transport kinetics. 
CORRELATION WITH BRAIN TRYPTOPHAN CONTENT 
The significant positive correlation between changes in brain 
tryptophan content and influx provides evidence of the possible relation-
ship between the two findings. As will be discussed further in the 
next section, tryptophan transport into the brain appears to be a 
major determinant of brain tryptophan content. However a cause and 
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effect relationship cannot be definitely assumed in the absence of 
more information; for example, decreased protein synthesis or in-
creased catabolism could also lead to a build-up of brain tryptophan, 
although this would lead to similar increases in other amino acids, 
such as the branched chain amino acids, in the brain. These amino 
acids showed no or very minor increases during hepatic failure (see 
Results Section II). 
CONCLUSIONS 
The changes in the transport kinetics observed during acute 
hepatic failure should result in increased influx of tryptophan, and 
could explain, at least partially, the high brain tryptophan content 
found in these rats in the presence of high concentrations of plasma 
competing amino acids. The high competitor concentrations cause a 
reduction in tryptophan transport by the low capacity system. However, 
total tryptophan entry across the blood-brain barrier is increased 
because of the altered kinetics of transport, i.e. the increased trans-
port capacity (Vmax> of the low capacity component reduces the effect 
of competition, and transport by the high capacity component is greatly 
increased, due to a higher K. The increase in influx predicted was 
not as large as the increase observed in brain tryptophan content. 
This may be due to the effect of changes in plasma unbound tryptophan 
which were not taken into consideration in the calculations. The two-
fold increase seen during acute hepatic failure (Section II) would 
undoubtedly contribute to increased tryptophan transport. 
The transport of amino acids and their incorporation into protein 
appear to be intimately related (Lajtha, 1974; Pardridge, 1977). 
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Serotonin synthesis seems to be even more sensitive to precursor avail-
ability possibly because this process is highly localized and does not 
reutilize tryptophan as occurs in protein metabolism. Therefore alter-
ations in transport of tryptophan and other amino acids, especially 
those also involved in neurotransmitter synthesis, may have serious 
consequences on cerebral metabolism and function. 
The finding of selective alterations in the blood-brain barrier 
implies that transport of other substrates may be differently affected. 
Since several pathways in the brain appear to be substrate-limited, 
e.g. acetylcholine synthesis (Cohen & Wurtman, 1976), glucose metabolism 
in some conditions (Betz, Gilboe & Drews, 1976) and ketone-body 
metabolism (Ruderman, Ross, Berger & Goodman, 1974), an investigation 
of possible changes in transport mechanisms seems justified in many 
conditions where brain metabolism is altered. 
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GENERAL DISCUSSION 
A. METABOLIC INTERRELATIONSHIPS 
This thesis is concerned with changes in brain metabolism in a 
condition of altered consciousness. Consciousness is believed to 
depend on the proper functioning of the reticular activating system of 
the brainstem and the modifying effect of the cerebral cortex (Breen 
& Schenker, 1972). A disturbance of consciousness may result from 
effects on specific areas involved or general effects on brain metab-
olism as a whole (Plum & Posner, 1972). Since no metabolic pathway 
has been specifically related to the maintenance of consciousness, 
all metabolic aspects must be considered. In addition, there are many 
interrelationships in brain metabolism (Figure 25) and the various 
systems do not operate independently of one another. Glucose is the 
source of carbon for most substrates except the essential fatty acids 
and essential amino acids. Therefore energy metabolism is closely 
linked to metabolism of the neuroregulator amino acids aspartate, 
glutamate, glutamine and GABA. These are in equilibrium with inter-
mediates of the Krebs cycle. Indeed it has been suggested that the 
large glutamate pool functions as a stabilizer for the energy require-
ments of the brain (Nicklas & Berl, 1973). 
Relationships have also been postulated to exist between energy 
metabolism, the amino acid neuroregulators and the neurotransmitters 
derived from the aromatic amino acids, namely the catecholamines and 
serotonin. For example: 
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FIGURE 25 
VARIOUS INTERRELATIONSHIPS AMONG COMPOUNDS OF NEUROCHEMICAL INTEREST 
(adapted from Cooper et al., 1978) 
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(a) Acids of the Krebs cycle, such as fumarate, stimulate the 
conversion of dopamine to noradrenaline in vitro (Goldstein, 
Joh & Garvey, 1968; Levin, Levenberg & Kaufman, 1960). 
(b) ca2+ is necessary for both release of neurotransmitters as 
well as normal metabolism of the glucose-derived amino acids 
(Berl, Clarke & Nicklas, 1970). 
(c) Reserpine stimulates turnover of these amino acids as well 
as releasing catecholamines by affecting vesicle storage. 
(These findings led to the suggestion that catecholamines 
have a role as metabolic regulators in addition to functioning 
as neurotransmitters [Nicklas, Berl & Clarke, 1974; Nicklas & 
Berl, 1973]). 
(d) Flux of carbon from glucose to amino acids is decreased by 
hepatectomy, administration of phenylalanine, tryptophan or 
L-dopa, and when brain concentrations of serotonin and 5-HIAA 
are increased. It was suggested that aromatic amino acids 
could affect brain glucose metabolism by competition for co-
factors, especially pyridoxal-5-phosphate which is needed for 
the formation of glutamine, glutamate, aspartate and GABA from 
Krebs cycle intermediates and also for L-amino acid decarboxyl-
ase and tyrosine amino-transferase (Wong & Tyce, 1978). 
These interrelationships are not surprising because of the de-
pendence of neuronal function and transmitter release on energy metab-
olism. Metabolic pathways concerned with specialized brain functions 
are separated to a certain extent from general metabolism by compartrnen-
tation and localization. This enables substances such as aspartate and 
glutamate, which are involved in intermediary metabolism, to function 
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as highly active neuroregulators. Similarly, a precursor used for 
several processes, e.g. tryptophan, (used for both protein and serotonin 
synthesis) is separated into different pools. 
B. NEUROCHEMICAL CHANGES IN HEPATIC ENCEPHALOPATHY 
During hepatic encephalopathy, alterations were found in many 
diverse brain metabolites, as well as in the transport mechanism for 
tryptophan across the blood-brain barrier. These were qualitatively 
similar in encephalopathy due to acute or chronic liver failure, and 
therefore, although the pathogenesis of the two conditions may be 
very different, the neurochemical changes are discussed together. 
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In general, the changes seen involved increases in inhibitory sub-
stances (GABA, glutamine, tryptophan and therefore probably serotonin), 
and decreases in excitatory substances (glutamate and aspartate). Since 
the general state of activity of the brain may be related to the rela-
tive levels of excitatory and inhibitory material (Hebb, 1970), these 
alterations may reflect a disturbance of this balance and thus lead to 
a disturbance of brain activity. 
1. AMINO ACID NEUROREGULATORS 
Decreases in brain aspartate or glutamate were found in all 
conditions examined. There was also an increase in GABA during acute 
hepatic failure . . Since ammonia is associated with the metabolism of 
these amino acids, the large increase in its brain concentration may 
influence the pools of these neuroregulator substances and thus contrib-
ute to the development of their imbalance. High brain content of 
ammonia also promotes increased synthesis of glutamine which may have 
an inhibitory effect by acting as a false neurotransmitter. Increases 
in glutamine concentrations are of special interest for several reasons: 
; ' 
a. ~lutarnine synthesis occurs exclusively in glial cells or 
astrocytes (Benjamin & Quastel, 1972; Martinez-Hernandez 
et al., 1977) which are the only brain structures to show 
morphological alterations during hepatic failure (Cavanagh, 
1974; Schenker et al., 1974). 
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b. In addition to possibly having false neurotransmitter 
activity (Baldessarini & York, 1974), glutamine may influence 
brain glutamate levels (Bradford, Ward & Thomas, 1978). 
c. An important role for glutamine has been suggested in the 
postulated enzymatic basis of neutral amino acid transport 
across the blood-brain barrier (Samuels, 1977) which involves 
the y-glutamyl cycle and the enzyme y-glutarnyl transpeptidase 
(Meister, 1974; Orlowski, Sessa & Green, 1974). In the 
original hypothesis, y-glutamyl transpeptidase was believed 
to catalyse the transfer of the y-glutamyl residue of 
glutathione to an amino acid at the blood-brain barrier. 
The y-glutamyl-amino acid is then translocated into the cell 
and the amino acid released and eventually glutathione re-
formed. y-Glutamyl transpeptidase is present at high con-
centrations in the choroid plexus and in brain capillaries 
(Tate, Ross & Meister, 1973; Shine, Hertz, Suddith & Haber, 
1979; Orlowski et al., 1974). Its activity increases after 
birth, concomittantly with the development of the blood-brain 
barrier (Sessa & Perez, 1975). There were several objections 
to this proposal; primarily the high energy requirements of 
the pathway and the low specificity of y-glutarnyl transpep-
tidase. In addition, the phenomenon of exchange diffusion 
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could not be accounted for by the pathway. To overcome 
these problems a second step in the operation of the cycle 
was postulated (Samuels, 1977). It was suggested that the 
donor compound is y-glutamyl-glutarnine and that glutamine is 
exchanged for the entering amino acid. If the supply of 
intracellular glutamine is adequate, regeneration of 
y-glutamyl-glutamine means that only a low expenditure of 
energy is required. Since the lipoprotein form of y-glutamyl-
transpeptidase is so firmly bound to the membrane, it was 
further suggested that access to this enzyme is dependent on 
the relative lipophilia of the entering large neutral amino 
acids. In this way a membrane sequestered enzyme of low 
specificity could mediate transport of neutral amino acids. 
Other free amino acids may be used in place of glutamine, 
thus accounting for the exchange phenomenon. Recently it 
was found that administration of an inhibitor of the 
y-glutamyl cycle, methionine sulphoximine, resulted in a re-
duced rate. of transport of tyrosine and valine from blood to 
brain (Samuels, Fish & Freedman, 1978). (Methionine sulphoxi-
mine, which inhibits glutamine synthesis in addition to one 
of the enzymes in the y-glutamyl pathway, also reduces toxic-
ity from ammonia [Warren & Schenker, 1964].) These results 
provided further support for the hypothesis. 
This postulated role for glutamine in blood-brain barrier transport 
of the neutral amino acids may suggest a link between two findings in 
hepatic encephalopathy, namely increased brain glutamine content and in-
creased tryptophan transport, as discussed further below. 
2. AMINE NEUROREGULATORS AND PLASMA AMINO ACIDS 
The aromatic amino acid tryptophan appears to have special im-
portance in brain function. The synthesis of the neurotransmitter 
serotonin, and possibly protein synthesis as well, is limited by 
tryptophan concentrations (Friedman et al., 1972; Roberts, 1974). 
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High levels of tryptophan have also been shown to inhibit catechola-
mine synthesis (Andrews et al., 1978). Together with the other two 
aromatic amino acids which were consistently increased in brain during 
hepatic failure, phenylalanine and tyrosine, tryptophan may influence 
metabolism of glucose to the glutamate-related amino acids as described 
above. Therefore the significant correlation between changes in 
brain tryptophan concentration in the various states studied and 
changes in behaviour and apparent brain dysfunction is very signifi-
cant. No other metabolite studied shows a similar high correlation. 
These findings provide further support that tryptophan metabolism may 
be involved in the development of hepatic encephalopathy. 
When whole brain tryptophan is measured, this reflects free 
tryptophan in cells, interstitial fluid and cerebrospinal fluid, as 
well as in contaminating blood. Most of the tryptophan in brain 
tissue (excluding blood) is believed to be intracellular, since extra-
cellular fluid concentrations are very low (Bito et al., 1966). 
Several factors are involved in determining the concentration and 
distribution of tryptophan in the brain (Figure 26). 
a. Plasma tryptophan binding 
Tryptophan is the only amino acid found in plasma both free 
and bound to albumin (McMenamy et al., 1957). This reversible 


























































































































































































































































































It has been shown that tryptophan is removed from albumin on 
passage through the brain {Yuwiler, Oldendorf, Geller & Braun, 
1977). In this last study the "effective" tryptophan concentra-
tion in tryptophan~albumin solutions {i.e., that required to 
account for the observed influx) was found to greatly exceed the 
measured free tryptophan and approximate half or more of the 
total tryptophan concentration. This suggests that rapid re-
equilibration between bound and unbound tryptophan occurs in the 
brain capillaries. 
Many conditions in which the dissociation constant of 
albumin binding is affected by changing plasma free fatty acid 
concentrations,have been shown to influence whole brain trypto-
phan content {for examples, see p.117). However, probably be-
cause of the dynamic situation described above, direct correla-
tions between unbound and brain tryptophan concentrations have 
often not been found, e.g. after carbohydrate intake,when brain 
tryptophan rises even though the resulting insulin secretion 
causes decreased plasma unbound tryptophan {by decreasing free 
fatty acids) {Madras et al., 1973, 1974; Fernstrom et al. ., 1976). 
In the present studies there were large parallel increases in both 
unbound plasma tryptophan and brain tryptophan, while total plasma 
tryptophan decreased, suggesting that the change in unbound trypto-
phan had some influence on entry into the brain. 
b. Blood-brain barrier transport 
A consequence of the low Km of the neutral amino acid trans-
port system is that at normal physiological concentrations, amino 
acids which share this system competitively inhibit one anothers' 
uptake. (Since the K values of other tissues are at least 10-
m 
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fold normal plasma amino acid concentrations, competition affects 
at these sites are probably not important [Pardridge, 1977].) The 
effects of competing amino acids on tryptophan transport into the 
brain have been extensively studied in normal animals (Fernstrom 
et al., 1976; Gessa et al., 1974; Colmenares et al., 1975; Perez-
Cruet et al., 1974; Etienne et al., 1976). Increasing the plasma 
competitors (within physiological limits) in these experiments, 
either by dietary means or infusions, resulted in lowered brain 
tryptophan uptake or content. Fernstrom et al. have repeatedly 
found positive correlations between brain tryptophan and the ratio 
of plasma total tryptophan to the sum of the competing amino acids. 
The hypothesis implicating altered plasma amino acid patterns in 
the development of hepatic encephalopathy (Munro et al., 1975; 
Soeters & Fischer, 1976), is based on these studies performed in 
normal rats. From the results described in this thesis it is clear 
that such extrapolations from the normal condition to that of 
hepatic encephalopathy cannot be made. As is most clearly evident 
in the case of acute hepatic failure, the plasma amino acid 
pattern, if it were the only factor involved, would have resulted 
in decreased brain tryptophan content rather than the increase 
observed. In chronic hepatic failure the plasma amino acid pattern 
obtained in the present study was similar to that described by 
others and used as a basis for the hypothesis. However, as dis-
cussed in Results Section III, thi_s pattern would not result in a 
change in the apparent K of transport sufficient to result in 
m 
increased tryptophan influx, and again an alteration in the 
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transport mechanism itself was suggested to account for the high 
brain tryptophan concentrations. 
Studies of tryptophan transport itself have been restricted 
to measurements of the rates of the unilateral influx of tracer 
quantities of tryptophan in single-injection (Pardridge & Olden-
dorf, 1975a) or steady-state methods (Pratt, 1976). With the 
exception of the branched chain amino acids, the net uptake of 
amino acids by brain (determined from arteriovenous differences) 
is not significantly different from zero (Betz & Gilboe, 1973). 
Net uptakes are lower than influx values because in the steady 
state, influx of amino acids into brain and subsequent metabolism 
is almost balanced by exit of amino acids from brain to blood. 
When competitors normally present in the circulation are taken 
into account, values for influx obtained by single injection tech-
niques are considerably lower (Table 26, 27) and there is less 
difference between these influx values and net uptake. It is 
likely that extensive reutilization of tryptophan within the 
brain obviates the need for entry of large quantities of plasma 
tryptophan. Efflux systems are difficult to demonstrate experi-
mentally. Since the ECF concentrations of amino acids are much 
lower than plasma or intracellular concentrations (Bito et al., 
1966), a facilitated diffusion mechanism such as the one which 
mediates influx and which is equilibrative, could not mediate the 
exit of the amino acids against a concentration gradient. Active 
efflux systems, requiring energy and able to work against con-
centration gradients, have been described for organic anions 
(Pardridge & Oldendorf, 1977) and more recently for the 
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nonessential amino acids glycine, alanine and serine (Betz & 
Goldstein, 1978), which are transported only to a very limited 
extent from blood to brain (Oldendorf, 1971b). Efflux may also be 
mediated by the process of counterdiffusion or hetero-exchange 
by which the entry of one substrate drives the exit of the same 
or related substrate. This process is characteristic of facili-
tated diffusion mechanisms in isolated systems from the brain 
such as slices or cells (Battistin, Piccoli & Lajtha, 1972; 
Christensen, 1969) and could take place as part of the y-glutamyl-
glutamine pathway as described above. Consideration of this 
phenomenon raises the possibility that increased brain concentra-
tions of substrates could actually cause increased transport 
into the brain instead of the opposite as usually assumed. This 
has been examined in the situation of decreased glucose transport 
during hypoxia and found not to be the case (Betz et al., 1976). 
Alterations in the blood-brain barrier in pathological 
conditions have only recently received attention (Livingstone, 
Potvin, Goresky, Finlayson & Hinchey, 1977; Cremer et al., 1977; 
James et al., 1978). They appear to be of vital importance during 
hepatic failure, and may therefore be significant in other condi-
tions. The changes found during hepatic failure are further dis-
cussed below. 
c. Cell membrane transport 
Brain cell membrane transport of tryptophan has been studied 
in slices, synaptosomes and cultured glial cells (Kiely & Sourkes, 
1972; Denizeau & Sourkes, 1977; Parfitt & Graham-Smith, 1974; 
Bauman et al., 1974). Two saturable transport systems were found, 
one low and one high affinity system. Transport was active 
(concentrative) and dependent on temperature and energy but not 
Na+. Stereospecificity and exchange diffusion have been demon-
strated in slice and synaptosome preparations (Battistin et al., 
1972; Parfitt & Smith, 1974). Active uptake by brain slices of 
the aromatic amino acids appeared to be unsaturated by extra-
cellular concentrations (Oja, Lahdesmaki & Vahvelainen, 1974). 
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In these experiments competitive inhibition among the aromatic 
amino acids was also demonstrated. Since the reported rate of 
cell uptake is several-fold higher than the estimated rate of 
influx of tryptophan across the blood-brain barrier, it is thought 
that cell transport is probably not rate-limiting in the overall 
transport of tryptophan from the plasma to brain cells (Pardridge 
& Oldendorf, 1977). 
Glial cell transport of tryptophan may be very important 
because brain capillaries are surrounded by glial endfeet and it 
is likely that substrates must pass through these cells before 
reaching neurons. 
d. Intracellular metabolism 
Intracellular tryptophan is used mostly for protein synthesis. 
It has been estimated that up to 400 times as much aromatic amino 
acid is used for protein as for neurotransmitter synthesis (Barondes, 
1974) even when the very short turnover time of the monoamines 
compared to that of the proteins is taken into acount. (The con-
centrations of the minor amines such as tyramine, tryptamine and 
phenylethylamine constitute only 2-5% of the monoamines [Pardridge, 
1977)). 
Synthesis of serotonin is anatomically separated from most 
of the protein synthesis in the brain in two ways: 
188 
(1) serotonin synthesis is confined to a small proportion 
of neurons that contain tryptophan hydroxylase. 
(2) most of the synthesis is believed to occur in the nerve 
terminals whereas protein is synthesized almost ex-
clusively in cell bodies (only 1% of the synthetic 
enzymes are present in the cell bodies where they 
themselves are made). 
This segregation of serotonin and protein synthesis prevents com-
petition for tryptophan between the two processes in whole brain. 
In serotoninergic neurons such competition has not been excluded. 
Amino acids for protein synthesis occur in several pools (Roberts, 
1974). Since tryptophan appears to be the limiting amino acid for 
protein synthesis in other tissues such as the liver (Munro, 1970) 
the same may be true of brain protein synthesis. In general, the 
supply of essential amino acids does influence the rate of cerebral 
protein synthesis (Roberts, 1968). Thus, the abnormal quantities 
and proportions of the brain amino acids found during hepatic en-
cephalopathy may conceivably affect protein synthesis. 
The cell bodies of the neurons containing serotonin are re-
stricted to nine clusters in the raphe regions of the pons and upper 
brain stern (Cooper et al., 1978). Areas innervated by these neurons 
include the cortex, striaturn, cerebellum and hypothalamus. Sero-
tonin synthesis is believed to take place in the nerve terminals 
to which tryptophan could be supplied by membrane transport into 
the terminals or by axoplasrnic flow from the cell body. Axoplasrnic 
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flow has been shown for some amino acids and proteins (Pardridge, 
1977). As described in detail in Results Section II, there is 
considerable direct and indirect evidence for the dependence 
of serotonin synthesis on brain tryptophan content. In many 
conditions where the concentration of tryptophan is increased, 
the cerebral turnover of serotonin is also increased (Gessa & 
Tagliamonte, 1974; Tagliamonte et al., 1971, 1973a; Guierinot 
et al., 1974; Perez-Cruet et al., 1971; Messing et al., 1976; 
Colmenares et al., 1975; Curzon et al., 1972, 1973b). Evidence 
that an increase in tryptophan in whole brain is also reflected 
in serotoninergic neurons was provided by work showing that 
single raphe neurons in the brain stem fluoresced more brightly 
(indicating increased serotonin content) when animals were in~ 
jected with large doses of tryptophan (Aghajanian & Asher, 
1971). These data emphasize the significance of altered 
tryptophan transport and brain metabolism in the development 
of hepatic encephalopathy. 
It is clear from the above that many transport and metabolic steps 
could be involved in regulating the utilization of tryptophan. However, 
there is much evidence that transport across the blood-brain barrier 
is of primary importance in determining the ultimate fate of trypto-
phan in the brain as well as whole brain content as it is usually 
measured. The significant correlation obtained between tryptophan 
transport rates and brain tryptophan content described in Results 
Section III supports this statement. 
3. BLOOD-BRAIN BARRIER CHANGES 
Until recently it was assumed that no matter what changes are 
occurring in blood or brain, the transport mechanisms of the blood-
brain barrier operate exactly as they do under normal conditions. 
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The present studies showing altered tryptophan transport during 
hepatic encephalopathy, together with earlier reports (Cremer et al., 
1977; Livingstone et al., 1974, 1977) suggest that this assumption 
may often not be true. Transport across the blood-brain barrier 
appears to be iimiting in the utilization of metabolites by the brain 
in several pathways as discussed above, therefore any alterations in 
the mechanisms controlling transport could have significant effects 
on brain metabolism and therefore function. 
The alterations in tryptophan transport found during hepatic 
encephalopathy cause an increased rate of transport which clearly 
contributes to the increased content of brain tryptophan found during 
hepatic failure. The demonstration of a nonsaturable component of 
transport, which contributed considerably to the total influx, may be 
of special significance, since this component is unaffected by com-
peting amino acids. The findings could thus explain the apparent 
paradox of increased brain tryptophan in the presence of very high 
plasma amino acids in acute hepatic failure. 
The changes found in the blood-barrier appeared to be selective 
and thus the effect on transport of other substrates cannot be predicted. 
The large increase in brain content of tyrosine and phenylalanine may 
suggest that entry of these amino acids is increased as well as that of 
tryptophan, since these all share the same transport mechanism. At 
this stage it is unknown whether the alterations in the blood-brain 
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barrier are entirely the result of some pathological change, or 
evidence of a regulatory process responding to abnormal substrate con-
centrations either within the brain or in the plasma. (Increased influx 
of ketone bodies into the brain has been found after prolonged keto-
nemia [Gjedde & Crone, 1975].) In both cases the changes could 
further contribute to the development of the condition. 
These studies emphasize the sensitivity of brain metabolism to 
blood metabolite levels, through its dependence on substrate transport. 
It is becoming clear that the brain is more responsive to changes in 
blood than was thought when the term "blood-brain barrier" was first 
used. Furthermore, these studies demonstrate the importance of in-
vestigating transport of precursors into brain in addition to metabolite 
changes within the brain for a fuller understanding of the neurochemical 
changes occurring during hepatic encephalopathy and very possibly 
other conditions where brain function is disturbed. 
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C. COMPARISON WITH OTHER METABOLIC COMAS 
The neurochemistry of other metabolic comas, with the exception 
of hypoglycaemic coma, has not been as extensively studied as that 
of liver failure. During hypoglycaemic coma there is a general decrease 
in brain glycolysis with depletion of glutamine, glutamate and alanine 
and an increase in aspartate and later ammonia (Goldberg, Passoneau & 
Lowry, 1966; Lewis, Ljunggren, Norberg & Siesjo, 1974; Ferrendelli, 
1974, 1975; Tews, Carter & Stone, 1965; Norberg et al., 1975; Norberg & 
Siesjo, 1976; Gorell, Dolkart & Ferrendelli, 1976). However the cause 
of disturbed consciousness remains unknown, since, as with hepatic 
coma, brain function appears to decrease before there is a shortage of 
energy intermediates (Ferrendelli & Chang, 1973; Lewis et al., 1974; 
Gorell, Law,Lowry& Ferrendelli, 1977). 
Changes in tryptophan metabolism similar to those in hepatic 
encephalopathy have been reported in uraemic coma. Reduced total 
plasma tryptophan and increased unbound tryptophan have been found 
both in patients with chronic renal failure (De Torrente, Glazer & 
Gulyassy, 1974; Sullivan, Murnoghan, Callaghan, Kantamaneni & Curzon, 
1978) and in rats with experimental chronic renal failure (Siassi, 
Wang, Kopple & Swendseid, 1977). Raised serotonin and reduced dopamine 
levels were found in postmortem brains of uraemic coma patients 
(Jellinger, Irsigler, Kothbauer & Riederer, 1977), while increased 
5-HIAA was found in the cerebrospinal fluid of patients and in the 
brains of rats with chronic renal encephalopathy (Sullivan et al., 
1978; Siassi et al., 1977). These findings suggest that disturbed 
neurotransmitter - and especially serotonin metabolism, may play an 
important role in the development of uraemic as well as hepatic 
encephalopathy. Altered neurotransmitter metabolism is also thought 
to be involved in hypoglycaemic coma (Duffy & Plum, 1976). 
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In most studies of brain metabolism during encephalopathic con-
ditions, including hepatic encephalopathy, whole brain metabolite con-
tent was studied. This has the disadvantage that changes in specific 
regions or small but important pools may be masked and therefore not 
detected. However the large changes seen in glutamine and tryptophan 
during hepatic encephalopathy, for example, although probably not 
reflecting the small glial and serotonin precursor pools respectively, 
very possibly affect these pools. Ideally, turnover of the various 
substrates, which may be more closely associated with brain function, 
should be determined in addition to their concentrations. However 
such studies are much more difficult to carry out experimentally. It 
is possible that investigations of specific brain regions may uncover 
more . changes that are shared by the various types of metabolic coma. 
One feature conunon to several types 0£ coma including those due 
to hepatic failure, kidney failure, hypoglycaemia, hypoxia, as well as 
posttraumatic coma and coma induced by various chemical agents (bar-
biturates, fatty acids, dimethylsulphide), is that transmission failure 
precedes energy failure (Brodersen, 1974; Siesjo, J6hannsson, Norberg 
& Salford, 1975; Berghof et al., 1970; Derr & Zieve, 1973; Ferrendelli, 
1975). This suggests that in the cases where there is decreased 
availability of essential substrates, there is a protective mechanism 
which initially reduces brain activity to preserve energy, possibly 
for more essential life-sustaining processes, or that transmission 
is directly affected by the condition. 
Blood-brain barrier transport does not appear to have been in-
vestigated in conditions of disturbed brain function other than 
hepatic encephalopathy or hypoxia {Betz et al., 1976). 
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D. HYPOTHESIS 
The pathogenesis of hepatic encephalopathy appears to depend 
on many factors. Instead of searching for a single causative agent 
it may therefore be necessary to consider multiple events which may 
be linked at the cellular and subcellular levels. Taking into con-
sideration the neurochemical alterations described in this thesis a 
sequence of events leading to brain dysfunction in hepatic failure 
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may be put forward as follows. Shunting of portal blood past the 
failing liver leads to high blood concentrations of amino acids, 
especially the aromatic amino acids tyrosine, phenylalanine and un-
bound tryptophan, as well as ammonia from other nitrogenous sub-
stances. When liver necrosis is present even more aromatic amino 
acids are released into the circulation. There is a change in the 
blood-brain barrier transport mechanism for the neutral amino acids 
which leads to increased transport of tryptophan and possibly phenyl-
alanine and tyrosine, thus causing higher brain content of these amino 
acids. The change in the transport mechanism may be caused by the ab-
normal plasma amino acid pattern, i.e. an induction or regulatory 
process. Alternatively, increased entry of ammonia from the blood 
into the glial cells surrounding the brain capillaries may promote in-
creased synthesis of glutamine which in turn may stimulate activity 
of the y-glutamyl-glutamine pathway for transport of the neutral amino 
acids. 
Increased brain tryptophan leads to increased serotonin synthesis, 
and both tryptophan and phenylalanine may inhibit catecholamine synthe-
sis at the aromatic-L-amino acid decarboxylase step. The aromatic 
t 
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amino acids can also interfere with the metabolism of the amino acid 
neuroregulators from glucose. The overall result of these changes is 
a disturbance of the balance between excitatory and inhibitory neuro-
regulators in the brain, i.e. decreased catecholamines, asparate and/or 
glutamate, and increased serotonin and GABA. High glutamine concen-
trations may also have an inhibitory effect. Such an imbalance in 
the neuroregulators then produces alterations in neuronal activity 
necessary for the normal maintenance of consciousness by acting on 
neuronal membranes. For example, serotonin is thought to cause in-
creased ca2+ inside neurons by increasing membrane permeability to 
calcium, as well as stimulating adenyl cyclase resulting in increased 
intracellular cAMP, which promotes ca2+ release from mitochondria. 
A rise in ca2+ lowers excitability by raising the membrane permea-
bility to K+ (Krnjevic, 1975; Rasmussen, 1975). 
In this way the various neurochemical changes which appear to 
be closely associated with the development of hepatic encephalopathy, 
may be part of a cascade of events ultimately resulting in decreased 
neuronal activity and brain function. 
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E. CONCLUSIONS 
Several main conclusions can be drawn from the preceding discus-
sion and earlier sections, and these are summarized below. 
ANIMAL MODELS 
1. The three different methods used to produce chronic and acute 
hepatic failure satisfy the biochemical requirements for these condi-
tions. However more sophisticated behavioural monitoring is needed to 
provide clearer evidence of encephalopathy and coma. 
2. Comparison of the results from the surgically and galactosa-
mine-induced acute hepatic encephalopathy confirmed that the plasma and 
brain changes observed were the result of acute liver failure. The use 
of galactosamine has some advantages over the surgical model. 
CHANGES IN NEUROREGULATORS AND ASSOCIATED METABOLITES 
1. Hepatic encephalopathy is associated with an imbalance in the 
brain content of neuroregulators, in the direction of an increase in 
those with inhibitory actions and a decrease in those with excitatory 
actions. The changes observed were more pronounced in acute hepatic 
failure, especially those involving tryptophan and annnonia. The most 
striking difference between the chronic and acute conditions was in 
the plasma amino acid concentrations, with very large increases in 
acute hepatic failure and only slight changes in chronic hepatic 
failure. 
2. Glutamine changes may be of special importance due to the 
alterations observed in glial cells (where glutamine is exclusively 
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synthesized), their proximity to the brain capillaries and the changes 
seen in the blood-brain barrier, and the possible involvement of 
glutamine in barrier transport. 
3. The importance of hyd~oxy-indole involvement in encephalopathy 
is confirmed by the correlation of changes in brain tryptophan content 
with the various stages of hepatic failure and encephalopathy .' 
4. With respect to the factors contributing to the increased 
brain tryptophan content found during hepatic failure, it is clear that 
at least three must be considered: plasma competing amino acids, 
plasma unbound tryptophan, and the kinetics of the transport system. 
BLOOD-BRAIN BARRIER CHANGES 
1. The alterations found in the kinetics of the tryptophan 
transport mechanism result in increased tryptophan influx across the 
blood-brain barrier and contribute to the increased brain tryptophan 
content. 
2. The changes appear to be selective, therefore there may 
be different changes in other barrier transport mechanisms transporting 
other essential substrates into the brain. 
3. It is suggested that transport mechanisms may also be 
affected in other pathological conditions, including those involving 
brain dysfunction. 
4. These possibilities suggest that caution should be used in 
extrapolating from the normal to pathological conditions and therefore 
in the suggested use of intravenous amino acids, other dietary pre-
cursors and drugs in the treatment of brain disease. 
INTERRELATIONSHIPS 
The work in this thesis emphasizes several facets of the neuro-
chemistry of a pathological condition. 
1. Brain metabolism of the amino acid and aromatic neuro-
regulators appears to be interrelated at many levels, which must be 
taken into account when searching for precipitating events in the 
development of the condition. 
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2. The dependence of neuroregulator synthesis on precursor 
availability stresses the importance of plasma substrate distributions 
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